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ABSTRACT OF DISSERTATION 
 
 
 
THE CRITICAL ROLE OF MECHANISM-BASED MODELS FOR 
UNDERSTANDING AND PREDICTING LIPOSOMAL DRUG LOADING, BINDING 
AND RELEASE KINETICS 
 
Liposomal delivery systems hold considerable promise for improvement of cancer 
therapy provided that critical formulation design criteria can be met. The main objective 
of the current project was to enable quality by design in the formulation of liposomal 
delivery systems by developing comprehensive, mechanism-based mathematical models 
of drug loading, binding and release kinetics that take into account not only the 
therapeutic requirement but the physicochemical properties of the drug, the bilayer 
membrane, and the intraliposomal microenvironment. 
Membrane binding of the drug affects both drug loading and release from liposomes. The 
influence of bilayer composition and phase structure on the partitioning behavior of a 
model non-polar drug, dexamethasone, and its water soluble prodrug, dexamethasone 
phosphate, was evaluated. Consequently, a quantitative dependence of the partition 
coefficient on the free surface area of the bilayer, a property related to acyl chain 
ordering, was noted. 
The efficacy of liposomal formulations is critically dependent on the drug release rates 
from liposomes. However, various formulation efforts to design optimal release rates are 
futile without a validated characterization method. The pitfalls of the commonly used 
dynamic dialysis method for determination of apparent release kinetics from 
nanoparticles were highlighted along with the experimental and mathematical approaches 
to overcome them. The value of using mechanism-based models to obtain the actual rate 
constant for nanoparticle release was demonstrated. 
A novel method to improve liposomal loading of poorly soluble ionizable drugs using 
supersaturated drug solutions was developed using the model drug AR-67 (7-t-
butyldimethylsilyl-10-hydroxycamptothecin), a poorly soluble camptothecin analogue. 
Enhanced loading with a drug to lipid ratio of 0.17 was achieved and the rate and extent 
of loading was explained by a mathematical model that took into account the chemical 
equilibria inside and outside the vesicles and the transport kinetics of various permeable 
species across the lipid bilayer and the dialysis membrane. 
Tunable liposomal release kinetics would be highly desirable to meet the varying 
therapeutic requirements. A large range of liposome release half-lives from 1 hr to 892 hr 
were obtained by modulation of intraliposomal pH and lipid composition using 
dexamethasone phosphate as a model ionizable drug. The mathematical models 
developed were successful in accounting for the change in apparent permeability with 
change in intraliposomal pH and bilayer free surface area. This work demonstrates the 
critical role of mechanism-based models in design of liposomal formulations. 
KEYWORDS: Liposomes, Membrane Binding, Loading, Release Kinetics, Models, 
Dexamethasone 
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CHAPTER ONE  
Statement of Aims 
 A major gap in the progress of liposomal delivery systems is that the loading and 
release kinetics are generally found empirically without the use of mechanistic models to 
guide the liposome design. This conventional approach turns out to be an arduous and 
time-consuming process that retards the pace of advancement of the delivery systems into 
the clinic. Hence, the ultimate goal in this field should be to develop a global, uniform 
mechanistic model that would enable design of  nanoparticle delivery systems that have 
predictable and reproducible in vitro characteristics that also lead to predictable and 
reproducible in vivo performance. This work, in particular, focuses on models to 
characterize the in vitro performance (loading, partitioning and release kinetics) in an 
attempt to contribute towards the ultimate goal while stimulating further research with 
more diverse compounds.  
The central hypothesis is that mathematical models that take into account the 
thermodynamics (ionization, membrane binding, complexation), intraliposomal 
microenvironment and permeability of the drug molecule across the bilayer are the keys 
for prediction of loading and release kinetics in liposomal formulations. The major 
driving force for the transport of a drug across a liposome is typically the activity 
gradient of the free unionized species, which is governed by the physicochemical 
properties of the drug. Another determining factor, among others, in the partitioning and 
transport of drug across liposomes is the bilayer barrier properties which can be described 
in terms of order parameter or free surface area. The model compounds explored in this 
study represent typical problem drug candidates that are likely encountered repeatedly by 
 1 
those trying to develop delivery systems for antitumor agents. Two of the model 
compounds, 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) and 
dexamethasone (Dex), represent drugs with low aqueous solubility and hydrophobic 
nature while the other, dexamethasone phosphate (Dex-P), is an amphipathic, water 
soluble molecule. Highly hydrophobic molecules are difficult to retain inside liposomes 
leading to premature leakage, while hydrophilic molecules are retained for a very 
prolonged period of time, failing to achieve therapeutic concentrations at the site of 
action. In addition, high drug loading in liposomes is critical for the maximum usefulness 
of its therapeutic potential. The aim with the liposomal delivery of any agent is to 
encapsulate the drug to the maximum possible extent and retain the drug inside the 
liposomes for long enough while in circulation but release the drug at an optimum rate 
once at the site of action. In other words, there is a need for tailored release kinetics to 
meet the various therapeutic requirements. The following specific aims have been 
explored to understand the various processes (loading, partitioning and release) in 
liposomes: 
a) Determine the membrane partitioning behavior of dexamethasone and its 21-
phosphate prodrug as a function of bilayer composition, temperature and pH and 
explore the inter-relationship between solute structure, bilayer chain ordering and 
membrane binding 
The loading and release of a drug from liposomes is profoundly influenced by the nature 
and extent of partitioning of the drug in the bilayer. Experimental conditions that 
facilitate the accurate determination of the membrane/water partition coefficient of the 
drug are important to obtain a true value which will additionally facilitate the 
 2 
mathematical modeling of the loading and release processes. The influence of bilayer 
composition and phase structure on the partitioning behavior of dexamethasone and its 
phosphate prodrug are studied in chapter three. A quantitative relationship between 
membrane water partition coefficient of these drugs and the bilayer order parameter (free 
surface area) is also developed. 
b) Overcoming the pitfalls of dynamic dialysis, a commonly used method for 
determination of release kinetics from nanoparticles 
Dynamic dialysis has been widely used, though often uncritically, for the determination 
of release kinetics from nanoparticles. The lack of proper understanding of the underlying 
principles and inaccurate data interpretation can lead to false conclusions regarding 
sustained release behavior. The pitfalls of dynamic dialysis are demonstrated in chapter 
four using model lipophilic drug-loaded liposomes varying in lipid composition to 
provide variations in bilayer permeability and membrane binding affinities. A 
mathematical model is proposed that can aid in deconvoluting the rate constant for drug 
release from the apparent kinetics in cases where drug binding effects and/or dialysis 
membrane transport may be partially contributing.  
c) Explore the use of supersaturated solutions to enhance active liposomal 
loading using AR-67 as a model “problem” drug candidate 
Active loading method is the method of choice for loading of ionizable drugs to achieve a 
higher encapsulated drug to lipid ratio. The loading is dependent on the trans-bilayer 
activity gradient of the drug, its permeability coefficient and the extraliposomal drug 
concentration. The low aqueous solubility of AR-67 limits its extraliposomal 
concentration for loading resulting in a very low drug to lipid ratio upon encapsulation. A 
 3 
novel method of supersaturating the drug for active loading by the pH-gradient method is 
proposed in chapter five. A mathematical model taking into account the various intra- and 
extra-liposomal ionic and binding equilibria and permeability coefficients was developed 
to predict the rate and extent of active drug loading. 
d) Optimize the liposome release kinetics of dexamethasone phosphate based on 
pH and lipid composition 
Dexamethasone has been shown to act as a chemotherapy adjuvant to increase the uptake 
of chemotherapeutic agents. However, its use is limited by the requirement of frequent 
high doses owing to the high clearance of the drug and serious side-effects. There is a 
need for controlled and tailored release kinetics for extracting the maximum therapeutic 
benefits of the drug. Dexamethasone phosphate, the water soluble prodrug of 
dexamethasone and an ionizable compound, was used for the formulation development. 
Previous studies have shown that the differences in permeability of the free and ionized 
forms can be several orders of magnitude. The pH-dependent permeability was explored 
for Dex-P to obtain the range of release kinetics possible with a change in intraliposomal 
pH and the corresponding change in the neutral, permeable fraction. The permeability as 
a function of bilayer order parameter was evaluated by studying the release rate of Dex-P 
in liposomes varying in lipid composition and a quantitative relationship was established 
between bilayer permeability and free surface area in chapter six. 
  
 4 
CHAPTER TWO 
Introduction 
 
Nanotechnology in Cancer 
Nanotechnology is an emerging field that can have an enormous positive impact on 
human health, especially in cancer treatment (1). The application of nanoparticles in drug 
delivery has the incredible potential of revolutionizing cancer therapy. Current cancer 
therapy is faced with numerous challenges including non-specific distribution of 
antitumor agents, inadequate drug concentrations at the tumor site, multiple drug 
resistances and limited ability to monitor therapeutic responses (2-7). Nanoparticles have 
come a long way in cancer chemotherapy, radically changing the diagnosis and treatment 
of cancers. Tremendous amounts of research being conducted for the development of 
nano-based therapies have advanced the field of cancer treatment significantly, with 
several nano-based products now on the market (8). The unique physical and chemical 
properties of these three dimensional nanostructures allows great flexibility in designing 
drug delivery systems. They may be tailored to provide several desired properties such as 
the ability to deliver poorly water soluble drugs, overcome biological barriers and carry 
the drug selectively to the target site while protecting it from degradation. One of the 
greatest advantages of nanotechnology over conventional therapies is their 
multifunctionality; in diagnosis, imaging, monitoring and therapeutics (9-13). 
Nanoparticles are sub-micron sized colloidal particles made of polymer, lipids or metals 
with drug either encapsulated within the matrix or conjugated on the surface. The primary 
reason for the ideal suitability of nanocarriers for the delivery of chemotherapeutics in 
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cancer treatment is their ability to take advantage of the EPR (Enhanced Permeation and 
Retention) effect, whereby the nanoparticles preferentially accumulate at the tumor site 
owing to the leaky, fenestrated vasculature and are retained there due to the 
underdeveloped lymphatic drainage system (14-17). Blood vessels in normal tissues have 
tight endothelial junctions preventing the entry of foreign particles while angiogenic 
blood vessels in tumor tissues, unlike those in normal tissues, have gaps as large as 600–
800 nm between adjacent endothelial cells. Poorly developed, fenestrated tumor blood 
vessels coupled with poor lymphatic drainage induces the EPR effect, which enables 
nanoparticles to extravasate through these gaps into extravascular spaces and remain in 
tumor tissue (14-17). Nanoparticles have been explored for both passive targeting via the 
EPR effect and active targeting.  Active targeting involves incorporation of a targeting 
ligand on the surface of nanoparticles that specifically binds to a receptor, which is either 
unique or overly expressed on tumor cell surfaces (18, 19). Passive or active targeting of 
therapeutics to tumor tissues is the main arena of nanoparticle use in cancer therapy, as it 
reduces side effects, increases efficacy and reduces systemic drug exposure. Liposomes, 
polymer nanospheres, nanorods, carbon nanotubes, solid lipid nanoparticles, fullerenes, 
nanocrystals, dendrimers etc. are some of the nanoparticles being widely explored for 
delivery of cancer chemotherapeutics.  A more quantitative understanding of the 
properties of nanoparticles both in vitro and in vivo will be key to their clinical success.  
Liposomal Drug Delivery 
Over several decades, liposomes have evolved from simple model membrane systems to 
sophisticated drug delivery systems for a large number of therapeutic agents (20-23).  
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Figure 2.1 Schematic of a liposome 
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Liposomal nanoparticles represent an advanced class of drug delivery systems, with 
many formulations on the market and several in clinical trials. Liposomes are 
nanoparticles comprising one or more concentric lipid bilayers enclosing an aqueous 
interior (Figure 2.1). The typical size range for large unilamellar (consisting of one 
bilayer) liposomes is ~50-200 nm. Liposomes are unique in their versatility as they can 
incorporate both hydrophobic and hydrophilic agents either in the membrane phase or in 
the enclosed aqueous compartment, respectively (24-26). Liposomes composed of natural 
lipids are biodegradable, non-immunogenic and they have limited intrinsic toxicity. The 
manifold applications of liposomes have been to enhance the drug solubility and stability, 
avoid rapid degradation, reduce drug toxicity, and improve unfavorable 
pharmacokinetics. They can function as controlled release systems as per the therapeutic 
requirement. Stealth liposomes are pegylated liposomes, designed to evade recognition 
by the immune system and thereby elongate the in vivo circulation half-life (27-29). The 
attainment of longer circulation times in vivo (t1/2~24 hrs) by polymer coating has led to 
the clinical success of several liposomal products (30-33).  
Liposomes are particularly useful in cancer chemotherapy because of their ability to 
increase the therapeutic efficacy and reduce the side effects of a given drug by the well-
known EPR effect. The potential benefit from a liposomal carrier depends on the nature 
of the drug, the desired pharmacological intervention and the site of application. The 
current pharmaceutical preparations of liposome based therapeutic agents mainly result 
from our understanding of membrane-drug interactions and liposome disposition kinetics. 
Despite the significant advances with liposomes as drug delivery systems, there is a big 
gap in the amount of research efforts invested and the clinical successes of the liposomal 
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formulations (33). This can be majorly attributed to the lack of quantitative mechanism 
based approaches in formulation design (34, 35). Other factors are poor understanding of 
the physical and chemical stability of the lipids, mechanisms affecting liposome 
clearance in vivo, scale-up issues and cost prohibitiveness of the lipids for large scale 
manufacturing of liposome formulations (36-38).  
The ability to entrap as much drug as possible, retain the drug inside the liposomes as 
long as they are in circulation, and subsequently release the drug content at an optimum 
rate once at the tumor site will be preeminent to the clinical success of any liposomal 
formulation. Understanding the physicochemical factors affecting the loading and release 
of a liposomal drug and developing mechanism-based models for quantifying and 
predicting these processes are the principal objectives of this thesis. 
Loading Methodologies 
One of the major challenges in the advancement of liposomes into clinical products has 
been the achievement of a high level of loading of the therapeutic agent in the liposome. 
The tiny intraliposomal volume (about 0.002 femtoliter for 150 nm liposome) demands a 
very efficient loading method in order to achieve meaningful drug concentrations at the 
site of action (39). Inadequate drug loading essentially defies the purpose of a targeted 
delivery vehicle and renders it insufficient. The two most common methods of loading 
are discussed below. 
(i) Passive Loading 
In the passive loading method, drug incorporation takes place while the liposomes are 
being formed. It is mainly driven by the water solubility and membrane water partition 
coefficient or hydrophobicity of the drug (40-42). For a highly water soluble drug, the 
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extent of drug loading will depend on the entrapped aqueous volume while for a highly 
hydrophobic drug, about 50% drug will be associated with the intraliposomal leaflet and 
the remaining 50% with the extraliposomal leaflet. In either case, only part of the drug 
will be encapsulated by the passive loading method. Thus, although it is a simple method, 
the drug to lipid ratio achieved by this method is not very high. 
(ii) Active Loading 
Active loading is preferred for ionizable drugs, where the loading takes place in response 
to a trans-membrane chemical potential gradient (43, 44). Several marketed products 
have been launched based on this approach, the most notable being the doxorubicin 
formulation, Doxil®. The active loading method adopted for Doxil® is based on an 
ammonium sulfate gradient as demonstrated in Figure 2.2 (36, 45). In general, in this 
method, a trans-bilayer pH gradient is first established by creating a concentration 
gradient of the weak acid or base, which causes the diffusion of the weak acid or base 
from inside to outside the liposomes. After development of the pH gradient, the weakly 
acidic or basic drug is allowed to diffuse into the liposomes, once again, in response to 
the concentration gradient of the drug. Upon encapsulation, the drug ionizes due to the 
pH difference and is trapped in the membrane impermeable form, which drives further 
loading (46-48). However, the loading is limited by the availability of the extraliposomal 
drug, which is a function of its aqueous solubility. Thus, achieving a high drug to lipid 
ratio by active loading remains a challenge for poorly water soluble drugs. 
Intraliposomal drug precipitates in the form of insoluble salts can significantly prolong 
the release half-life. The formulation may exhibit zero order kinetics until the drug 
concentration reaches below the saturation solubility of the drug in the aqueous entrapped 
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volume (49). However, with active loading methods based on pH-gradient, the 
maintenance or the collapse of the pH gradient in vivo can affect the drug release rate. 
Therefore, it would be desirable to evaluate the release kinetics of active loaded 
liposomes in physiologically relevant media to predict the in vivo performance (50).  
Liposome Release Kinetics 
Determination of the release kinetics of the encapsulated drug from liposomes is a 
critically important aspect of the formulation characterization. The rate of liposomal drug 
release will determine the extent of premature drug leakage from the liposomes while 
they are in the systemic circulation prior to reaching the target site. Once at the site of 
action, the drug needs to be released at an optimal rate as per the therapeutic requirement 
because rates that are either too slow or too fast can result in poor efficacy. Thus, the 
drug release rate potentially determines the therapeutic efficacy of the formulation. A 
bell-shaped curve can be expected between liposomal release rate and therapeutic effect 
in tumors (51-53). Profiles describing antitumor efficacy versus release rates are 
necessary in order to predict therapeutic outcome for a particular tumor type. Extensive 
physicochemical and medical characterization is needed for translation of these 
formulations into clinical products. 
(i) Factors Controlling Liposome Release Kinetics 
The kinetics of drug release from liposomes depends on the permeability of the solute 
and its concentration gradient across the bilayer. The permeability, in turn, is a function 
of the membrane-water partition coefficient of the drug, the diffusion coefficient of the 
permeable species and the nature of the bilayer (54). The major understanding of the  
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Figure 2.2 Schematic depicting the active loading into liposomes based on ammonium 
sulfate gradient method for weak bases. 
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barrier properties of liposomes comes from studies aimed at exploring the factors 
governing the bilayer permeability using liposomes as model membrane systems.  
Partitioning and permeability of solutes in lipid bilayers is dependent on the physical and 
chemical properties of the solute and the bilayer structure. 
(a) Bilayer Phase Structure 
Liposomes are most often made up of phospholipids, the most common being 
phosphatidylcholine (PC) molecules. Some of the phospholipids used in this study are 
shown in Figure 2.3. Phosphatidylcholines, owing to the double fatty acid chains, differ 
from other amphipathic molecules (e.g., detergents, lysolecithin) in having a preference 
to form bilayers rather than micellar structures. The structure of the bilayer is influenced 
by the phospholipid composition, acyl chain length of the phospholipid, its phase 
transition temperature and presence of cholesterol among some of the major factors (55-
57). Although liquid crystalline bilayers are said to mimic the phase structure of most 
physiological membranes, in drug delivery the goal is to optimize the release rate of the 
entrapped drug and therefore gel and liquid–crystalline phases, both are explored. Solute 
permeability has been observed to be strongly dependent on the phase structure of the 
bilayer (58-63). For a long time, the passive transport of small molecules across 
membranes was explained by a bulk-phase solubility diffusion model (56, 64). However, 
with the increasing research interests and efforts in the field of bilayer permeability, the 
role of lipid chain packing in the membranes on the permeability was realized. Owing to 
the physical and chemical heterogeneity of lipid bilayers, its treatment as a bulk solvent  
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Figure 2.3 Chemical structures of the phospholipids employed in this study. 
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was not sufficient. Dramatic increases in bilayer permeability on transitioning from a gel 
to liquid crystalline phase emphasized the more ordered nature of the gel phase due to 
tighter lipid chain packing and reduced lateral motions in lipid bilayers. Xiang and 
Anderson proposed the barrier-domain model whereby they introduced a permeability 
decrement factor to account for the decrease in permeability from that predicted by 
solubility diffusion theory owing to chain ordering in lipid bilayers (61, 65). 
(b) Solute Size and Structure 
Lipid bilayer permeability has been shown to be sensitive to the solute size, attributed to 
the effect of lipid chain ordering which cannot be explained by the bulk solubility 
diffusion theory. The sensitivity of the permeability coefficient of solutes to bilayer chain 
packing was shown to exhibit linear dependence on the minimum cross-sectional area of 
the permeants (using seven short-chain monocarboxylic acids) (61). It was suggested that 
the permeants prefer to orient with their long principal axis along the bilayer normal and 
correlate better with the permeant cross sectional area rather than molecular volume. The 
size selectivity for transport across lipid bilayers may be credited to size dependent 
effects on both partitioning and diffusion in lipid bilayers.  
The preferred site for solute partitioning is dependent on the hydrophobicity of the solute. 
Hydrophilic solutes or compounds having polar functional groups may reside 
preferentially at the bilayer interface while hydrophobic nonpolar solutes may locate in 
the interior of the bilayer upon partitioning. Similarly, amphipathic solutes may orient at 
the interface to maximize the interaction of their polar groups with the aqueous region 
and the non-polar parts with the hydrocarbon region of the bilayer. The chemical nature 
of the solute (i.e., functional groups, number of –CH2 groups, hydrogen bonding 
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potential) impacts its release kinetics across the bilayer (61). For example, in the more 
ordered gel phase bilayer, the permeability coefficient decreased with increasing chain 
length for short-chain monocarboxylic acids from formic acid to propionic acid, followed 
by a reversal in the trend at higher chain lengths whereas in liquid crystalline bilayer, an 
approximately monotonic increase in permeability coefficient with permeant chain length 
was observed. The results suggested the interplay of both the lipophilicity of the 
permeant and the chain ordering within the membrane and that the unfavorable steric 
interactions associated with the addition of a methylene group may dominate over the 
accompanying increase in lipophilicity (61). 
The ionization potential of the solute also has an important role in its permeability across 
the bilayer. For ionizable solutes, the apparent permeability changes with a change in pH 
and the corresponding change in fraction unionized. This is largely based on 
experimental evidence accumulated over several years indicating that neutral species are 
often orders-of-magnitude more permeable than their ionized counter-parts (60, 61, 64-
67). The pH dependent permeability of ionizable compounds has been used successfully 
in the active loading of several weak bases and few acids in the liposomes to achieve high 
drug to lipid ratios. In this work, the use of intravesicular pH to modulate the release 
kinetics of an ionizable drug, dexamethasone phosphate (Dex-P) was demonstrated.  
(ii) Methods Used to Assess Liposome Release Kinetics 
There are several methods used for the determination of drug release rates from 
nanoparticles. Each method has its own advantages and disadvantages. One of the 
methods is to dilute the nanoparticles with buffer and then separate the carrier from drug 
at different time points. For separation by ultrafiltration, the issue is that some 
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nanoparticles (e.g. liposomes) being non-solid flexible structures may pass through the 
filter membranes.  Separations using ultracentrifugation may alter  release rates due to the 
high centrifugal force (68). The reverse dialysis method, (69) where the nanoparticle 
formulation is diluted in the large volume to maintain sink conditions and free drug is 
sampled from the dialysis tubes immersed in the sink solution, requires a highly sensitive 
analytical method for quantitative determination of the drug. In dynamic dialysis, one of 
the most commonly used methods, the nanocarrier dispersion is suspended inside a 
dialysis tube/cassette of semipermeable membrane having a particular molecular weight 
cut off and dialyzed in a large volume of sink medium (70). During the kinetic study, the 
free drug is separated from the carrier by the dialysis membrane and does not require a 
separate separation step at each time point. Unfortunately, there exists an inadequate 
understanding of the dynamic dialysis method leading in some cases to a false notion of 
sustained release behavior from nanoparticles. Owing to the popularity of nanoparticle 
drug delivery systems, there is a critical need to understand the processes underlying the 
dynamic dialysis method and use the method appropriately to obtain reliable estimates of 
nanoparticle release rates.  
Camptothecins 
Camptothecin and its related analogues constitute an important class of drugs that gained 
considerable interest for their anti-tumor activity and unique mechanism of action (71, 
72). Camptothecins form non-covalent complexes with the topoisomerase I-DNA cleaved 
complex and thereby interfere with the DNA unwinding step of DNA replication. 
Prolonged exposure of replicating cells to camptothecins results in double strand breaks 
and consequently cell death (73, 74). One of the characteristics of this class is the pH 
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dependent chemical hydrolysis of the α-hydroxy δ-lactone ring (E-ring) moiety to form a 
ring-opened camptothecin carboxylate. The lactone moiety is thought to be the 
therapeutically active form and therefore, ring opening to form the carboxylate leads to 
diminished in vivo activity (73). 
Two compounds of this class, topotecan (Hycamptin®) and irinotecan (Camptosar®) 
have received FDA approval. In addition, several analogues are in clinical trial. One such 
analogue is AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin), which was 
synthesized in an attempt to improve its lactone stability in blood by promoting the 
binding of the lactone form to red blood cell membranes (75-78). The substitution of 
nonpolar groups imparted hydrophobicity to the compound resulting in a very low water 
solubility. Liposomal delivery of AR-67 was pursued to increase the solubility and 
stability of the compound along with the targeting potential of the nanosized liposomes to 
enhance the overall efficacy of the drug and reduce its systemic toxicity (79, 80). 
Besides, a prolonged schedule of camptothecin administration given continuously at low 
doses or frequently fractionated appeared to be more effective clinically (81-83). 
However, owing to the high lipophilicity, AR-67 has a high permeation rate across the 
liposome bilayer and therefore rapidly leaks from vesicles. In addition, the low aqueous 
solubility poses a challenge in achieving high encapsulation of the drug by the active 
loading method. Consequently, a novel strategy to enhance the encapsulated drug to lipid 
ratio of this and other poorly water soluble compounds by the active loading method was 
proposed and evaluated in this thesis.  
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Glucocorticoids 
Glucocorticoids are a class of steroidal agents that bind to glucocorticoid receptors and 
are mainly known for their anti-inflammatory and immunosuppressive responses (84, 85). 
Dexamethasone is a prominent member of the synthetic group of this class and one of the 
most widely used. In addition to its anti-inflammatory action, it has been used as an 
adjuvant in chemotherapy. In some of the recent pre-clinical and clinical trials, pre-
treatment with dexamethasone was shown to reduce the toxicity associated with 
chemotherapeutic agents and even increase the efficacy (86-89). This is potentially 
attributed to the down-regulation of pro-inflammatory cytokines (e.g., vascular 
endothelial growth factor (VEGF), interleukin 1β (IL-1β)) by dexamethasone and as a 
consequence, a reduction in the interstitial fluid pressure within tumors. Reduced 
intratumoral pressure facilitates the uptake and diffusion of chemotherapeutic agents (90-
92). Despite the beneficial effects of dexamethasone, its use is limited by substantial side 
effects. In addition, due to its rapid clearance from the body, frequent high doses are 
required to achieve efficacy which in turn causes serious side effects (84). To better 
exploit the therapeutic potential of dexamethasone, targeted delivery systems with 
tailored release kinetics are desirable (86, 87, 93).  
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CHAPTER THREE 
Bilayer Composition, Temperature and Speciation Effects on Partitioning of 
Dexamethasone and its 21-phosphate: The Role of Bilayer Chain Ordering 
INTRODUCTION 
The partitioning of drugs into lipid bilayers and biological membranes is a significant 
factor governing their tissue distribution and bioaccumulation (94-97). These properties, 
in turn, directly influence efficacy or toxicity when the mode of drug action involves 
interaction with membrane components (98, 99) and may also affect efficacy and toxicity 
indirectly through their role in modulating drug delivery, pharmacokinetics, metabolism 
and clearance (100, 101). As drug candidates have become more lipophilic and less water 
soluble there is a greater need for rapid and reliable screening methods and/or 
computational approaches to allow pharmaceutical scientists to select lead candidates 
based on their developability, as indicated by properties such as their potential to exhibit 
good oral bioavailability (102, 103). Guided by the perception originating in Overton’s 
rule and the solubility-diffusion model that the equilibrium membrane-water partition 
coefficient should correlate with permeability across biomembranes (102, 104, 105) 
numerous researchers have attempted to devise experimental systems and computational 
models that link drug permeation to membrane affinity. As yet, however, there are no 
models that can quantitatively predict either biomembrane partitioning or transport solely 
from a knowledge of the structure of the drug and composition of the membrane. 
For decades, it has been a common practice to predict membrane-water partitioning of 
drugs and also in vivo absorption based on various bulk solvent-water partition 
coefficients (103, 106, 107). Although different bulk solvents have been used to 
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determine the partition coefficient, octanol has been the most referenced system (106). 
However, with time, deficiencies of bulk solvents as models for membranes have become 
more widely appreciated. Conceptually, these deficiencies mainly reflect the fact that 
bulk solvents are homogeneous and isotropic while lipid bilayer membranes are 
anisotropic interfacial phases with properties that vary as a function of internal distance 
from the bilayer-water interface (57, 108-110). One striking experimental discrepancy 
noted in several recent publications is that linear free energy relationships based on bulk 
solvent/water partitioning fail to predict lipid bilayer/water partitioning. This has been 
particularly apparent in the lack of correlation between octanol/water partition 
coefficients and membrane water partition coefficients for drugs containing ionizable 
substituents (102, 111-113). Ionized solutes may have higher affinity for lipid bilayer 
membranes than octanol due to the anisotropy of lipid bilayers, their high surface area-to-
volume ratios, and electrostatic interactions of ionized solutes with charged moieties in 
the bilayer headgroups (111, 112, 114-116). Within the anisotropic microenvironment of 
the bilayer interface, solutes preferentially adopt conformations and orientations that 
maximize hydrophobic and van der Waals interactions between non-polar regions of the 
solute and acyl chains within the bilayer interior while retaining electrostatic interactions 
with the polar head groups and water molecules (117-120). The complexity of factors 
leading to that preferred solute conformation, orientation, and position within the bilayer 
that constitutes a minimum in free energy appears to have no close correlate in bulk 
solvent/water partitioning. 
Another discrepancy between lipid bilayer/water versus bulk solvent/water partitioning is 
the well-known dependence of lipid bilayer/water partition coefficients on bilayer phase 
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behavior and chain ordering. For example, decreasing the temperature below the phase 
transition temperature, inclusion of cholesterol in the bilayer, or elongating the 
phospholipid chain length, cause significant decreases in partition coefficient values (55, 
121, 122) that are not easily rationalized using only bulk solvent models for the 
partitioning process. 
In addition to their importance in drug delivery, liposomes are widely used as model 
membrane systems for studying the partitioning behavior of drugs (57, 98, 123-125). 
Determination of the liposome/water partition coefficient is essential for characterizing 
drug loading and the driving force governing release kinetics from liposomal delivery 
systems (126-128). More generally, such information can contribute to an understanding 
of several biological phenomena including passive transport and biodistribution (103, 
129).  
A unified quantitative mathematical model that could predict the membrane-water 
partition coefficient as a function of drug structure, membrane composition, and the local 
aqueous microenvironment would be valuable both from a practical standpoint in 
assessing drug developability and for understanding drug biodistribution, clearance, 
efficacy, and toxicity. Such a model would need to take into account the concentrations 
of the various neutral and ionized drug species that may exist as a function of the pH of 
the aqueous microenvironment; the hydrophobic regions of the solute, the nature and 
location of various polar functional groups in the solute molecule and its conformational 
flexibility; and the surface charge, chain ordering and phase behavior, and other 
properties of the bilayer that in turn depend on lipid composition and the temperature, pH 
and ionic strength of the solution.   
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In the present study, the influence of bilayer composition and phase structure on the 
partitioning behavior of the anti-inflammatory steroid dexamethasone (Dex) was 
explored. These studies demonstrate a quantitative dependence of the partition coefficient 
of dexamethasone on the free surface area of the bilayer, a property related to acyl chain 
ordering that is modulated by changes in bilayer composition and temperature. 
Comparison of the present results to previous literature studies of drug partitioning into 
lipid bilayers suggests that this concept may have general applicability, as it has been 
previously shown for drug permeability across lipid bilayer membranes (122, 130, 131). 
Phosphorylation of dexamethasone to produce the water soluble prodrug dexamethasone 
21-phosphate (Dex-P) complicates its membrane binding behavior. The dependence of 
the apparent partition coefficient of Dex-P, as a function of pH after correction for drug 
concentration effects, was determined in order to generate species-specific partition 
coefficients. Comparison of these species-specific partition coefficients for Dex-P to that 
for Dex in bilayers varying in lipid composition suggests that the influence of chain 
ordering as quantified by free surface area on partitioning behavior affects both nonpolar 
and polar solutes similarly.  
MATERIALS AND METHODS 
Phospholipids including DSPC (1,2-distearoyl-sn-glycero-3-phosphatidylcholine, >99% 
purity), DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine, >99% purity), DMPC (1,2-
dimyristoyl-sn-glycero-3-phosphocholine, >99% purity), m-PEG DSPE (1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]), m-PEG 
DPPE (1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene 
glycol)-2000]) and m-PEG DMPE (1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-
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N-[methoxy(polyethylene glycol)-2000]) were purchased as powders from Avanti Polar 
Lipids (Alabaster, AL). Dexamethasone (Dex) (≥98%, powder) was purchased from 
Sigma-Aldrich Co., St. Louis, MO. Dexamethasone sodium phosphate (Dex-P), USP, 
was from Spectrum Chemical Mfg. Corp., New Brunswick, NJ. Dialysis flat sheets 
(Spectra/Por® RC Membrane, MWCO: 3.5 kD) were purchased from Spectrum 
Laboratories (Rancho Dominguez, CA). HPLC grade solvents and other chemicals were 
purchased from Fisher Scientific (Florence, KY). Deionized water was used for all 
experiments. 
Liposome Preparation 
Blank liposomes were prepared based on a previously reported method (127). Briefly, 
DMPC: mPEG DMPE, DPPC: mPEG DPPE and DSPC: mPEG-DSPE (95:5 mol%, 120 
mg) were separately dissolved in 2 mL of chloroform. The solvent was evaporated under 
a stream of nitrogen while rotating the container and the resulting film was dried 
overnight in a vacuum oven. For determination of partition coefficient of Dex in different 
lipid systems, the lipid film was hydrated with 2 mL of phosphate buffered saline (PBS) 
(pH 7.4) and for Dex-P; 20 mM acetate buffer (pH 4) was used. For pH-dependent 
partition coefficient of Dex-P in DMPC liposomes, several buffers at different pH were 
used (20 mM KCl-HCl buffer, pH 1.5; 20 mM glycine buffer, pH 2; 20 mM acetate 
buffer, pH 4 and 5; 20 mM MES buffer, pH 6; 20 mM phosphate buffer, pH 8). To 
uniformly suspend the lipid, the suspension was alternately vortexed and heated in a 
water bath at a temperature above the phase transition temperature of the respective 
lipids. The lipid suspension was then extruded 10 times through two stacked 100 nm 
polycarbonate membranes (GE Water and Process Technologies, Trevose, PA) using an 
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extrusion device (Liposofast®, Avestin, Canada) at 30, 50 and 60 °C for DMPC, DPPC 
and DSPC, respectively, to obtain unilamellar liposomes. Liposomes were allowed to 
cool to room temperature for 3 hr and stored at 4 °C until further use. Particle sizes of 
blank liposomes were measured at 25 °C by dynamic light scattering (DLS) using a 
Delsa™ Nano submicron particle size analyzer (Beckman Coulter Inc., Brea, CA). The 
liposomes were diluted in the same buffer as that used in their preparation.  
Lipid Analysis 
Lipid concentrations in the liposomal suspensions were determined by high performance 
liquid chromatography (HPLC) using an evaporative light scattering detector (ELSD) as 
reported previously for DSPC liposomes (132). Briefly, separation was achieved using an 
Allsphere™ Silica Column (Grace Davison Discovery Sciences, Deerfield, IL) (5 µ, 4.6 x 
150 mm) with a guard column (Allsphere silica, 5 µ, 7.5 x 4.6 mm). A linear gradient 
method was employed starting with 100% (v/v) mobile phase A (80% chloroform:19.5% 
methanol:0.5% (v/v) ammonium hydroxide solution (30%) and changing to 80% mobile 
phase A:20% mobile phase B (80% methanol:19.5% water:0.5% (v/v) ammonium 
hydroxide solution (30%)) over 3 min. This composition was maintained from 3- 7 min 
followed by a return to 100% mobile phase A by 14 min. The total run time was 15 min 
at a flow rate of 1 mL/min with the ELSD setting at a gain of 8, pressure of 3.4 bar, and 
temperature of 40 °C. The sample compartment temperature was set at 4 °C and the 
column was at ambient temperature. Standards of DSPC, DPPC and DMPC were 
prepared in mobile phase A and linearity was observed between log concentration and 
log peak area.  
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Aliquots of liposomal suspension (10 µL) were dried under nitrogen and reconstituted in 
mobile phase A for lipid analysis before the start of each experiment. Since 95% of the 
phospholipid content in the liposomes was non-pegylated and the chain lengths for the 
pegylated and non-pegylated components were same, the liposomes were assumed to 
contain 100% DMPC, DPPC or DSPC, respectively, for the determination of lipid 
content. Lipid stability was assessed under two representative conditions (Dex-P, pH 1.5 
and 6, DMPC liposomes). Stability samples were withdrawn at different time points 
during dialysis for lipid analysis. 
Determination of Membrane-Water Partition Coefficients 
Equilibrium Dialysis Method 
Membrane-water partition coefficients of Dex and Dex-P (Figure 3.1) were determined at 
25 °C and varying lipid concentrations in three different liposomal systems (DMPC, 
DPPC and DSPC) by equilibrium dialysis using one mL Teflon® cells (Equilibrium 
Dialyzer (Spectrum Labs)). A liposome stock suspension of 60 mg/ml was diluted to 
varying concentrations and mixed with a drug solution having a fixed concentration. One 
ml of this mixture was introduced into one compartment (donor) of the equilibrium 
dialyzer and one ml of the corresponding blank buffer was added to the other 
compartment (receiver). The dialyzer, which consists of five pairs of one mL cells, was 
then placed in an incubator at 25 °C and allowed to equilibrate. Aliquots (100-150 µL) 
were withdrawn at 24, 48 and 72 hours from each compartment, diluted in 900 µL 
methanol and analyzed by HPLC. Equilibrium was considered to have been established 
when two subsequent time points yielded constant values. Partition coefficients of Dex 
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were also determined in DPPC liposomes at 37 °C and 45 °C following the same 
procedure. 
Equilibrium Solubility Method  
Partition coefficients of Dex in DMPC, DPPC and DSPC liposomes were also 
determined by the equilibrium solubility method. Excess solid (Dex) was equilibrated 
with blank liposomes at different lipid concentrations at 25 °C. After equilibration, 
samples were filtered through 0.45 µ PVDF filters and the filtrates were analyzed for 
drug concentration by HPLC after a 10-fold dilution in methanol. Errors due to filter 
adsorption were eliminated by analyzing successive aliquots of the filtrate to attain 
constant values. Aliquots of filtrate (10 µL) were dried under nitrogen and reconstituted 
in mobile phase for lipid analysis. 
Simultaneous Determination of Dex and Dex-P by HPLC 
A new isocratic HPLC method was developed and validated for the simultaneous 
determination of Dex and Dex-P with UV detection at 240 nm. Four independent 
standards for Dex-P (100-800 µM) in water and Dex (100-800 µM) in methanol were 
prepared. A Waters Alliance 2695 Separations Module coupled to a UV detector (Waters 
996, Photodiode Array Detector) at 240 nm was employed. A Waters Symmetry® C18 
column (5 µm, 3.9 x 150 mm) and guard column (3.9 x 20 mm) were used at an injection 
volume of 10 µL with a mobile phase composition of 32% acetonitrile and 68% (v/v) pH 
5.5 triethylamine acetate (2%) buffer. The retention times for Dex-P and Dex at a flow 
rate of 1 mL/min were 2.5 and 6.4 min, respectively. The stability of Dex-P during 
equilibrium dialysis was monitored using this method as it allowed the simultaneous 
determination of Dex and Dex-P.  The HPLC response was linear within the range of  
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Figure 3.1 Structures of Dex and Dex-P with different ionization states of the 21-
phosphate. 
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100-800 µM for both Dex and Dex-P. The response factor for both analytes yielded a 
coefficient of variation less than 3% intraday and interday. 
THEORY 
Membrane-Water Partition Coefficient 
At equilibrium, the total mass of drug in the donor (liposomal) compartment is the sum of 
the masses in the bilayer membrane and the aqueous phase:    
𝐶𝑑𝑉𝑑 =  𝐶𝑤𝑉𝑤 + 𝐶𝑚𝑉𝑚                  𝐸𝑞 3.1   
where 𝐶𝑑 is the total drug concentration in the donor compartment, 𝐶𝑚 and 𝐶𝑤 are the 
drug concentrations in the lipid and aqueous phases, respectively, and 𝑉𝑑, 𝑉𝑚, 𝑉𝑤 are the 
respective volumes. The aqueous concentration in the donor compartment (𝐶𝑤) should 
equal the aqueous concentration in the receiver compartment (𝐶𝑟) at equilibrium. 
The volume based partition coefficient can then be defined by 
𝐾𝑝 = 𝐶𝑚𝐶𝑤 = 𝐶𝑑𝑉𝑑 − 𝐶𝑤𝑉𝑤𝐶𝑤𝑉𝑚 = 𝐶𝑑𝑉𝑑 − 𝐶𝑟𝑉𝑤𝐶𝑟𝑉𝑚                      𝐸𝑞 3.2 
Saturable Binding Correction for Neutral Dex-P 
The concentrations of membrane bound Dex divided by the lipid concentration were 
proportional to the free drug concentration in solutions approaching infinite dilution. 
However, deviations from linearity were observed for Dex-P partitioning at pH 1.5 and 2, 
necessitating a correction for membrane saturation. At pH 1.5 and 2, membrane bound 
Dex-P exists predominantly as the neutral species (the reported first pKa of Dex-P in 
aqueous solution is 1.9 (133)). Therefore, the following equation was employed to fit the, 
 30 
the ratios of bound drug to lipid concentration (𝐵) as a function of the free drug 
concentration (𝐶𝑢): 
𝐵 = 𝐾𝑝𝑎𝑝𝑝𝐶𝑢1 +  𝐶𝑜𝑛𝑠𝑡.𝐶𝑢                    𝐸𝑞 3.3 
where 𝐾𝑝
𝑎𝑝𝑝 is the partition coefficient at infinite dilution at the solution pH specified.  
Gouy-Chapman Correction for the Partition Coefficient of Bound Monoanion 
For membrane binding of ionized molecules, the partition coefficient decreases with the 
adsorbed concentration and needs to be adjusted to infinite dilution using Gouy-Chapman 
theory (134-139). At pH 4 - 6 in this study, the membrane bound drug was assumed to be 
predominantly monoanionic. Monoanion binding contributes to the development of a 
charge on the membrane surface, which in turn changes the surface potential as given by 
Gouy-Chapman equation: 
𝜎2 = 2000𝜖0𝜖𝑟𝑅𝑇�𝐶𝑖 �exp �−𝑍𝑖𝐹Φ0𝑅𝑇 � − 1�                        𝐸𝑞 3.4 
where 𝜎 is the surface charge density, 𝜖0 is the permittivity of vacuum, 𝜖𝑟 is the relative 
permittivity of water, R is the gas constant, 𝐶𝑖 is the molar concentration of the ith 
electrolyte in the bulk solution, 𝑍𝑖 is the signed charge number of that electrolyte, 𝐹 is the 
Faraday constant and Φ0 is the surface potential in volts. 
Based on the number of moles bound per mole of lipid and the surface area of the 
phospholipids, 𝜎 was calculated and then using eq. 3.4 the surface potential, Φ0, was 
calculated. The apparent partition coefficient at infinite dilution 𝐾𝑝
𝑎𝑝𝑝 𝑤𝑎s calculated 
from observed 𝐾𝑝𝑜𝑏𝑠 by the following equation, 
𝐾𝑝
𝑎𝑝𝑝 = 𝐾𝑝𝑜𝑏𝑠 exp �−𝑍𝐷𝐹Φ0𝑅𝑇 �               𝐸𝑞 3.5 
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where 𝑍𝐷 is the signed charge number of the drug. 
pH Dependence of the Partition Coefficient (for Dex-P) 
The apparent partition coefficient of Dex-P obtained at each pH value can be related to 
the concentrations of species 𝐷 (unionized),  𝐷− (monoanion) and 𝐷2−(dianion) (Figure 
3.1) in the membrane and aqueous phases as follows, 
𝐾𝑝
𝑎𝑝𝑝 = 𝐷𝑚 + 𝐷𝑚− + 𝐷𝑚2−
𝐷𝑤 + 𝐷𝑤− + 𝐷𝑤2−                𝐸𝑞 3.6 
𝐾𝑝
𝑎𝑝𝑝 = 𝐾𝑝1 + 𝐾𝑝2𝐾𝑎1 𝐻+⁄ + 𝐾𝑝3𝐾𝑎1𝐾𝑎2 (𝐻+)2⁄1 + 𝐾𝑎1 𝐻+⁄ + 𝐾𝑎1𝐾𝑎2 (𝐻+)2⁄              𝐸𝑞 3.7 
where the subscripts m and w refer to the membrane and aqueous phases, respectively, 
𝐾𝑎1 and 𝐾𝑎2 are the two ionization constants of Dex-P; and 𝐾𝑝1, 𝐾𝑝2 and 𝐾𝑝3 are the 
intrinsic partition coefficients of the three species 𝐷 , 𝐷− and 𝐷2−, respectively. Over the 
pH range of interest in this study (pH 1.5-8) the properties of the DMPC bilayer itself 
were assumed to be independent of pH because the intrinsic pKa of the 
phosphatidylcholine head group of 0.8 (140) is still well below pH 1.5. 
Bilayer Surface Density/ Free Surface Area 
The normalized surface density is a parameter related to relative acyl chain ordering in 
the bilayer.  It is defined as 𝜎 = 𝐴0/𝐴, where 𝐴 is the area occupied per phospholipid 
molecule and 𝐴0 is its area in the crystal (40.8 Å
2) (55, 121, 131). The normalized surface 
density varies from 0-1 with the value of 1 representing a completely ordered crystalline 
state. In the present study, the surface density values for the various liposome 
compositions were taken from a single compilation in the literature (131) and 
quantitatively related to the generated partitioning data.  
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Xiang and Anderson (131) related the surface density to the free surface area 𝑎𝑓𝑟𝑒𝑒 of the 
bilayer by the following equation: 
𝑎𝑓𝑟𝑒𝑒 = 𝐴 − 𝐴0 = 𝐴0(1 𝜎 − 1)                      𝐸𝑞 3.8⁄  
They showed that the free surface area (𝐴0/𝑎𝑓𝑟𝑒𝑒 = 𝜎/(1 − 𝜎)) served as a unified 
fundamental molecular packing parameter in lipid bilayers for describing the 
permeability of solutes across both liquid crystalline and gel phases of the bilayer. An 
observed  dependence of the lipid bilayer permeability coefficient on the inverse of free 
surface area was attributed, at least in part, to the sensitivity of solute partitioning into the 
interior hydrocarbon barrier domain of the bilayer to chain ordering as expressed by the 
following equation (131): 
𝐾𝑝 = 𝐾0exp (−𝑎∗ 𝑎𝑓𝑟𝑒𝑒)                            𝐸𝑞 3.9⁄  
𝐾𝑝 in Eq. 3.9 refers to the barrier domain/water partition coefficient, not the overall 
bilayer/water partition coefficient that is of interest in this study, and K0 is the partition 
coefficient for the same solute in a bulk solvent (e.g., a hydrocarbon) that was found to 
most closely mimick the chemical selectivity of the bilayer barrier domain and water.  
Xiang and Anderson (130) later examined the lipid bilayer permeability coefficients of a 
series of mono-carboxylic acids varying in the size of their alkyl portion to probe the 
dependence of bilayer transport on molecular size. When relative bilayer permeability 
coefficient measurements were ascribed to relative changes in apparent partitioning of the 
permeant into the barrier domain with increasing solute size, the quantity 𝑎∗ in Eq. 3.9 
was demonstrated to be proportional to the minimum cross-sectional area of the solute. 
Thus, sensitivity of lipid bilayer permeability coefficients to free surface area of the 
bilayer is a function of the permeant size.  
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A few previous studies of small molecule partitioning into lipid bilayers have revealed 
correlations between partition coefficients and the normalized surface density (55, 121, 
122).  However, the solutes employed in previous studies (i.e., hexane, benzene, and 
acetic acid) are hardly representative of typical drug molecules either in terms of their 
size or complexity.  Herein, whether or not a dependence of the partition coefficient on 
bilayer free surface area is a more general phenomenon applicable to a broader array of 
drug molecules was examined. 
RESULTS 
Liposome Characterization  
Blank liposomes of DMPC, DPPC and DSPC, prepared for partitioning studies, had the 
particle size in the range of 85-100 nm, with a polydispersity index in the range of 0.05-
0.09, indicating monodisperse formulations. The extrusion procedure employed in this 
study was previously shown by 31P-NMR to produce unilamellar vesicles (141).  
A simple analytical method using gradient HPLC and ELSD for evaluation of lipid 
concentration was developed for three different lipids DMPC, DPPC and DSPC. Figure 
3.2 shows the chromatograms of the three lipids with retention times for DSPC, DPPC 
and DMPC being 7.9, 8.0 and 8.2 min, respectively. Lipid concentrations were 
determined from log-log plots of peak area versus concentration which were linear over 
the concentration ranges of 150-800 µM for DMPC, 100-400 µM for DPPC, and 150-400 
µM for DSPC.  
Lipid concentrations in the liposomal samples were analyzed prior to equilibrium dialysis 
and used for calculation of volume based partition coefficients. The analyzed lipid 
concentrations were typically 25-35% lower than the theoretical concentrations indicating  
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Figure 3.2 Representative chromatograms of DPPC, DMPC and DSPC obtained by 
HPLC with ELSD (Evaporative Light Scattering Detection) detection. 
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some lipid loss during the extrusion process. This highlights the necessity for analyzing 
the lipid concentration in order to obtain reliable partition coefficient values rather than 
just assuming no lipid loss. In order to assess lipid stability during the time required for 
equilibration (48 hr), lipid concentrations were analyzed versus time for up to 72 hr in 
representative experiments in DMPC liposomes (Dex-P) at pH 1.5 and 6 (Figure 3.3). No 
significant change was observed in lipid concentration as judged by the 95% confidence 
interval of the slope from a first-order fit at pH 6. However, some degradation of the lipid 
was detected at pH 1.5, with a first-order rate constant of 0.006±0.0003 h-1 corresponding 
to a half-life of 115 ± 5 hr, consistent with previous evidence that phospholipid 
hydrolysis is acid catalyzed (142, 143). Importantly, no change in partition coefficients 
was discernible with time after equilibration indicating that a small percentage of lipid 
hydrolysis did not alter the lipid volume within the liposomes or the membrane affinity 
for the solute.  
Membrane-Water Partition Coefficients 
Dexamethasone 
The membrane-water partition coefficient of Dex in DMPC, DPPC and DSPC liposomes 
at 25 °C was determined at varying lipid concentrations by two different methods – 
equilibrium dialysis and equilibrium solubility. In the equilibrium dialysis experiments, 
the total drug concentrations were kept low and approximately constant with increasing 
lipid concentration (drug to lipid ratios varied from 0.0006 to 0.0052) to determine the 
partition coefficient in the linear region of binding isotherm (Figure 3.4). The bound drug 
to lipid ratios increased linearly with increasing unbound drug concentration (Figure 3.4 
inset) and the partition coefficients (705 ± 24 in DMPC, 106 ± 11 in DPPC and 58 ± 9 in  
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Figure 3.3 Fraction of DMPC remaining vs. time during equilibrium dialysis experiments 
at pH 1.5 and 6. Each data point is the average of five different concentrations and the 
error bars are the standard deviations. 
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Figure 3.4 DMPC, DPPC and DSPC membrane-water partition coefficients of Dex in 
PBS buffer at pH 7.4 as a function of lipid concentration determined by equilibrium 
dialysis at 25 °C. Inset shows the corresponding binding isotherms. 
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DSPC liposomes) were constant in the lipid concentration range studied. In the 
equilibrium solubility method, excess solid Dex was equilibrated with liposomes 
resulting in linear increases in solubility as a function of lipid concentration for DMPC, 
DPPC and DSPC liposomes (Figure 3.5). The membrane-water partition coefficients 
determined from the equilibrium solubility method were also independent of the lipid 
concentration (Figure 3.5 inset).  
Partition coefficients of Dex in all three lipid systems determined by the equilibrium 
dialysis and solubility methods were combined in Figure 3.6 to examine the effect of 
drug-to-lipid ratio on the partition coefficient, since the drug-to-lipid ratios at equilibrium 
were significantly higher in the equilibrium solubility method relative to the equilibrium 
dialysis method. In DPPC and DSPC liposomes, no significant differences in partition 
coefficients were observed at low vs high drug/lipid ratios as judged by the overlap of 
95% confidence intervals for the average values from two methods. However, the drug-
to-lipid ratios for Dex in DMPC liposomes were substantially higher for the equilibrium 
solubility method (~0.07) than those employed in equilibrium dialysis (<0.01), and in this 
case the partition coefficients differed significantly between the two methods.   
The dependence of the partition coefficients on temperature was determined in DPPC 
liposomes using the equilibrium dialysis method, as shown in Figure 3.7. Partition 
coefficients increased with temperature, varying from 106 ± 11 at 25 °C to 478 ± 20 at 45 
°C (Figure 3.7A). Linear binding isotherms were observed (Figure 3.7A inset) in all 
cases, indicating that the partition coefficients represent the infinitely dilute region. The 
slope of a linear least squares fit of the van’t Hoff plot shown in Figure 3.7B yielded the  
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Figure 3.5 Relationship between total equilibrium solubility of Dex and the lipid 
concentration in DMPC, DPPC, and DSPC liposomes at 25 °C. Inset shows the effect of 
lipid concentration on the partition coefficients. 
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Figure 3.6 DMPC, DPPC and DSPC liposomal membrane-water partition coefficients of 
Dex at 25 °C vs. the bound drug-to-lipid ratios. The partition coefficients at bound 
Dex/lipid ratios below 0.01 were obtained by equilibrium dialysis and those above 0.01 
were obtained by equilibrium solubility. 
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molar enthalpy (ΔH°=58.6 kJ/mol) and entropy of transfer (ΔS°=235.1 J/mol.K) of Dex 
from water to DPPC liposomes.  
Dexamethasone Phosphate 
The 21-phosphate prodrug of Dex is ionizable and therefore partition coefficients of Dex-
P were generated in DMPC liposomes at 25 °C as a function of aqueous solution pH from 
1.5-8.0 to study the species dependence of its partitioning behavior. The partition 
coefficients generated at a fixed concentration of Dex-P and at various pH values are 
plotted versus lipid concentration in Figure 3.8. At pH 1.5 and 2, systemic increases in 
the partition coefficients with increasing lipid concentration are evident. In this pH 
region, neutral Dex-P is the predominant bound species present because, although the 
first pKa of Dex-P is 1.9 (133), preferential binding of the neutral species relative to the 
monoanion results in a pKa shift for the membrane bound drug of approximately one 
unit. The binding isotherms (drug/lipid (mol/mol) ratio versus unbound drug 
concentration) for the data at pH 1.5 and 2 displayed in the inset to Figure 3.8 suggest 
that membrane saturation may have been responsible for the decreasing partition 
coefficients with increasing unbound drug concentrations that accompany a decrease in 
liposome concentration. The solid lines in Figure 3.8 (inset) represent fits of the data at 
pH 1.5 and 2 to Eq. 3.3.  𝐾𝑝
𝑎𝑝𝑝, respresenting the partition coefficient at infinite dilution 
at the solution pH of interest, could be obtained from the linear portion of these fitted 
lines. 
The partition coefficients at pH 4-6 are nearly constant with increases in lipid 
concentration (Figure 3.8), though a slight upward drift is discernible at pH 4. In this pH 
region, the predominant membrane bound species is Dex-P monoanion. This conclusion  
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Figure 3.7 (A) Influence of lipid concentration on the DPPC membrane-water partition 
coefficients of Dex at different temperatures. Inset shows the corresponding binding 
isotherms.  (B) Van`t Hoff plot of the DPPC membrane-water partition coefficients for 
Dex. 
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Figure 3.8 Effect of lipid concentration on the apparent DMPC membrane-water partition 
coefficients of Dex-P at different pH values (25 °C). Inset shows the binding isotherms 
(bound drug/lipid ratio versus unbound aqueous drug conc.) for data at pH 1.5, 2, 4, 5 and 
6. The solid curves at pH 1.5 and 2 represent non-linear least-squares fits of the data to 
Eq. 3.  Data at pH 4, 5 and 6 were corrected using the Gouy-Chapman equation (Eq. 5). 
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is based on the experimentally determined pKa2 value for Dex-P of 6.27 ± 0.13 (pH 
solubility method, our unpublished data) in aqueous solution combined with the 
observation in Figure 3.8 that the partition coefficient for Dex-P at pH 8 is not 
significantly different from zero indicating that the concentration of Dex-P dianion in the 
membrane between pH 4-6 should be negligible. Anion partitioning to neutral 
phospholipid membranes imparts a negative charge to the membrane that increases with 
the bound drug/lipid ratio. Typically, the Gouy-Chapman theory can be employed to 
correct for the effects of charge repulsion on the activity coefficient of the membrane 
bound anion in order to obtain a partition coefficient at infinite dilution (134-139). Such a 
correction, as described in Eqs. 4 & 5, was applied to the monoanion partitioning data at 
pH 4-6 resulting in the plots of drug/lipid ratio versus unbound drug concentration shown 
in the Figure 3.8 inset. 
After the appropriate corrections, 𝐾𝑝
𝑎𝑝𝑝 values for each pH applicable at infinite dilution 
were obtained and plotted in Figure 3.9. These data were fit to Eq. 3.7 by nonlinear 
regression to generate the solid curve shown. For this analysis, pKa1 and pKa2 were fixed 
at their previously determined solution values of 1.9 and 6.27, respectively, and the 
partition coefficient for Dex-P dianion was assumed to be equal to zero. The partition 
coefficient for the neutral species was estimated to be 241 ± 38 (95% C.I.) and for the 
monoanion, it was 48 ± 9 (95% C.I). 
Membrane water partition coefficients of Dex-P (at pH 4) were determined in DMPC, 
DPPC and DSPC liposomes as a function of lipid concentration by equilibrium dialysis 
(25 °C) as shown in Figure 3.10. The highest partitioning was observed in DMPC  
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Figure 3.9 Effect of pH on apparent partition coefficients of Dex-P in DMPC liposomes. 
The solid curve represents the best fit of Eq. 7 to the data by nonlinear least-squares 
regression analysis. 
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Figure 3.10 DMPC, DPPC and DSPC liposomal membrane-water partition coefficients of 
Dex-P at pH 4 and 25 °C determined by equilibrium dialysis versus lipid concentration. 
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liposomes (62 ± 8 in DMPC (after Gouy-Chapman correction) while the values were 
dramatically lower in DPPC (2 ± 4) and DSPC liposomes (6 ± 2).  
Effect of Bilayer Free Surface Area on Membrane-Water Partition Coefficients 
The membrane water partition coefficients were significantly higher in DMPC liposomes 
as compared to DPPC and DSPC liposomes for both Dex and Dex-P (at pH 4).  At 25 °C 
DMPC, with a gel->liquid crystalline phase transition, Tm, of 23 °C is liquid crystalline 
while both DPPC (Tm=41 °C) and DSPC (Tm=55 °C) are in their gel states. Therefore, 
the acyl chain region in DPPC and DSPC bilayers is more highly ordered at 25 °C in 
comparison to those in DMPC. To quantitatively probe the dependence of the partition 
coefficient on the degree of bilayer chain ordering, the natural logarithms of the partition 
coefficients (Kp) are plotted versus the inverse of free surface area as suggested by Eq. 
3.9. For Dex, a linear relationship was observed between 𝑙𝑛(𝐾𝑝) and free surface area of 
the bilayer ( 1 𝑎𝑓𝑟𝑒𝑒⁄ = 𝜎/(1 − 𝜎) ) as illustrated in Figure 3.11. In one of the 
partitioning system (Dex in DPPC liposomes), the free surface area of the bilayer was 
altered by varying the temperature from 25 °C to 45 °C, through phase transition 
temperature (41 °C) of DPPC. Figure 3.11 shows the combined data for Dex partition 
coefficients when free surface area was varied either by varying phospholipid chain 
length (DMPC, DPPC, and DSPC) or varying temperature (DPPC, 25-45 °C). The Dex-P 
partition coefficients at pH 4 appear to show a similar trend though the number of data 
points and poor precision of the values in DPPC and DSPC do not allow one to assess 
linearity. There are numerous studies in the literature that have reported lipid 
bilayer/water partition coefficients of various solutes in similar fully saturated  
 
 48 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Natural logarithms of the liposomal membrane-water partition coefficients of 
Dex and Dex-P versus the inverse of the bilayer free surface area, a measure of chain 
ordering as altered by phospholipid chain length and temperature.  
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phospholipids as a function of either phospholipid chain length or temperature. Some 
representative examples taken from the literature (55, 141, 144-146) conducted in 
liposomal systems for which surface density data were available from the same source 
used in the present study (131) are plotted in Figure 3.12 along with the partition 
coefficients generated for Dex and Dex-P in the present study versus the inverse of free 
surface area. In all cases explored, a similar trend of decreasing partition coefficient 
versus the inverse of bilayer free surface area was found with slopes in the plots of ln 
(Kp) vs.1/afree (see Figure 3.12 legend) varying over a narrow range of approximately -0.2 
to -0.3.   
DISCUSSION 
Liposomal partitioning studies appear to offer clear advantages in predicting the 
biodistribution of drugs because ordered lipid bilayers more accurately mimic biological 
membranes than bulk solvents. These advantages are particularly apparent for ionizable 
compounds (111, 112, 114). Additionally, a quantitative understanding of liposomal 
partitioning is essential for designing liposomal drug delivery systems with predictable 
loading and tunable release characteristics (126, 127, 132, 147). However, the interfacial 
nature of lipid bilayers adds complexity both in terms of generating reliable experimental 
data and in interpreting the values obtained. Proper correction for surface charge effects 
on binding of ionized species (134) and saturation phenomena for neutral species (138, 
148) may be necessary with increasing drug concentration. For ionizable drug molecules, 
quantitative mathematical models describing the contributions of neutral and ionized drug 
species are needed to account for the pH dependence of membrane partitioning. Finally, 
the experimental partitioning system employed in terms of liposome composition (e.g.,  
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 Figure 3.12 Natural logarithms of membrane-partition coefficients for various solutes 
versus the inverse of free surface area (1/afree). 
Key: hexane (55) (○,slope=-0.28); 17-β-estradiol (149) (◊,slope=-0.34); Dex (♦,slope=-
0.22); hydrocortisone acetate (145) (✳,slope=-0.21); sulfamethoxazole (144) (◍,slope=-
0.21); Dex-P (●,slope=-0.24); sulfathiazole (144) (∆,slope=-0.17); and acetic acid (122) 
(□,slope=-0.26). (The partition coefficient values are in mole fraction for hexane and in 
molarity for the other solutes).  
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head group, acyl chain length, degree of unsaturation, presence of cholesterol, etc.), size 
and lamellarity, temperature, and the like can be significant factors in determining the 
results obtained. Presently, a different LFER equation is required for each lipid system 
(146), highlighting the need for unifying relationships that could quantitatively predict 
membrane-water partitioning from a knowledge of drug structure, membrane 
composition, and the environmental conditions.  
Some of the pioneering work on bilayer/water partitioning has revealed that factors such 
as decreasing the temperature below the phase transition temperature, inclusion of 
cholesterol in the bilayer, or elongating the phospholipid chain length cause decreases in 
partition coefficients that can be correlated with order parameters such as surface density 
of the bilayer chains (55, 121) or free surface area of the bilayer (122). The solutes 
typically employed in these studies have been simple, small molecules such as benzene, 
hexane, and acetic acid. Whether or not such relationships exist for larger and more 
structurally complex drug molecules has not been established. The present study of the 
partitioning behavior of Dex and Dex-P provides an opportunity to begin to explore the 
hypothesis that the bilayer free surface area is a “universal” variable useful in relating 
membrane-water partition coefficients to bilayer composition.   
Factors Governing the Membrane-Water Partition Coefficient  
Drug Concentration & Drug-to-Lipid Ratio 
An important factor in the determination of reliable membrane-water partition 
coefficients is the bound drug-to-lipid ratio at equilibrium. As noted by De Young and 
Dill, it is very important to extrapolate partitioning data to infinite dilution for their 
proper interpretation. Unlike adsorption to solids that might be construed as having a 
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fixed number of binding sites, solute binding to bilayer membranes may involve partial or 
complete insertion into the membrane with accompanying changes in both bilayer surface 
area and the chemical nature of the surface, with an increase in the bound drug/lipid ratio. 
These alterations with increasing solute uptake may lead to either increases or decreases 
in the apparent partition coefficient with drug concentration (121, 136, 150, 151). 
Alternatively, self-association of drug molecules with each other at high aqueous drug 
concentrations may reduce the activity of the free available drug for the partitioning 
(152). 
The importance of determining partition coefficients at concentrations approaching 
infinite dilution is evident from the difference in the partition coefficients obtained for 
Dex from the two different methods employed in this study. In the equilibrium dialysis 
method, the drug-to-lipid ratio could be varied with values approaching infinite dilution 
(~0.001) (Figure 3.4 inset) whereas in the equilibrium solubility method, the drug to lipid 
ratio in DMPC was constant at 0.07 (±0.004) even with varying lipid concentration as 
dictated by the equilibrium solubility of Dex and the DMPC-water partition coefficient. 
The equilibrium solubility method could not be used to probe DMPC partitioning in a 
concentration region approaching infinite dilution and therefore the values obtained using 
this method differed from those obtained by equilibrium dialysis (Figure 3.6).  This was 
not the case for Dex partitioning in DPPC and DSPC where the drug-to-lipid ratios at 
equilibrium were <0.02 using the solubility method. For DPPC and DSPC, the partition 
coefficients were the same by either method.  
While generally higher drug-to-lipid ratios are possible for neutral molecules in 
comparison to ionized compounds before deviations from linearity in sorption isotherms 
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become apparent, the borderline appears to vary with the compound and lipid. Escher 
found no deviations from linearity in neutral compound sorption isotherms up to drug-to-
lipid ratios of 0.1 (116) while Austin et al. suggested that the ratio of lipid to bound 
neutral compound should be greater than 60 (111) which would translate to a drug-to-
lipid ratio of <0.017. As noted above, a significant deviation was found in the partition 
coefficient for Dex at a drug-to-lipid ratio of 0.07 but using equilibrium dialysis at drug-
to-lipid ratios <0.007 the partition coefficients were independent of drug-to-lipid ratio 
(Figure 3.4 & 3.7 insets).  
Deviations in the sorption isotherms for Dex-P at pH conditions where the bound drug is 
neutral were clearly evident at drug-to-lipid ratios above 0.04. Eq. 3.3 was therefore used 
to extrapolate these results to infinite dilution. Langmuir-type adsorption models are 
commonly employed to account for saturation effects in membrane partitioning of drug 
molecules (153, 154). While the assumption of a fixed number of binding sites may not 
accurately reflect the nature of the binding of molecules to flexible bilayer membranes, it 
might be justifiable for drugs that bind predominantly at the membrane surface (137). 
Changes in partitioning at high drug concentration are more likely due to changes in the 
membrane or in the affinity of the drug molecule for the modified membrane surface 
rather than a depletion of binding sites (136). However, at infinite dilution, partitioning 
and association models are equivalent.  
Sorption isotherms for ionized molecules become non-linear mainly because of the 
repulsive forces between the charged species upon membrane binding (134, 135, 137-
139, 148). Austin et al suggested that for ions also, a ratio of lipid to bound ion >60 
should be sufficient to render surface charge effects insignificant (111), although the 
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Gouy-Chapman theory can be used to correct for surface charge effects at higher drug 
concentrations (Figure 3.8 inset) (109, 116, 134, 135, 137, 138, 148, 155, 156).   
Temperature Dependence of Partition Coefficients  
The fundamental driving force for transfer of nonpolar solutes from water to a lipid 
environment is generally assumed to be the hydrophobic effect but specific solute 
interactions with the ordered bilayer structure modulate the overall thermodynamics of 
the process (157, 158). The dependence of the membrane-water partition coefficient of 
Dex was measured in DPPC liposomes as a function of temperature from 25-45 °C, a 
range that crosses the gel->liquid crystalline transition temperature of 41 °C. These 
results are displayed in the van’t Hoff plot in Figure 3.7B.  The standard free energy 
change (∆G°) upon transfer of Dex from water to DMPC liposomes was negative at all 
temperatures indicating an energetically favorable process, driven by a positive entropy 
(ΔH°=58.6 kJ/mol and ΔS°=235.1 J/mol.K). The thermodynamic parameters for the 
transfer of Dex compare reasonably well qualitatively with values reported elsewhere for 
corticosteroid transfer into DMPC bilayers both above and below its Tm, supporting the 
observations of an entropy driven process for the partitioning of steroids into saturated 
phospholipids (145, 159). One contribution to the positive entropy is that associated with 
the removal of the steroids from water (57, 159, 160).  
Kwon et al obtained the enthalpy and entropy changes for partitioning of several 
endocrine disruptors between water and liposomes formed from DOPC, POPC, DMPC, 
DPPC, and DSPC at temperatures ranging from 11 – 37°C (149). Over this temperature 
range DOPC and POPC liposomes are liquid crystalline and DPPC and DSPC liposomes 
are in a gel phase. DMPC undergoes a phase transition within the middle of this 
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temperature range at 23 °C.  Generally, they found negative enthalpies of solute transfer 
from water to liquid crystalline bilayers consisting of unsaturated lipids and positive 
enthalpies for the transfer of solutes from water to gel phase membranes composed of 
saturated phospholipids. Others have reported similar findings (161, 162). Such 
disparities illustrate the greater complexity of the membrane binding process relative to 
that for solute partitioning from water to bulk solvents. 
Xiang and Anderson (131) determined that apparent energies of activation for acetic acid 
permeability across liquid crystalline bilayer membranes increase in a dramatic fashion 
with increases in chain ordering, with an Ea value of only 13 kcal/mol in DLPC 
containing 20% cholesterol increasing to 20 kcal/mol in DMPC, and 37 kcal/mol in 
DPPC. The enthalpy of transfer of acetic acid from water to decane, a bulk solvent that 
mimics the chemical selectivity of phospholipid bilayers toward permeants, is only 4.8 
kcal/mol (122). Thus, the elevated apparent energies of activation for acetic acid transport 
were attributed largely to an increase in enthalpy for acetic acid insertion into the bilayer 
barrier domain (i.e., the ordered acyl chain bilayer interior) with increases in chain 
ordering. This unfavorable enthalpic contribution should be less important for solute 
partitioning in comparison to transbilayer permeation because most drug molecules are 
likely to be only partially inserted into the ordered chain region of the bilayer at 
equilibrium, but this factor may nevertheless contribute to the positive enthalpies 
generally observed for solute transfer from water into gel phase bilayers as observed by 
Kwon et al. and others (144, 149, 163). On the other hand, the liquid crystalline bilayers 
such as the DOPC and POPC systems explored by Kwon et al are highly disordered. For 
such systems, the enthalpy associated with partial solute insertion into the acyl chain 
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region likely consists of a small positive hydrophobic contribution that is often more than 
compensated for by the negative enthalpic contribution accompanying hydrogen bonding 
interactions or other electrostatic interactions between polar functional groups within the 
solute and polar phospholipid head groups. 
The thermodynamic driving force for the interaction may vary depending on the location 
of binding, nature and structure of the solute and physical state of the bilayer (149, 163). 
Removal of a hydrophobic solute from water and partitioning presumably into the 
hydrophobic core of the membranes is entropically driven. Whereas, if a drug is 
preferentially bound to the interface due to electrostatic interactions between the charged 
drug and phospholipid headgroups, favorable enthalpy may dominate over the entropy, 
example, cationic drugs have exothermic partitioning as compared to neutral (114). Thus, 
the relative contribution of entropy driven hydrophobic effect and enthalpy driven 
hydrophobic and electrostatic interaction between drug and membranes to the overall free 
energy of transfer will really determine the thermodynamic driving force.   
Structure-Partitioning Relationships – 21-Phosphate Group Contribution & Ionization 
As reported in Table 3.1, the Kp value for Dex at 25 °C varies from 705 ± 24 in liquid 
crystalline DMPC to 106 ± 11 in DPPC and 58 ± 9 in DSPC bilayers, both of which are 
in their gel state at room temperature.  These results illustrate the dramatic effect that 
simply changing the chain length of the phospholipid can have on the partition 
coefficient.  Given such differences, it is understandable that a different LFER equation is 
required for each lipid system (146).   
The contribution of the polar phosphate group at the 21-position of dexamethasone to the 
free energy of transfer from water to DMPC depends on its state of ionization. Fitting the 
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Kpapp vs. pH data in Figure 3.9 to the model described in Eq. 3.7 generated values of Kp 
for the neutral and monoanion forms of Dex-P of 241 ± 38 (95% C.I.) and 48 ± 9 (95% 
C.I.), respectively.  Comparing the neutral Kp values for Dex vs. Dex-P, phosphorylation 
of Dex reduces its partition coefficient by only 3-fold, giving a group contribution for the 
unionized phosphate residue to the transfer free energy from water to DMPC of only 
Δ(ΔG°) = 2.66 kJ/mol (0.64 kcal/mol).  Monoanion formation reduces Kp by another 5-
fold and dianion formation leads to a further decrease such that at pH 8, Kp is close to 
zero.     
Several reports indicate that amphiphilic molecules orient themselves at the interphase of 
bilayers such that charged or polar groups interact with lipid head groups while their non-
polar regions are embedded in the hydrocarbon region of the bilayer (119, 164-166). 
Vijayan et al. (166) conducted MD simulations of the location and orientation of 
cortisone, a corticosteroid similar in structure to Dex, in a model lipid bilayer. They 
observed that, unlike cholesterol which aligns itself approximately parallel to the bilayer 
chains, cortisone adopts an orientation that is nearly parallel to the bilayer surface such 
that its polar groups are able to maximize favorable contacts in the heterogeneous bilayer 
interface region. With the increase in charge and hydrogen bonding potential 
accompanying 21-phosphorylation, the molecule is likely pulled further towards the 
interface such that particularly the phosphate monoanion residue remains solvated by 
water.  The reduction in the partition coefficient reflects the greater amount of energy 
needed to break the hydrogen bonds and remove the hydrophobic portions of the solute 
from water (112, 167). 
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Effect of Bilayer Free Surface Area 
Unlike bulk solvents, lipid bilayers are interfacial phases having properties that depend 
on surface density or free surface area. The acyl chain in bilayers are more highly ordered 
near the headgroups and the order diminishes with distance towards the bilayer center 
(61). The free surface area and the length of the phospholipid acyl chains are the principal 
independent variables that determine the chain organization (55). We studied the effect of 
changes in free surface area by altering the phospholipid acyl chain lengths and by 
varying temperature. 
In the current study, DMPC was in liquid crystalline state at 25 °C, DPPC was in gel state 
at 25 and 37 °C and in liquid crystalline state at 45 °C and DSPC in a gel phase at 25 °C. 
Irrespective of the ordering mechanism (temperature or lipid composition), the partition 
coefficient of Dex was found to be negatively dependent on the inverse of free surface 
area (Figure 3.11).  A linear relationship was obtained between 𝑙𝑛(𝐾𝑝) and the inverse of 
free surface area (1/afree = σ/(1- σ)) for Dex (slope=-0.22).  Dex-P at pH 4.0 exhibited a 
similar dependence on free surface area with a similar slope (=-0.24). Dex-P, the prodrug 
of Dex having the same steroidal parent structure and differing only in the presence of a 
phosphate at the 21-position, is predominantly monoanionic at pH 4.0. The similarity in 
slopes indicates that the two molecules, one neutral and one anionic, have nearly equal 
sensitivities to bilayer chain ordering as quantified by the free surface area parameter. 
There are numerous reports in the literature of decreases in membrane partition 
coefficients of various solutes with increases in alkyl chain length of the phospholipids, 
changes in the degree of chain unsaturation, decreases in temperature, or incorporation of 
cholesterol into liquid crystalline bilayers (55, 121, 122, 145, 146, 151). Yamamoto and 
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Liljestrand (146) observed a 20-fold decline in the room temperature partition coefficient 
of estradiol when the liposome composition was changed from POPC to DPPC. This 
substantial effect of lipid composition on solute partitioning was attributed to the 
influence of chain saturation on the main transition temperature. At room temperature 
POPC liposomes exist as a liquid crystalline phase while DPPC is in a gel phase. 
The lattice theory developed by Marqusee and Dill (108) suggests that solute partitioning 
will decrease with increasing surface density due to the increasingly unfavorable entropy 
associated with solute insertion as orientational ordering of the phospholipid chains is 
increased. Experimentally, correlations have been observed between the partition 
coefficient for small molecules (hexane, benzene and acetic acid) and surface density of 
the lipid bilayer (55, 121, 122). Xiang and Anderson combined statistical mechanical 
theory with molecular dynamic simulation to show that the lateral pressure in a bilayer 
increases steeply with surface density and that increased lateral pressure results in higher 
local order and exclusion of solutes from the interphase (110). In other words, increased 
chain-chain interaction at higher chain density inhibits solute incorporation (146, 151, 
152, 168). 
These results suggest that solute exclusion accompanies chain ordering but the magnitude 
of the effect may be solute dependent. To explore whether a general, quantitative 
relationship can be found between bilayer chain ordering and membrane-water partition 
coefficients, the natural logarithms of the bilayer-water partition coefficients of several 
drugs from studies published by other labs against the inverse of free surface area, 1/afree 
was plotted in Figure 3.12. These studies employed similar phospholipids as those in the 
present study. The average of the slopes was -0.26 with a 95% confidence interval of -
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0.22 to -0.29, emphasizing the negative relationship between the partition coefficient and 
inverse of free surface area of the bilayers. 
Xiang and Anderson (131) previously determined both partition coefficients and 
permeability coefficients for acetic acid as a function of surface density. A slope of -0.26 
for the natural logarithm of the partition coefficient of acetic acid versus the inverse of 
free surface area was found in Figure 3.12 which compares to a much steeper slope (-
0.71) when their permeability data for acetic acid are plotted in the same manner, a 2.7-
fold difference. This is attributed to the requirement for passage of the solute across the 
bilayer barrier region for permeation whereas partitioning involves only partial insertion 
into the interfacial region of the bilayer for acetic acid (122, 131). In all cases, there is a 
dependence of the partitioning on the available free surface area, as demonstrated by 
Figure 3.12 for several different solutes varying in size and chemical properties. 
Generally, drug molecules having both polar and hydrophobic residues may bind in the 
interfacial region of bilayers with only portions of their structures embedded into the 
ordered alkyl chain region depending on their lipophilicity. The similarity of the slopes 
obtained for all of the representative solutes illustrated in Figure 3.12 suggests that the 
dependence of partitioning on chain ordering is not highly sensitive to either the overall 
size or chemical structure of the solute. The relatively uniform but modest dependence of 
membrane binding on bilayer free surface area may reflect the availability of 
hydrophobic surface area on the membrane, which is the surface property that increases 
with an increase in free surface area. While the above relationship appears to be valid for 
partitioning to a sub-set of bilayers composed of saturated phospholipids both above and 
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below their phase transition temperatures, further studies in a more diverse set of 
membranes are necessary to determine the universality of this relationship. 
CONCLUSIONS 
The partition coefficient of a drug in bilayer is dependent upon several factors such as the 
bound drug-to-lipid ratio, pH, temperature, membrane composition, etc. Appropriate 
corrections for neutral and ionized species at high concentrations are required in order to 
determine a reliable partition coefficient value (at infinite dilution). The membrane-water 
partition coefficient of Dex at infinite dilution was studied in liposomes of varying 
composition. Increasing the negative charge of Dex-P gradually reduced the partition 
coefficient, ultimately overcoming the hydrophobic contribution to membrane insertion 
provided by the steroid rings. In order to explore the possible existence of a relationship 
between membrane-water partition coefficients and bilayer chain ordering, the partition 
coefficients were related to the inverse of bilayer free surface area. For both, Dex and 
Dex-P, the natural logarithms of the partition coefficients in liposomes decreased linearly 
with the inverse of free surface area in the bilayer as modulated by increasing 
phospholipid chain length or decreasing temperature. Inclusion of membrane partitioning 
data in saturated lipid systems for other solutes from the literature, showed a similar 
dependence on the free surface area. These results may be useful in the development of 
more comprehensive quantitative models relating membrane-water partition coefficients 
of drug molecules to bilayer properties.  
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CHAPTER FOUR 
Determination of Drug Release Kinetics from Nanoparticles: Overcoming Pitfalls of 
the Dynamic Dialysis Method 
INTRODUCTION 
Interest in nanoparticle drug delivery systems has grown dramatically in recent years due 
to their manifold potential applications in solubilizing poorly soluble drug candidates, 
reducing drug toxicity, prolonging circulation times, controlling drug release kinetics, 
drug targeting, and monitoring drug delivery to enhance therapeutic efficacy (1-3, 169-
171). Nanoparticles have been particularly attractive in cancer because of their passive 
targeting potential through the enhanced permeability and retention (EPR) effect (172-
174) and the perception that with the right size, shape, and cell surface properties, 
nanoparticles can circulate systemically for a prolonged period, accumulate in tumor 
tissue and release drug locally to cancer cells (20, 45, 175, 176). To maximize the 
effectiveness of nanoparticle targeting, drug release from nanoparticles needs to be slow 
enough to avoid substantial drug loss before the carrier reaches the site of action thereby 
reducing toxicity (177, 178). After nanoparticle accumulation at the target site, 
optimizing efficacy will require tunability of the drug release rate (51, 52, 126). Thus, the 
kinetics of drug release from nanoparticles should be an essential feature of their design 
and a property monitored for the quality control of nanoparticle formulations.  Reliable 
determination of in vitro release kinetics is also a prerequisite for establishing in vitro - in 
vivo correlations which in turn define the formulation performance in vivo. 
Dynamic dialysis is one of the most commonly used methods for the determination of 
release kinetics from nanoparticles. Very recently, Zambito et al. pointed out that out of 
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90 literature reports on in vitro drug release from nanoparticles surveyed in the year 
2011, nearly 40 used dynamic dialysis to measure the release kinetics (70). The reason 
for the popularity of dynamic dialysis over other methods (e.g., ultracentrifugation and 
ultrafiltration) is that the additional step of separating nanoparticles from the free drug at 
various time points during the kinetic study is eliminated. The external pressure applied 
for separation in other methods can disturb the equilibrium and incomplete separation can 
lead to significant measurement errors (68, 179). 
In dynamic dialysis, the appearance of drug in the “sink” receiver compartment is the 
result of diffusion from the nanoparticles followed by diffusion across the dialysis 
membrane, though it is generally treated as a simple first-order process. Experimentally, 
either disappearance of drug from the donor compartment containing the nanoparticles or 
appearance in the receiver compartment can be measured. Because the apparent release 
rate is the net result of drug transport across two barriers in series, the rate constant 
obtained may not necessarily reflect the rate of drug release from the nanoparticles. Both, 
the barrier properties of the dialysis membrane and the driving force for drug transport 
across that membrane must be considered. The latter quantity, the driving force, is not the 
total drug concentration in the nanoparticle dispersion but the free aqueous drug 
concentration, a quantity that is of critical importance but never measured directly.  
Therefore, assessment of the reliability of rate constants determined by dynamic dialysis 
demands a careful consideration of the pitfalls in interpreting apparent release data. 
Some authors have recognized the potential sources of error in data generated using 
dynamic dialysis for the determination of release rates from nanoparticles.  As mentioned 
above, the inherent barrier properties of the dialysis membrane itself may impose a limit 
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on the rate constant of release from nanoparticles that can be measured (180, 181). Others 
have highlighted the issue of drug partitioning between the phases present in dispersed 
systems and their influence on the driving force for drug transport across the dialysis 
membrane (70, 182-184). Reversible drug binding to the nanocarrier reduces the driving 
force governing drug transport across the dialysis membrane which may alter the overall 
apparent rate of release.  Currently, there is not only a lack of general agreement on the 
reliability of the dynamic dialysis method, but also uncertainty as to the lower limit of 
nanoparticle release half-lives that can be accurately determined using this method. 
In this paper, the practical limitations of the commonly used dynamic dialysis method for 
determination of apparent release kinetics was highlighted along with the value of using 
mechanism-based models both to obtain the actual rate constant for nanoparticle release 
and to estimate its level of certainty.  The experiments utilize liposomes as representative 
nanocarriers and two model hydrophobic drugs, one of which is ionizable. A 
comprehensive analysis of the interplay of the critical factors (membrane/water partition 
coefficient, lipid concentration, and liposomal and dialysis membrane permeability 
coefficients) that govern the apparent release kinetics illustrates the potential pitfalls 
underlying this method. The mathematical models and their utility in extracting reliable 
rate constants for drug release are demonstrated in cases where drug binding effects 
and/or dialysis membrane transport may be partially contributing to the apparent release 
kinetics. There are situations where dynamic dialysis can be safely used with simple first-
order treatment of the data and situations requiring detailed, mechanistic modeling of the 
data. 
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MATERIALS AND METHODS 
AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) was provided by Novartis 
Pharmaceuticals Corporation (East Hanover, NJ). Dexamethasone (Dex) (≥98%, powder) 
was purchased from Sigma-Aldrich Co., St. Louis, MO. Lipids ( DSPC (1,2-distearoyl-
sn-glycero-3-phosphatidylcholine, >99% purity), DPPC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, >99% purity), DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine, 
>99% purity), m-PEG DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy (polyethylene glycol)-2000]), m-PEG DPPE (1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) and m-PEG DMPE (1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000])) were purchased as powders from Avanti Polar Lipids (Alabaster, AL). 
Sephadex® pre-packed (PD-10) size exclusion columns (GE Healthcare Bio-sciences 
Corporation (Piscataway, NJ)), containing about 8.3 ml of Sephadex G-25 M medium, 
were used for separation of free drug from encapsulated. Dialysis tubes (Float-A-Lyzer®, 
MWCO (Molecular Weight Cut Off): 100 kD) of 1 and 5 ml volumes were purchased 
from Spectrum Laboratories (Rancho Dominguez, CA). HPLC grade solvents and other 
chemicals were purchased from Fisher Scientific (Florence, KY). Deionized water was 
used for all experiments. 
Liposome Preparation 
Blank and drug loaded liposomes were prepared based on a previously reported method 
(127). Briefly, DMPC: mPEG DMPE, DPPC: mPEG DPPE and DSPC: mPEG-DSPE 
(95:5 mol%, 120 mg) were separately dissolved in about 2 ml of chloroform. The solvent 
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was evaporated under a stream of nitrogen and the resulting film was dried overnight in a 
vacuum oven.  
AR-67 loaded liposomes 
Drug loaded DSPC: mPEG-DSPE liposomes were prepared at pH 4.2 and 9.5.  Blank 
liposomes at pH 4.2 were prepared by hydrating the dried lipid film in 85 mM acetate 
buffer (pH 4.2). Drug loading at pH 4.2 was accomplished by adding 10 µl of an AR-67 
stock solution in DMSO (~80 µM) to 2 ml of blank liposomes and incubating at 60°C for 
about 2 hours. Drug loading at pH 9.5 was carried out by hydrating the dried lipid film in 
2 ml of 100 mM borate buffer (pH 9.5) containing AR-67 (1.2 µM) by alternate vortexing 
and heating at 60°C. In all cases, the lipid suspensions were then extruded 10 times 
through two stacked 200 nm polycarbonate membranes (GE water and Process 
Technologies, Trevose, PA) using an extrusion device (Liposofast®, Avestin, Canada) at 
60°C to obtain unilamellar liposomes. 
Dexamethasone loaded liposomes 
Blank DMPC, DPPC and DSPC liposomes were prepared by hydrating the dried lipid 
films in 2 ml of phosphate buffered saline (PBS, pH 7.4). Dexamethasone loaded 
liposomes were prepared by hydrating the dried lipid films in 2 ml of a PBS solution of 
dexamethasone (~0.05-0.06 mg/ml) to give a lipid concentration of 60 mg/ml.  The 
suspensions were alternately vortexed and heated in a water bath to temperatures above 
the phase transition temperature of the respective lipid to uniformly suspend the lipid. 
The lipid suspensions were then extruded 10 times through two stacked 100 nm 
polycarbonate membranes using the extrusion device at 30°C, 50°C and 60°C for DMPC, 
DPPC and DSPC, respectively, to obtain unilamellar liposomes.  
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Blank and drug (AR-67 and Dex) loaded liposomes were allowed to cool to room 
temperature for 3 hours and stored at 4°C until further use. Particle sizes of the liposomes 
were measured by dynamic light scattering (DLS) using a Delsa™ Nano submicron 
particle size analyzer (Beckman Coulter Inc., Brea, CA) at 25°C. The liposomes were 
diluted in the same buffer as that used in their preparation. 
Dynamic Dialysis Experiments  
All drug loaded liposome suspensions were passed through a Sephadex® G25 column 
pre-equilibrated in the same buffer as that used in the preparation of liposomes in an 
attempt to separate free from entrapped drug. Aliquots (0.1-0.5 ml) of the drug loaded 
liposome suspensions were applied to the top of a Sephadex column and eluted with the 
same buffer as that used in the preparation in the increments of 1 ml. The eluent fraction 
containing liposomes was collected between 2.5 to 5 and analyzed for drug and lipid 
concentration. The residual extravesicular membrane bound fraction was determined 
from model fitting (vide infra). The eluent fraction containing drug loaded liposomes was 
diluted (if needed) in the same buffer to obtain a desired lipid concentration and 
introduced into the dialysis tube.  
AR-67 loaded liposome suspensions were diluted to a lipid concentration of about 0.48 
mg/ml before placing in the dialysis tube. Total drug concentration in the dialysis tube 
was monitored versus time for pH 4.2 drug loaded liposomes and blank liposomes spiked 
with drug (~75 nM) at 37°C after immersion in 1 L of acetate buffer (85 mM, pH 4.2) to 
provide sink conditions in the receiver solution. Dialysis experiments for drug loaded 
liposomes at pH 9.5 were conducted similarly after immersion of the dialysis tube in 1L 
of borate buffer (100 mM, pH 9.5). Aliquots (50 µl) withdrawn from inside the dialysis 
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tube at different time points were diluted with cold (−25 °C) 2:1 v/v methanol: 
acetonitrile and analyzed by HPLC. 
Dynamic dialysis experiments for Dex loaded liposomes were conducted at high (~12-15 
mg/ml) and low lipid concentrations (~4-5 mg/ml). Total drug concentration in the 
dialysis tube was monitored versus time after immersed in 1 L of PBS.  Similar 
experiments were conducted using blank liposomes spiked with Dex (~20 µM for low 
and ~50 µM for high lipid concentration) and free Dex solution (100 µM) at 25°C. 
Dedicated dialysis tube was used for drug loaded, spiked and free drug profile in a 
particular lipid system in order to eliminate variability introduced by dialysis tubes. 
Aliquots (10-100 µl) withdrawn from inside the dialysis tube at various time points were 
diluted with an appropriate volume of methanol and analyzed by HPLC. 
Drug Analyses 
AR-67 
Samples from release experiments were analyzed using a previously developed and 
validated isocratic high performance liquid chromatography (HPLC) method with 
fluorescence detection (126, 127). Both, lactone and carboxylate were monitored at pH 
4.2 and 9.5. A Waters Alliance 2695 Separations Module coupled to a Waters Scanning 
Fluorescence Detector (M474) was employed with excitation and emission wavelengths 
at 380 and 560 nm, respectively. A Waters Symmetry® C18 column (5 µm, 3.9 X 150 
mm) and guard column (3.9 X 20 mm) were used with a mobile phase composition of 
48% acetonitrile and 52% (v/v) pH 5.5 triethylamine acetate (2%) buffer. Standards for 
AR-67 carboxylate (0.2-2 µM) were prepared in 10 mM sodium carbonate buffer (pH 
10.4) and standards for AR-67 lactone (0.5-2.5 µM) were prepared in acidified methanol. 
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The retention times at an injection volume of 10 µl and a flow rate of 1 ml/min were 1.7 
and 5.9 min for AR-67 carboxylate and lactone, respectively. 
Dexamethasone 
Samples from liposome release studies and partitioning experiments were analyzed using 
an isocratic HPLC method with UV detection. Four independent standards of 
dexamethasone (50-800 µM) in methanol were prepared and the relative standard 
deviation for the response factor was less than 3%. A Waters Alliance 2695 Separations 
Module coupled to a UV detector (Waters 996, Photodiode Array Detector) was 
employed at a wavelength of 240 nm. A Waters Symmetry® C18 column (5 µm, 3.9 X 
150 mm) and guard column (3.9 X 20 mm) were used with a mobile phase composition 
of 32% acetonitrile and 68% (v/v) pH 5.5 triethylamine acetate (2%) buffer. The 
retention time for Dex at an injection volume of 10 µl and a flow rate of 1 ml/min was 
about ~6.4 min.  
Lipid Analysis 
Lipid concentrations in blank and drug loaded liposome dispersions were analyzed by 
HPLC using ELSD (Evaporative Light Scattering Detector), as reported previously (126). 
Briefly, an Allsphere™ Silica Column (Grace Davison Discovery Sciences, Deerfield, 
IL) (5 µ, 4.6X150 mm) and guard column (5µ, 7.5 X 4.6mm) were employed with a 
linear gradient method starting with 100% (v/v) mobile phase A (80% chloroform:19.5% 
methanol:0.5% (v/v) ammonium hydroxide solution (30%) and changing to 80% mobile 
phase A:20% mobile phase B (80% methanol:19.5% water:0.5% (v/v) ammonium 
hydroxide solution (30%)) over 3 min. Standards were made in mobile phase A and 
linearity was observed between log concentration and log area of the peak over the 
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concentration ranges of 150-800 µM for DMPC, 100-400 µM for DPPC, and 150-400 
µM for DPPC. Aliquots of blank and drug loaded liposomes (10-20 µl) were transferred 
to test tubes, dried under nitrogen and stored at -20°C until further analysis. For analysis, 
the dried lipid films were re-constituted in mobile phase A.  
MATHEMATICAL MODELING AND SIMULATIONS 
Data fitting and simulations were done based on previously developed mathematical 
models (126, 127, 132). The models take into account the inner and outer aqueous 
volumes, the volumes of the inner and outer bilayer leaflets in the liposome suspension, 
and the membrane-water partition coefficient of drug to determine the fractions bound 
inside and outside the liposomes. The rate of bilayer transport of the encapsulated drug is 
determined by the concentration gradient of the unbound neutral drug concentration. The 
extravesicular unbound concentration is dictated by the partition coefficient and the rate 
of drug transport across the dialysis membrane into a large volume of the reservoir 
solution to provide sink conditions.  Thus, 
𝑑(𝐷𝑖)
𝑑𝑡
= −𝑘𝑚(𝐷𝑖𝑤 − 𝐷𝑜𝑤)                  (4.1) 
𝑑(𝐷𝑖)
𝑑𝑡
= −𝑘𝑚(𝛼𝑖𝐷𝑖 − 𝛼𝑜𝐷𝑜)            (4.2) 
𝑑(𝐷𝑜)
𝑑𝑡
= 𝑘𝑚
𝑥
(𝐷𝑖𝑤 − 𝐷𝑜𝑤) − 𝑘𝑑(𝐷𝑜𝑤) … … 𝑥 = 𝑉𝑜𝑉𝑖                (4.3) 
𝑑(𝐷𝑜)
𝑑𝑡
= 𝑘𝑚
𝑥
(𝛼𝑖𝐷𝑖 − 𝛼𝑜𝐷𝑜)−𝑘𝑑(𝛼𝑜𝐷𝑜)                    (4.4) 
𝑤ℎ𝑒𝑟𝑒,    𝛼𝑖 = 𝑎𝑏𝑏 + 𝑎𝐾𝑝 ,𝛼𝑜 = 𝑐𝑑𝑑 + 𝑐𝐾𝑝 ;𝑎 = 𝑉𝑖𝑉𝑖𝑤 , 𝑏 = 𝑉𝑖𝑉𝑖𝑚 , 𝑐 = 𝑉𝑜𝑉𝑜𝑤 ,𝑑 = 𝑉𝑜𝑉𝑜𝑚  
where, Di and Do are the total intravesicular and extravesicular (within the dialysis tube) 
drug concentrations respectively; a and b are volume ratios to account for the differences 
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in aqueous and membrane volumes with respect to the total intravesicular volume; c and 
d are volume ratios to account for the differences in aqueous and membrane volume with 
respect to the total extravesicular volume in the dialysis tube. Vi is the total liposomally 
entrapped aqueous volume plus the lipid volume in the inner bilayer leaflet of liposomes 
in the suspension, Viw and Vim are the volumes of the inner aqueous compartment and 
inner monolayer in each vesicle, respectively. Vo is the extravesicular aqueous volume 
along with the volume of lipid in the outer bilayer leaflet of suspended liposomes in the 
dialysis tube; Vom is the volume of the outer monolayer in each vesicle and Vow is the 
volume of the extravesicular aqueous compartment in the dialysis tube. Kp is the 
membrane-water partition coefficient, αi and αo are the factors that account for the 
binding of drug to lipid membrane and convert total intravesicular and extravesicular 
concentrations to the aqueous free concentrations, respectively; km and kd are the rate 
constants for drug transport across the lipid bilayer and dialysis membrane respectively 
and x is the ratio of extravesicular to intravesicular volume in the dialysis tube.  
To account for non-instantaneous drug binding to the dialysis membrane, modifications 
to the model were made to account for release profiles of Dex,  
𝑑(𝐷𝑜)
𝑑𝑡
= 𝑘𝑚
𝑥
(𝛼𝑖𝐷𝑖 − 𝛼𝑜𝐷𝑜) − (𝑘𝑜𝑛 + 𝑘𝑑)𝛼𝑜𝐷𝑜 + 𝑘𝑜𝑛𝐾 𝐷𝑚            �𝐾 = 𝑘𝑜𝑛𝑘𝑜𝑓𝑓�          (4.5) 
𝑑(𝐷𝑚)
𝑑𝑡
= 𝑘𝑜𝑛𝛼𝑜𝐷𝑜 − 𝑘𝑜𝑛𝐾 𝐷𝑚           (4.6) 
where, Dm is the drug concentration bound to the dialysis membrane and kon and koff are 
the association and dissociation constants, respectively, for binding of drug to the dialysis 
membrane. 
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Simulations were conducted to evaluate the impact of variations in the membrane-water 
partition coefficients of the drug and the lipid concentration inside the dialysis tube on the 
overall release profiles from liposomes at various km values. To determine the region of 
the variable space in which reliable rate constants for drug release could be obtained (in 
the absence of experimental variability), simulations were performed using the above 
detailed mathematical model assuming an intrinsic rate constant and then the simulated 
data were fit using a simple first order rate equation. For an assumed higher intrinsic rate 
constant, the apparent kinetics (kapp) can be slower at high partition coefficient because 
kapp=km*αi where αi is the factor that accounts for intravesicular binding. The effective 
rate constant was deemed to be determinable by dynamic dialysis and a first-order 
treatment if the fitted rate constant from first order model was within ± 20% of the input 
or assumed value. 
RESULTS AND DISCUSSION 
Liposome Characterization  
The particle sizes of blank and AR-67 loaded DSPC liposomes (pH 4.2 and 9.5) were 
180±15 nm, with polydispersity indices in the range of 0.04-0.07.  Blank and Dex loaded 
DMPC, DPPC and DSPC liposome particle sizes were in the range of 90±20 nm, with 
polydispersity indices between 0.05-0.08, indicating monodisperse formulations. The 
extrusion procedure employed in this study was previously shown by 31P-NMR to 
produce unilamellar vesicles (141).  
In order to assess the impact of lipid concentration on the apparent release kinetics, it was 
important to analyze the actual lipid concentrations in blank and drug loaded liposomal 
suspensions used in release studies. Lipid concentrations were analyzed prior to release 
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experiments by gradient HPLC with evaporative light scattering detection and were 
typically 25-35% lower than the theoretical concentrations indicating some lipid loss 
during the extrusion process. The retention times of DMPC, DPPC and DSPC were 8.2, 
8.0 and 7.9 min, respectively. 
Determination of the particle size and actual lipid concentration of liposomal suspensions 
was critical for mathematical modeling of the release data as the calculation of αi and αo 
in Eqs. 4.2, 4.4, and 4.5 requires this information. The parameters a and b (internal 
volume ratios) needed to determine αi are directly dependent on particle size while the 
parameters c and d (external volume ratios) necessary for the determination of αo are 
dependent on both particle size and lipid concentration.  
Factors Governing the Apparent Release Rate Constants using Dynamic Dialysis 
As depicted for liposomal release in Figure 4.1, four major factors govern the 
determination of reliable release rate constants from nanoparticles by dynamic dialysis:  
1) the effective drug concentration within the nanoparticle provides the driving force for 
release from the particle (i.e., Diw in Figure 4.1); 2) the rate constant (km) for nanoparticle 
release reflects the properties of the barrier domain within the carrier (i.e., for liposomes 
this is the ordered chain region of the bilayer); 3) drug binding/partitioning to the 
nanoparticles and the dialysis membrane influences Dow, the effective drug concentration 
within the dialysis tube that serves as the driving force for drug transport across the 
dialysis membrane once the drug is released from the nanoparticle; and 4) the dialysis 
membrane itself constitutes a second transport  barrier as represented by kd.  The 
effective liposomal drug concentration, Diw, is the unbound intravesicular aqueous 
concentration   of the permeable drug species.  Referring to Eqns. 1-6, Diw = αiDi where 
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Di is the total intravesicular drug concentration and αi accounts for the binding of drug to 
the inner leaflet of the bilayer.  The mathematical model treatment, developed based on 
the equilibrium and transport processes and described by Eqns. 4.1-4.6, is applicable to 
nonionizable drugs.  For an ionizable drug where the neutral species is the permeant, Diw 
would be reduced by both membrane binding and ionization as demonstrated in previous 
work (126).   
The rate of neutral drug release from nanoparticles that would be expected under true 
sink conditions,  as would likely prevail in the systemic circulation in vivo, is reflected in 
the first term of Eqn. 4.2, 𝑑(𝐷𝑖) 𝑑𝑡⁄ = −𝑘𝑚𝛼𝑖𝐷𝑖.  Thus, the first two factors outlined 
above govern drug release under sink conditions while factors (3) and (4) come into play 
when release rates are monitored using dynamic dialysis.  In dynamic dialysis all four 
factors are intertwined although one process may dominate over the others, depending 
upon the drug and nanoparticle properties, the nanoparticle concentration, drug loading, 
and the dialysis membrane selected. Herein, we demonstrate the effect of these factors on 
the determination of release rates using liposomes as representative nanoparticles, but the 
general principles should be more broadly applicable.  
Release Kinetics of AR-67 from DSPC Liposomes at pH 4.2 and 9.5 
The release kinetics of AR-67 from liposomes at pH 4.2 and 9.5 demonstrate two 
contrasting scenarios that may be encountered in determining release profiles by dynamic 
dialysis. The first and most straightforward situation to be presented is that for the release 
of AR-67 at a constant (intra- and extravesicular) pH of 9.5 as shown in Figure 4.2.  AR-
67 is a camptothecin analogue having a α-hydroxy-δ-lactone moiety that undergoes pH-
dependent chemical hydrolysis to a ring-opened carboxylate form. In its lactone form, the  
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Figure 4.1 Schematic depicting the ionization and binding equilibria along with transport 
pathways representing the study of drug release kinetics from liposomes by dynamic 
dialysis method.  
Diw and Dim are the intravesicular aqueous and membrane bound drug concentration 
respectively, Dow and Dom are the extravesicular aqueous and membrane bound drug 
concentration respectively. Dm is the dialysis membrane bound drug concentration. km 
and kd are the rate constants for permeation across the bilayer membrane and dialysis 
membrane respectively. kon and koff are the apparent association and dissociation 
constants for the binding of drug to the dialysis membrane. 
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Figure 4.2 Fractions of initial amount of AR-67 remaining in dialysis tube versus time. 
(A) First order fits of release profiles of AR-67 loaded DSPC liposomes at pH 4.2 
(lactone) and pH 9.5 (carboxylate). (B) Simultaneous model fitting of the AR-67 loaded 
(pH 4.2). DL stands for drug loaded liposomes. 
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predominant species at pH 4.2, this compound is highly hydrophobic with a 
cLogP=5.4±1.3.  The aqueous solubility of the lactone form is extremely low at 0.11 
µg/ml (127, 185).  However, at pH 9.5, AR-67 exists predominantly in its membrane 
impermeable carboxylate form and the overall release rate is very slow due primarily to 
the small fraction of lactone present at that pH (126). In this case, the liposomal release is 
clearly rate-determining and a first-order fit of the observed concentration versus time 
profile generated in a dynamic dialysis experiment can reliably be used to obtain the 
effective release rate constant that would also be expected under true sink conditions at 
the same pH. The first-order rate constant for AR-67 transport from DSPC liposomes at 
9.5 estimated from Figure 4.2A is 0.0034 h-1 corresponding to a half-life of 204 hr.  (It 
should be noted that the actual release half-life achieved in plasma for the above pH 9.5 
liposomes was dramatically reduced due to CO2 mediated dissipation of the internal-
external pH gradient (126).  Such considerations have not been taken into account in the 
present analysis.) 
At pH 4.2, however, the rate of AR-67 release from DSPC liposomes is much faster, with 
an apparent first-order rate constant of 0.123 h-1 corresponding to a half-life of 5.6 hr. 
Given the hydrophobic nature of this drug in its lactone form and its substantial binding 
affinity toward liposome membranes (132) the question arises as to whether or not this 
apparent half-life truly reflects the rate constant for nanoparticle release.        
In order to explore the potential confounding effects of extravesicular membrane binding 
and dialysis membrane transport in the pH 4.2 release experiment, blank liposomes at pH 
4.2 were spiked with AR-67 solution at the same concentration as that present in the 
drug-loaded liposomal suspensions and subjected to the same dialysis procedure, as 
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shown in Figure 4.2B.  Eqns. 4.2 & 4.4 were then employed to simultaneously fit the two 
release profiles in Figure 4.2B. The intrinsic rate constant km obtained for nanoparticle 
AR-67 release at pH 4.2 was 44 ± 18 h-1  (km.αi = 0.22 h-1) corresponding to a half- life of 
3.1 ± 0.9 hr, in close agreement with the value of 2.8 ± 0.3 hr reported previously when a 
similar simultaneous fit of spiked and loaded liposomes was conducted (132).  The 
intrinsic rate constant for free drug transport across the dialysis membrane (kd) obtained 
from the simultaneous model fitting in Figure 4.2B was 1.2 ± 0.2 h-1 corresponding to a 
half-life of 0.52 ± 0.07 hr. In the presence of liposomes, the half-life for AR-67 
disappearance in a spiked experiment increased to 0.73 hr due to the effect of 
extravesicular drug binding to the outer leaflet of the liposome bilayers (i.e., reduction in 
αo). This example illustrates the importance of probing for drug binding to nanoparticles 
after release. It also highlights the potential value of conducting a spiking experiment at 
the same nanoparticle concentration in conjunction with simultaneously fitting the two 
release profiles to obtain a more reliable estimate of the true rate constant for drug release 
from the nanoparticles. 
The Unencapsulated Initial Drug Concentration 
In simultaneously fitting Equations 2 and 4 to drug loaded and spiked liposome release 
data such as those shown in Figure 4.2B, the fraction of unencapsulated drug present in 
drug-loaded liposomes at t=0 must be considered. In practice, a liposome/drug system is 
never completely free of unencapsulated drug (186).  For blank liposomes, the term D0 
representing the extravesicular drug concentration can be assumed to represent 100% of 
the drug added at t=0 but for drug loaded liposomes, D0 is unlikely to be zero despite 
attempts to separate free from entrapped drug by Sephadex column chromatography or 
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other techniques. In part, this is due to drug release from nanoparticles after the 
separation has been completed but prior to the start of a dialysis experiment.  Another 
likely factor is that, depending on its binding affinity, drug bound reversibly to the 
nanoparticle may not be completely removed by separation on a Sephadex column.  
Shown in Figure 4.3A is an elution profile for the separation of liposome associated from 
free AR-67 on passage through a mini-Sephadex G-25 column such as that typically 
employed for separating free from encapsulated drug. The relatively small free drug peak 
(after 20 ml) compared to the drug peak in the liposome fraction eluting within 5 ml 
suggests that nearly all of the drug eluted in the liposome fraction.  However, the passive 
loading technique used to prepare these liposomes should have led to no more than about 
50% entrapment for a highly membrane bound drug, because approximately 50% of the 
bound drug should reside on the outer bilayer leaflet.  Indeed, simultaneous fitting of the 
release data in Figure 4.2B indicated an initial unentrapped percentage in the drug-loaded 
liposomal suspension of 30 ± 14 %.   
The efficiency of separation of free from encapsulated or membrane bound drug in a 
Sephadex column will be determined by several factors including the membrane/water 
partition coefficient, the sample load applied to the column, and the number of theoretical 
plates.  Previously, Joguparthi et al obtained a value of 𝐾𝑝=2440 ± 230 for the partition 
coefficient of AR-67 with DSPC liposomes (187). To explore the possibility that external 
liposome binding may reduce separation efficiency, we conducted a spiking experiment 
using dexamethasone and DPPC liposomes.  The partition coefficient for dexamethasone 
binding to DPPC liposomes is 𝐾𝑝=106 (188), much lower than that for AR-67 with 
DSPC liposomes.  Blank DPPC liposomes were spiked with Dex solution and 0.5 ml of 
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this suspension was immediately added to a Sephadex column and eluted with PBS (pH 
7.4). Figure 4.3B shows that about 40% of the added drug was associated with the 
liposome (first 5 ml) while the remaining drug continued to elute from the column over 
the next 15-20 min. Given that, as shown in the next sections, the half-life for Dex release 
from DPPC liposomes is ~ 4 hr, it is most likely that the high apparent concentration for 
entrapped Dex in this spiking experiment is due to binding to the outer leaflet of DPPC 
liposomes. These results justify the need to include a parameter to allow for an initial 
concentration of unencapsulated drug in fitting release data even after a Sephadex 
treatment.   
Determination of Release Kinetics of Dex from DMPC liposomes  
Dexamethasone is a non-ionizable corticosteroid having a log P= 2.03 and an aqueous 
solubility of 0.035 mg/ml (ACD/Labs V11.02). Initially, release kinetics of Dex 
encapsulated in DMPC liposomes were evaluated by dynamic dialysis in a manner 
similar to that described previously for AR-67 at pH 4.2.  That is, drug loaded liposomal 
release was compared to that for blank liposomes spiked with Dex.  A parallel 
experiment with an aqueous Dex solution was also included (Figure 4.4A). Unlike AR-
67, the release profiles of Dex from loaded and spiked liposomes were virtually 
indistinguishable at a lipid concentration of ~13.9 mg/ml. A possible explanation for the 
similarity between drug loaded and spiked profiles was that entrapped drug release is 
relatively rapid. Simultaneously, the significant deviation of the spiked from free drug 
profile suggests that Dex binding to the liposomal bilayer reduces the driving force for 
Dex transport across the dialysis membrane.  
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Figure 4.3 (A) Elution profiles of free and liposomal entrapped AR-67 (Kp=2440) as 
determined by HPLC after passing 0.1 ml through Sephadex G25 and eluted with acetate 
buffer (85 mM, pH 4.2). (B) Elution profile of blank liposome spiked with Dex (Kp=106) 
after passing 0.5 ml through Sephadex G25 and eluted with PBS (pH 7.4). 
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 The influence of liposomal membrane binding on the apparent release kinetics can be 
minimized by reducing the lipid concentration. To probe this, release experiments were 
repeated at lower lipid concentrations (~4.6 mg/ml) in Figure 4.4B. This caused a 
significant increase in the apparent rates of drug release from both drug loaded and 
spiked liposomes. Also noteworthy, the concentration vs. time profiles for spiked 
liposomes and free drug solution nearly overlap with virtually identical terminal slopes.  
This suggests that the effect of drug binding to liposomes on the driving force for dialysis 
membrane transport has been minimized and nearly eliminated at this lower lipid 
concentration. Nevertheless, it is unclear from a visual examination of Figure 4.4B 
whether or not there is sufficient information content to enable a reliable estimation of the 
effective rate constant for liposomally entrapped drug release.  
Before attempting to apply more sophisticated modeling to data such as those displayed 
in Figure 4.4, the rate constant for Dex transport across the dialysis membrane, kd, was 
examined by determining the disappearance of free Dex from solution in six independent 
experiments with different dialysis tubes having a molecular weight cut-off of 100 kD 
(Figure 4.5). The observed biphasic profile obtained suggests non-instantaneous 
reversible binding or partitioning of the drug in the dialysis membrane, which was 
incorporated into the mathematical model by replacing Eqn. 4.4 with Eqns. 4.5 & 4.6.  
The data in Figure 4.5 highlight the potential importance of monitoring free drug 
disappearance over a sufficient time frame to capture the relevant contribution of the 
dialysis membrane transport and binding to the overall release processes of interest.   
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Figure 4.4 Release profiles of Dex in DMPC liposomes at 25°C using dynamic dialysis 
method. (A) Release profiles of drug loaded and blank liposomes spiked with Dex at high 
lipid concentration (~13.9 mg/ml) along with free drug profile (B) Release profiles of 
drug loaded and blank liposomes spiked with Dex at low lipid concentration (~4.6 
mg/ml) along with free drug profile. DL stands for drug loaded liposomes. HL and LL 
represents high and low lipid concentrations respectively. 
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Comparison of Dex Binding and Release from DMPC, DPPC, and DSPC liposomes 
While the impact of drug binding to the nanoparticle on the apparent release kinetics can 
be probed by the studies described above, the actual quantitative determination of binding 
constants might be best obtained separately to avoid introduction of another fitted 
parameter in the transport models described in Eqs. 4.1-4.6.   To better understand and 
quantify the role of membrane binding in modulating the apparent release kinetics, the 
partition coefficients of Dex in DMPC, DPPC and DSPC liposomes was determined. The 
values obtained by equilibrium dialysis at 25°C were 705±24 in DMPC, 106±11 in DPPC 
and 57±9 in DSPC liposomes (188) as displayed graphically in Figure 4.6.   
Further, the range of release rates from liposomes that can be reliably determined by 
dynamic dialysis was determined by including studies employing DPPC and DSPC to 
take advantage of the expected reduction in release rates accompanying the higher acyl 
chain ordering present in these longer chain lipids as detailed in the barrier domain model 
for lipid bilayer permeability previously (131, 189). Release profiles at 25°C generated 
by dynamic dialysis of Dex loaded liposomes and blank liposomes spiked with Dex at 
low (~4-5 mg/ml) and high lipid concentrations (~12-15 mg/ml) are compared with those 
from free Dex solution in Figure 4.7. The upper panel of Figure 4.7 shows the 
comparison of drug loaded liposomal release profiles at low and high lipid concentrations 
while the lower panel compares spiked profiles at low and high lipid concentrations in 
DMPC, DPPC and DSPC, respectively, along with the free drug profile.  
Evident from Figure 4.7 (upper panel) is that differences between the release profiles 
from drug loaded liposomes at low and high lipid concentrations (i.e., low vs high  
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Figure 4.5 Release profile of free Dex solution across the dialysis membrane (MWCO: 
100kD) at 25°C. Average of six independent profiles across six different tubes, error bars 
are the standard deviations.  
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Figure 4.6 Liposome-water partition coefficient of Dex in DMPC, DPPC and DSPC 
liposomes determined by equilibrium dialysis at 25°C. 
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Figure 4.7 Release profiles of Dex loaded liposomes, blank liposomes spiked with Dex 
and free Dex solution at 25°C. The upper panel compares the release profiles of drug 
loaded (DL) DMPC, DPPC and DSPC liposomes at low and high lipid concentration. 
The lower panel compares the release profiles of free Dex solution in the absence and 
presence of low and high concentrations of liposomes. DL stands for drug loaded 
liposomes. HL stands for high lipid concentration (~12-15 mg/ml) and LL stands for low 
lipid concentration (~4-5 mg/ml) inside the dialysis tube. 
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nanoparticle concentrations) can be related to the partition coefficients observed in these 
systems. The largest partition coefficients prevalent in DMPC liposomes resulted in the 
greatest difference between the profiles at low and high lipid concentration, in both drug 
loaded and spiked liposomes. At high lipid concentrations, drug released from the DMPC 
liposomes undergoes relatively extensive external membrane binding inside the dialysis 
tube leading to a slower apparent release that is rate-limited by transport across the 
dialysis tube. Thus, a dynamic dialysis experiment performed at the highest DMPC 
concentration displayed in the upper left panel of Figure 4.7 would erroneously suggest a 
liposomal release half-life of ~ 10 hr when in fact it is at least 3-fold less than that.  With 
a substantial decrease in partition coefficient, the apparent release kinetics become less 
sensitive to lipid concentration and in DSPC at a low lipid concentration no influence of 
lipid binding can be discerned.  Particularly noteworthy, there is no influence of liposome 
concentration on the Dex release profiles from drug loaded DSPC liposomes (upper right 
panel, Figure 4.7) and the slopes are significantly smaller than those obtained from free 
drug solution or from spiked DSPC liposomes (lower right panel, Figure 4.7).  These 
combined observations provide confidence that a reliable rate constant for Dex release 
from DSPC liposomes can be generated by dynamic dialysis.  
The value of establishing the free drug permeation across the dialysis membrane in order 
to assess its contribution to the kinetic profiles obtained from drug loaded nanoparticles 
during dynamic dialysis has been well documented (66, 182, 190, 191) but this may not 
be a sufficient control.  Although it has also been understood for decades that the rate of 
diffusion of small molecules through a dialysis membrane is proportional to the 
concentration of the unbound species (192, 193) systematic studies are seldom conducted 
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to account for both drug binding to the nanocarrier and its influence on dialysis 
membrane transport.  The effect can be dramatic for the drugs having high affinity for the 
formulation and can be probed by varying the concentration of the carrier particles.  
The release profiles from Dex loaded DMPC, DPPC and DSPC liposomes at low and 
high lipid concentration were fit simultaneously to the mathematical model represented 
by Figure 4.1 and Eqs. 4.2 & 4.5-4.6.  The DPPC and DSPC results are shown in Figure 
4.8. As discussed earlier, the percentage of unencapsulated drug at time t=0 was included 
as a fitted parameter for each system in the model fitting.  The values obtained were 31 % 
and 53 % at high and low DPPC concentrations, respectively, and 15 % and 20 % at high 
and low DSPC concentrations, respectively. To test the reproducibility of the release 
profiles generated by dynamic dialysis and to confirm that the variation observed in 
release profiles with changes in lipid concentration was not due to variability of the 
method, the release profiles from Dex loaded DPPC liposomes were determined in 
triplicate, at both low and high lipid concentrations along with free drug. Six drug loaded 
profiles in DPPC when fitted simultaneously gave an intrinsic rate constant (km) of 2.13 ± 
0.43 h-1 (95% confidence interval) while that obtained from simultaneous fitting of 
average profiles at high and low lipid concentrations was 2.08 ± 0.36 h-1. The effective 
rate constant for liposomal release that takes into account the effect of intravesicular 
binding on the driving force (kmαi) was 0.17 h-1 corresponding to the half-life of 4.2 hrs 
for release from DPPC liposomes. Similarly, the intrinsic rate constant obtained from 
simultaneous fitting of profiles of Dex loaded DSPC liposomes was 0.43 ± 0.08 h-1 and 
kmαi was 0.05 h-1, yielding a half-life of 13.6 hrs.  While the same modeling approach 
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Figure 4.8 Release profiles of Dex across DPPC (A) and DSPC (B) liposomes at high and 
low lipid concentrations along with the free drug profile determined using dynamic 
dialysis method. Each of the three profiles in (A) is the average of three independent 
experiment and the error bars represent the standard deviation. DL stands for drug loaded 
liposomes. HL and LL represents high and low lipid concentrations respectively. 
  
 91 
also fit the DMPC data, the 95% confidence limits for km in DMPC were too large (8.2 ± 
12 h-1) to allow a reliable estimate of km in that system. 
Determination of the Intrinsic Permeability Coefficient using Dynamic Dialysis Method 
A significant advantage of mathematical modeling of dynamic dialysis data is that it 
enables the determination of the true apparent release half-life from the nanocarrier – the 
value that is expected under true sink conditions.  Another advantage of the approach for 
liposomal systems is that when combined with measured liposome/water partition 
coefficients it enables the calculation of the intrinsic permeability coefficient of the drug 
from the intrinsic rate constant, km. This is possible because both the intra- and 
extravesicular unbound species concentrations are determined.  These are the quantities 
that constitute the driving force for permeation across the bilayer. Accordingly, the 
intrinsic permeability coefficient of AR-67 across DSPC bilayers was calculated from the 
fitted km of 44.3 hr-1 value at pH 4.2 (Figure 4.2B) to be 3.7 x 10-8 cm/sec, using the 
following relation:  
𝑘𝑚 = 𝑃𝑚𝐴𝑉𝑖 ≅ 3𝑃𝑚𝑅  
where km is the intrinsic first-order rate constant for drug release from liposomes, A and 
R are the area and radius of the liposome, respectively, and Vi is the total intravesicular 
volume. Permeability coefficients calculated from the fitted km values of 2.0 hr-1 and 0.43 
hr-1, for the release of Dex from DPPC and DSPC liposomes are 1.8 x 10-10 cm/s and 8.9 
x 10-10 cm/s, respectively. 
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Exploration of the Variable Space - Simulations 
Effect of Lipid Concentration: Extravesicular Binding 
Model simulations were conducted to show the effect of lipid (i.e., liposome) 
concentration on the observed release kinetics for drugs with varying binding affinity and 
a constant intrinsic permeability (Figure 4.9).  For these simulations, a constant km of 32 
hr-1 was assumed, corresponding to a situation where, in the absence of significant 
intravesicular binding, the drug release rate from liposomes would be too fast to measure 
(recall that kd for dialysis membrane transport in the experiments discussed previously in 
this paper was on the order of 1 hr-1).  Thus, for Kp=60 (Figure 4.9, left panel), the overall 
drug release is dialysis membrane rate-limited regardless of lipid concentration and no 
information regarding the release rate from the nanoparticles can be obtained by dynamic 
dialysis under these conditions. With higher Kp values (700 and 2440, corresponding to 
values for Dex in DMPC and AR-67 in DSPC liposomes, respectively), the effect of lipid 
concentration is more dramatic. This can be attributed to the substantial amount of 
extravesicular membrane bound drug inside the dialysis tube and the reduction in driving 
force across the dialysis membrane that accompanies this binding.  Figure 4.10A provides 
estimates of the increases in extravesicular bound fraction accompanying increases in 
lipid concentration in the dialysis tube for drugs with different partition coefficients. For 
example, for a drug with moderate binding affinity (Kp=700), almost 70% drug is bound 
extravesicularly at a lipid concentration of 10 mg/ml.  Both Figure 4.9 (center and right 
panels) and Figure 4.10A illustrate the importance of using low nanoparticle 
concentrations when the drug binding affinity is high.  For example, Figure 4.9 shows 
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that lipid concentrations <0.5 mg/ml are necessary to minimize the confounding influence 
of nanoparticle binding within the dialysis tube when the binding affinity is high. 
Effect of Intravesicular Binding 
Liposomes differ from other matrix type nanoparticles (e.g., solid lipid nanoparticles, 
polymer micelles, etc.) in that there is an aqueous core.  The aqueous core concentration 
of the membrane permeable species, which provides the driving force for drug release, 
may be substantially reduced by intravesicular membrane binding.  Drugs having a high 
liposome/water partition coefficient (Kp) may be mostly bound to the intravesicular 
membrane due to the high membrane surface to aqueous core volume ratio.  Figure 4.10B 
illustrates the decrease in intravesicular free drug fraction with an increase in partition 
coefficient.  Notably, this quantity is not affected by the liposome concentration but the 
free drug fraction for a given Kp does decrease with a decrease in size of the liposome 
(132). Intravesicular membrane binding as reflected in the value of αi reduces the 
effective rate constant (km·αi) across the bilayer (Eq. 4.2).   
Simulations at a low lipid concentration (0.5 mg/ml) to minimize the impact of 
extravesicular binding and varying intrinsic rate constants (km) are shown in Figure 4.11 
at three values of Kp. Consider the curve representing the release profile maximally 
separated from that of a solution of the free drug in each panel.  With an increase in Kp, 
there is a corresponding systematic increase in the intrinsic rate constant, km, or bilayer 
permeability that can be clearly differentiated from the free drug profile. . In other words, 
for a drug with low partition coefficient (Kp=52), an apparent half-life of approximately 7 
hours is obtained when the intrinsic rate constant (km) is about 1 h-1; for a drug with Kp of 
700, a similar half-life is obtained with km of 10 h-1 while for a drug with very high Kp 
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Figure 4.9 Simulations showing the effect of the liposome/water partition coefficient on 
the observed release kinetics from 90 nm liposomes at varying lipid concentrations 
(km=32). 
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Figure 4.10 Simulations for extravesicular bound and intravesicular free fractions with 
increasing lipid concentration and different membrane-water partition coefficients in 90 
nm liposomes. 
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Figure 4.11 Simulations showing the effect of the liposome/water partition coefficient on 
the observed release kinetics from 90 nm liposomes at varying intrinsic rate constants 
(Lipid concentration=0.5 mg/ml). 
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 (2440), the same half-life is obtained for a km of more than 32 h-1. Thus, in the case of 
liposomes, a high partition coefficient can be advantageous in slowing the transport rate 
from liposomes by reducing the intravesicular driving force.  If extravesicular binding 
can be minimized by using a low liposome concentration, dynamic dialysis may still 
provide a reliable measurement of the effective release rate constant. 
The above observations can be used to rationalize why an intrinsic rate constant for 
liposomal release could be determined for AR-67 in DSPC liposomes but not for Dex in 
DMPC liposomes.   AR-67, a highly hydrophobic compound in its lactone form (pH 4.2), 
has a significantly higher Kp in DSPC compared to Dex in DMPC (> 3 times greater). 
Yet, an intrinsic rate constant and permeability coefficient for AR-67 was determined 
using the same dynamic dialysis method as that failed for Dex in DMPC.  One principal 
reason for this is the lower intravesicular driving force for AR-67 due to its high 
intravesicular membrane binding. Also, a lower liposome concentration (0.48 mg/ml) 
was possible for the AR-67 release study as compared to Dex in DMPC (4.6 mg/ml) due 
to the higher sensitivity of the fluorescent method of analysis employed for AR-67. 
Therefore, extravesicular binding effects were nearly negligible for AR-67. 
The simulated effect of liposome concentration on the dynamic dialysis profiles for AR-
67 is shown in Figure 4.12.  A lipid concentration of 0.48 mg/ml was a suitable 
concentration for optimizing the separation of the drug loaded and spiked release profiles. 
Below this concentration, the profiles did not change significantly but above this 
concentration slowing of the apparent kinetics was observed along with the decrease in 
the gap between the drug loaded and spiked profiles 
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Figure 4.12 Simulations of the effect of lipid concentration on the dynamic dialysis 
profiles for AR-67 from drug loaded (DL) and blank liposomes of DSPC spiked with the 
drug (Kp=2440). 
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Considering the above observations, it follows that before inferring that a given drug 
release profile obtained by dynamic dialysis truly reflects the rate of release from the 
nanoparticle formulation and not an artifact due to rate-limiting dialysis membrane 
transport, perhaps resulting from high extravesicular membrane binding of the drug, one 
of the following validation experiments should be undertaken: (a) evaluate the profiles 
obtained from a free drug solution and drug-spiked nanoparticle suspension at the same 
nanoparticle concentration as the drug-loaded nanoparticle system. Nanoparticle binding 
effects can be considered negligible at the nanoparticle concentration explored if the 
kinetic profiles are the same; (b) alternatively, release profiles from drug loaded 
nanoparticles should be generated at different dilutions and compared with the profile 
obtained from a free drug solution. If the drug-loaded system release profiles at different 
dilutions are not significantly different from each other but significantly slower than the 
free drug profile, then the effect of nanoparticle binding can be ignored and a reliable 
effective rate constant for nanoparticle release can be determined by application of the 
appropriate model.  
Effect of the Dialysis Membrane 
The cellulose ester dialysis membranes employed in these studies had a molecular weight 
cut-off (MWCO) of 100 kD but membranes having a MWCO up to 1000 kD are 
available from the manufacturer (Spectrum Labs).  Membranes having a MWCO between 
12-15 kD or smaller have been commonly used in the literature (181, 194-200).  Morino-
Bautista and Tam (181) demonstrated that the smaller the pore size (or MWCO), the 
higher the resistance offered by the membrane to the diffusion of small solutes 
(specifically, procaine hydrochloride). Thus, the initial rate of diffusion of procaine was 7 
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times greater across a 10 kD membrane in comparison to a 2 kD MWCO membrane. 
Considering that the dialysis membrane should be selected with a maximum possible 
pore size to maximize the rate of diffusion of the drug molecule while serving as a barrier 
to the carrier, a 1000 kD MWCO may be feasible for nanoparticles in the 100 nm size 
range.  
Three-Dimensional Response Surfaces: Reliability of Results from Dynamic Dialysis 
As dictated by the principles of chemical kinetics, the rate determining step governs the 
rate of an overall reaction.  In dynamic dialysis, this principle can be relied upon to 
unambiguously determine the nanoparticle release rate constant when the rate of transport 
across the dialysis membrane far exceeds that for nanoparticle release.  For liposomes, 
this situation is most likely realized for polar or ionized drugs that have relatively low 
membrane permeabilities and negligible membrane/water partition coefficients.  In many 
instances, there may be no single process that is so predominant that it completely 
determines the rate of drug disappearance from the dialysis chamber, yet there may be 
sufficient information content in the concentration versus time profile to obtain a reliable 
rate constant for nanoparticle release even using a simple first-order fit.   
In the above paragraphs, the effect of lipid concentration, partition coefficient and the 
intrinsic rate constant on the observed release kinetics from liposomes using dynamic 
dialysis was demonstrated. Figs. 4.13A and B systematically define in a 3-dimensional 
plot the intrinsic liposomal release rate constants and apparent liposomal release half-
lives that can be reliably determined by a simple first-order kinetic treatment of dynamic 
dialysis data as a function of the membrane/water partition coefficient and lipid  
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Figure 4.13 Three dimensional surface plots showing the boundary intrinsic rate 
constants (A) and release half-lives (B) that can be reliably determined in liposomal 
systems under the given conditions of lipid concentration inside the dialysis tube and the 
membrane-water partition coefficient of the drug. The values below the surface can be 
determined by dynamic dialysis and simple first order fit with 80% accuracy. The 
experimental error is not included and there has been no provision in the simulations for 
the presence of unencapsulated drug at t=0. 
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concentration employed in the experiment.  The intrinsic rate constant and apparent 
liposomal release half-life were deemed to be determinable by dynamic dialysis and a 
first-order treatment if the fitted constant from a first-order fit was within ± 20% of the 
input value. 
Figure 4.13A shows the impact of intra- and extravesicular binding on what intrinsic rate 
constant can be reliably estimated. If the effects of extravesicular binding can be 
minimized by using the lowest possible lipid concentration, then a reliable estimate can 
be obtained even for a drug having a relatively high intrinsic liposomal release rate 
constant and a high membrane/water partition coefficient by a simple first order model. 
Figure 4.13B shows the effect of extravesicular binding on the determination of apparent 
half-lives. With an increase in partition coefficient and lipid concentration, relatively 
slower apparent rate constants or longer release half-lives are required for the accurate 
estimation by this method. The values of the intrinsic rate constants and half-lives that 
can be determined with 80% accuracy using dynamic dialysis and a simple first order 
model in the absence of experimental error are those below the response surfaces shown 
in Figs. 4.13A and B.  For example, for a drug with a dialysis membrane transport half-
life from solution of 0.7 h, a Kp of 60, and at a liposome concentration of 0.2 mg/ml, a 
minimum half-life of 3.5 hr can be determined with an 80% accuracy by dynamic dialysis 
using a simple first-order fit.   
The simulations shown in Figure 4.13 have not included experimental errors nor have the 
effects of the presence of a certain fraction of unencapsulated drug at the start of an 
experiment been taken into account.  An appropriate mechanism-based mathematical 
model treatment, such as that described in this study, would extend the region in which 
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reliable intrinsic rate constants and apparent release half-lives could be determined from 
real data. Then, the decision as to reliability should be based on the 95% confidence 
limits of the parameters of interest.  
CONCLUSIONS 
In the early literature, dynamic dialysis became a useful and well validated technique for 
studying protein binding of small molecules because the rate of transport could be 
correlated to the extent of protein binding. The principle was based on the change in the 
permeation rate of the small molecule across the dialysis membrane with the change in 
the free fraction (or fraction bound) inside the dialysis chamber (192, 193). The 
application of the dynamic dialysis method for determining release kinetics from 
nanoparticles seems to have grown in popularity in part due to the willingness of 
investigators to ignore such binding effects.  With ever increasing research efforts in the 
field of nanoparticles as drug delivery systems, it is critical to understand the limitations 
of this widely adopted dynamic dialysis method for determination of release kinetics. 
With experiments and simulations, the various scenarios were demonstrated where the 
interpretation of release data using dialysis can be either straightforward or completely 
misleading. As shown in this study, consideration of the binding affinity of the drug to 
the nanoparticles, appropriate control experiments, and suitable mechanism-based 
mathematical treatment of the data should aid in the judicious use of the dialysis method 
for determination of the release kinetics from nanoparticles.  
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CHAPTER FIVE 
Enhanced Active Liposomal Loading of a Poorly Soluble Ionizable Drug Using 
Supersaturated Drug Solutions 
INTRODUCTION 
Liposomes are attractive delivery systems in cancer therapy because of their potential to 
passively target solid tumors (33, 44, 170, 201, 202). However, in order for liposomes to 
be useful from a practical standpoint for antitumor therapy in patients, maximum drug 
loading and optimization of drug retention and release rates are likely to be necessary 
(39, 203-205). Liposomal drug loading can be achieved by either passive or active 
methods. In passive loading, liposomes are formed in the presence of a solution of the 
drug to be loaded; in active loading, drug internalization occurs into preformed liposomes 
typically driven by a transbilayer pH gradient which in turn produces a chemical potential 
gradient, of the unionized, permeable form of the drug across the bilayer. Active loading 
has been proven to be more effective for achieving higher drug to lipid ratios compared 
to the passive loading method (39, 44). 
Several reports (47, 48, 84, 206-208) on different active loading methods have 
emphasized the dependence of loading on experimental conditions such as 
transmembrane pH gradient, membrane-water partitioning, internal buffering capacity, 
aqueous solubility of the drug, lipid composition, etc. Zucker et al (48) developed a 
decision tree by computational data mining to qualitatively predict loading efficiency 
(i.e., low, medium, or high) based on loading conditions and the drug`s physicochemical 
properties. As described in their model, good aqueous solubility of the drug is one of the 
requirements for efficient active loading. High drug-to-lipid ratios are more difficult to 
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achieve for drug candidates exhibiting poor aqueous solubility because the mass flux 
across the bilayer is governed by the extra-liposomal concentration of the permeating 
species as well as its permeability coefficient. Extremely low drug solubility reduces the 
external driving force for liposomal uptake during active loading leading to low final 
drug-to-lipid ratios.  
In this paper, the use of supersaturated drug solutions to facilitate active liposomal 
loading by the pH-gradient method was explored in order to overcome the 
aforementioned limitations in actively loading poorly soluble drugs. A highly lipophilic 
and poorly water soluble camptothecin analogue (AR-67, 7-t-butyldimethylsilyl-10-
hydroxycamptothecin) served as a model compound for this study. AR-67 is a novel, 
blood-stable camptothecin analogue currently in phase II clinical trials in patients with 
brain cancer (75, 79, 209). It possesses an α-hydroxy-δ-lactone moiety that undergoes 
pH-dependent chemical hydrolysis to ring-opened carboxylate form (75, 79, 80), a 
property that can be exploited for active loading. It was demonstrated that active loading 
coupled with methods to create and maintain drug supersaturation can dramatically 
enhance drug-to-lipid ratios for this poorly soluble drug. A mathematical model taking 
into account the various intra- and extra-liposomal ionic and binding equilibria and 
permeability coefficients has been developed to predict the rate and extent of active drug 
loading. Quantitative comparison of the experimental results with the predictions from 
this mechanism-based model should advance understanding of these complex 
phenomena.  
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MATERIALS AND METHODS 
DSPC (1,2-distearoyl-sn-glycero-3-phosphatidylcholine, >99% purity) and m-PEG DSPE 
(1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-
2000] (MW=2806, >99% purity) were purchased as powders from Avanti Polar Lipids 
(Alabaster, AL). AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) was obtained 
from Novartis Pharmaceuticals Corporation (East Hanover, NJ). Dialysis tubes (Float-A-
Lyzer®, MWCO: 100 kD) were purchased from Spectrum Laboratories (Rancho 
Dominguez, CA). Sulfobutyl ether β-cyclodextrin sodium salt (SBE-CD, Captisol®) 
having an average degree of substitution of 7- sulfobutyl ether residues per β-
cyclodextrin molecule was purchased from CyDex Pharmaceuticals, Inc. (Lenexa, 
Kansas). All other reagents and HPLC grade solvents were purchased from Fisher 
Scientific (Florence, KY). Deionized water was used for all experiments. 
Passive Loading 
Liposomes were prepared based on a previously reported method (132). Briefly, DSPC 
and mPEG-DSPE (95:5 mol%, 32 mg) were dissolved in 2 ml of chloroform. The solvent 
was evaporated under a stream of nitrogen while rotating the container and the resulting 
thin film was dried overnight in a vacuum oven at 40°C. For preparation of liposomes at 
pH 9.5, 2 ml of 100 mM borate buffer (pH 9.5) containing AR-67 (1-1.5 mM) was added 
to the dried lipid film to give a lipid concentration of 16 mg/ml. After alternate vortexing 
and heating at 60°C in a water bath to uniformly suspend the lipid, the lipid suspension 
was extruded 10 times through two stacked 200 nm polycarbonate membranes (GE water 
and Process Technologies, Trevose, PA) using an extrusion device (Liposofast®, 
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Avestin, Canada) at 60°C to obtain large unilamellar liposomes. Drug loaded liposomes 
were allowed to cool to room temperature for 3 hours and stored at 4°C until further use. 
Active Loading Methods 
Dried DSPC:mPEG-DSPE (95:5 mol%, 120 mg) lipid films, prepared as described 
above, were hydrated with 2 ml of 0.25 M calcium acetate solution or 0.5 M sodium 
acetate solution to produce a lipid concentration of 60 mg/ml. Alternate vortexing and 
heating at 60°C followed by the same extrusion process described above provided 
unilamellar liposomes. Following their preparation, blank vesicles were allowed to cool 
to room temperature and dialyzed against 1 L of 0.9% NaCl solution at room temperature 
for about 2 hours to remove the extravesicular calcium or sodium acetate and create a pH 
gradient. Active loading was carried out either in the presence of excess solid AR-67 or 
in the presence of supersaturated AR-67 solutions, at pH 7.5 and at two different 
temperatures, 37°C and 60°C. Two methods were employed to produce and maintain 
supersaturated solutions of AR-67, as described below:  
Supersaturation Method I  
AR-67 was solubilized by adjusting a 0.1 mg/ml suspension to a high pH (10.5-11) by 
adding 1 M NaOH with continuous stirring followed by readjustment to pH 7.5 by 
addition of 1 M HCl at either 37°C or 60°C to achieve supersaturation. Thereafter, on 
each occurrence of precipitation (approximately every 6 hours) pH was again raised to 
redissolve the precipitated drug followed by readjustment to pH 7.5.  
Supersaturation Method II  
Aliquots of a filtered (0.2 µm, PVDF syringe filter) 20 mg/ml AR-67 stock solution in 
0.1 N NaOH were added into a 2% SBE-CD solution containing HEPES buffer (3 mM) 
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in 0.9% NaCl and adjusted to pH 7.5 with dilute HCl to produce supersaturated loading 
solutions at varying total drug concentrations (0.1, 0.2, 0.4 and 0.6 mg/ml). These 
solutions were at varying degrees of supersaturation (𝐷𝑆 = 𝐶/𝐶𝑠): 3.8 for 0.1 mg/ml, 7.5 
for 0.2 mg/ml, 15.1 for 0.4 mg/ml and 22.7 for 0.6 mg/ml where 𝐶 is the total 
supersaturated solution concentration and 𝐶𝑠 is the equilibrium solubility of AR-67 in the 
presence of 2% SBE-CD at pH 7.5. Degrees of supersaturation higher than that 
represented by a total drug concentration of 0.6 mg/ml could not be sustained over the 
desired loading period. 
Liposomal suspensions (1 mL) in dialysis tubes were dialyzed for 48 hours 
(supersaturation was maintained for 48 hours by method II) at 37°C in the supersaturated 
drug loading solutions (200 mL). During loading, 10 µl samples were withdrawn from 
inside the dialysis tube at various time points and diluted with 900 µl of cold (-25°C) 2:1 
v/v methanol:acetonitrile to stop the interconversion between lactone and carboxylate. 
The samples were stored at -25°C until further analysis by HPLC. Loading studies at the 
lowest (0.1 mg/ml) (n=3) and highest (0.6 mg/ml) (n=4) drug concentrations in loading 
solution were repeated to test the reproducibility of the loading process. The loading 
study at the highest drug loading solution concentration (0.6 mg/ml) was also repeated 
using 0.5 M sodium acetate (rather than calcium acetate) liposomes to assess the role of 
the entrapped cation, if any, in the rate and extent of drug loading. The total drug 
concentration in the liposomal suspension inside the dialysis tube was analyzed for the 
loading experiments. These concentrations were then fitted to the model (derived in the 
mathematical model section) to obtain intravesicular drug concentrations. The drug-to-
lipid ratios reported were calculated from these intravesicular drug concentrations. 
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Studies of AR-67 uptake into the dialysis tubes were also carried out in the absence of 
liposomes at the same pH, with and without cyclodextrin in the bulk loading solution, to 
determine the rate constants for free and cyclodextrin-complexed drug transport across 
the dialysis membrane. For determination of kd (rate constant for the reversible transport 
of AR-67 across the dialysis membrane), dialysis tubes containing 1 ml of HEPES buffer 
(3 mM) in 0.9% NaCl adjusted to pH 7.5 with dilute HCl were placed in 200 mL of AR-
67 solution (at 0.1, 0.05 and 0.05 mg/ml) in the same buffer solution and the AR-67 
concentration inside the tube versus time was monitored.  Simultaneous first-order fits of 
the three experiments were conducted to generate kd. Two additional uptake experiments 
(without liposomes) were conducted in the same buffers but also containing 2% SBE-CD 
at AR-67 concentrations of 0.2 and 0.6 mg/ml to generate Kdcd (rate constant for the 
transport of SBE-CD and SBE-CD/AR-67 complexes across the dialysis membrane).   
AR-67 Equilibrium Solubility and SBE-CD Complexation Constants 
Determinations 
The equilibrium solubility of AR-67 was determined at 37°C and pH 6.5, 7.0 and 7.5 in 
the presence of 0, 1, 2, and 3% SBE-CD to determine the lactone and carboxylate 
monoanion complexation constants with SBE-CD and to use in calculations of degree of 
supersaturation achieved in loading solutions. Briefly, 2-4 mg of AR-67 was added to 4 
ml of 10 mM MES buffer (pH 6.5) or HEPES buffer (pH 7.0 and 7.5) containing 0, 1, 2 
and 3% SBE-CD. The vials were rotated in an incubator at 37°C. At different time points, 
1 ml of sample was withdrawn using a needle and syringe and filtered through 0.45 µ 
PVDF syringe filters (13 mm). A filter adsorption study was carried out and subsequently 
the first 6-7 drops of filtrate were discarded before collecting filtrate for analysis. Filtrate 
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was diluted with cold (-25°C) 2:1 v/v methanol: acetonitrile, when required. Three 
independent samples were analyzed by HPLC at each condition and time point. 
Equilibrium was considered to have been established when two subsequent time points 
yielded similar values (8-12 days).  
Particle Size Measurements 
Particle sizes of blank and drug loaded liposomes were measured by dynamic light 
scattering (DLS) using a Delsa™ Nano submicron particle size analyzer (Beckman 
Coulter Inc., Brea, CA) at 25°C. The liposomes were diluted in the same buffer as that 
used in their preparation.  
HPLC Analyses  
Samples from equilibrium solubility experiments and liposome loading experiments were 
analyzed using a previously developed and validated isocratic HPLC method with 
fluorescence detection (126, 132). Standards for AR-67 carboxylate (0.2-2 µM) were 
prepared in 10 mM sodium carbonate buffer (pH 10.4) and standards for AR-67 lactone 
(0.5-2.5 µM) were prepared in acidified methanol. A Waters Alliance 2695 Separations 
Module coupled to a Waters Scanning Fluorescence Detector (M474) was employed with 
excitation and emission wavelengths at 380 and 560 nm, respectively. A Waters 
Symmetry® C18 column (5 µm, 3.9 X 150 mm) and guard column (3.9 X 20 mm) were 
used with a mobile phase composition of 48% acetonitrile and 52% (v/v) pH 5.5  
triethylamine acetate (2%) buffer. The retention times at an injection volume of 10 µl and 
a flow rate of 1 ml/min were 1.7 and 5.9 min for AR-67 carboxylate and lactone, 
respectively.  Generally, unless otherwise specified, AR-67 concentrations reported in the 
“Results” section refer to total concentrations considering all drug species. 
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MATHEMATICAL MODEL 
A mathematical model was developed for AR-67 uptake into calcium acetate vesicles, 
taking into account the chemical equilibria inside and outside the vesicle, mass balance, 
charge balance, and the transport kinetics of various permeable species across both the 
dialysis membrane and the liposome bilayer. Built into the model were the concentrations 
of various components, ionization constants, the different solution complexes present and 
their association/dissociation constants, binding constants for each species of AR-67 with 
the lipid bilayer, and permeability coefficients for the transport of permeable species 
across the dialysis membrane (including all AR-67 species, SBE-CD and AR-67/SBE-
CD complexes) and the lipid bilayer (i.e., AR-67 lactone and acetic acid). 
AR-67 may exist in a combination of four different species at any given pH (Figure 
5.1A). While the lactone (I) is considered to be the therapeutically active form, it exists in 
reversible equilibrium with its ring-opened carboxylate form under physiological 
conditions (76, 210). The fraction of the unionized ring-opened (carboxylic acid, II) 
species has been shown to be negligible in solution (211) and therefore an effective pKa 
for simultaneous ring-opening and ionization, denoted by 𝐾𝑎 (𝐾𝑎 = 𝐾 ∗ 𝐾𝑎1) of the E-
ring lactone, can be employed. The various equilibria (ionization, complexation, 
membrane partitioning, etc.) and transport processes governing liposome uptake from the 
aqueous solution inside the dialysis tube are shown in Figure 5.1B.  The concentrations of 
the various species in the extravesicular solution inside the dialysis tube are also 
governed by their reversible transport across the dialysis membrane separating the 
contents within the dialysis tube from the external loading solution.  These processes 
were also built into the mathematical model. The assumptions of the present model are: 
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(a) the lipid bilayer permeabilities of ionized species are negligible while both neutral and 
charged drug species cross the dialysis membrane with equal permeability coefficients;  
(b) SBE-CD and its complexes with AR-67 undergo transport across the dialysis 
membrane with identical permeability coefficients but liposomal uptake of these species 
is negligible; and c) an instantaneous equilibrium exists between the various species 
inside the vesicle during the loading process (126, 132, 187). All of the ionization 
constants and equilibrium constants for membrane binding of AR-67 were taken from 
previously published results (126, 132, 187, 212, 213). The permeability value for AR-67 
lactone across the liposome was determined from model fitting of experimental data 
under various loading conditions. The rate constants for free and bound drug transport 
across dialysis tube were also determined experimentally.  
Establishment of the pH gradient  
During dialysis of calcium acetate (or sodium acetate) containing vesicles, some of the 
entrapped acetate is released due to the diffusion of unionized acetic acid across the 
liposome bilayer, resulting in an increase in the intraliposomal pH. AR-67 uptake is 
accompanied by efflux of additional acetic acid, resulting in the maintenance of a high 
intraliposomal pH as a function of time during drug loading.  
The changes in acetate concentration in the intra- and extravesicular compartments due to 
the reversible transport of unionized acetic acid can be described by the following rate 
equations: 
𝑑𝐶𝑖
𝑑𝑡
= 3𝑃𝑚𝑎
𝑅
(𝑓𝑜𝐶𝑜 − 𝑓𝑖𝐶𝑖)            (5.1𝑎) 
𝑑𝐶𝑜
𝑑𝑡
= 3𝑃𝑚𝑎
𝑥𝑅
(𝑓𝑖𝐶𝑖 − 𝑓𝑜𝐶𝑜)            (5.1𝑏) 
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𝑓𝑖 = 𝐻𝑖+𝐾2𝐻𝑖+𝐾2 + 𝐾𝑎𝑎𝑐𝐾2 + 𝐾𝑎𝑎𝑐𝐶𝑎𝑖+2          (5.1𝑐) 
𝑓𝑜 = 𝐻𝑜+𝐻𝑜+ + 𝐾𝑎𝑎𝑐                    (5.1𝑑) 
where 𝐶𝑖 and 𝐶𝑜 are the intra- and extravesicular concentrations of total acetate; 𝑓𝑖 and 𝑓𝑜 
are the intra- and extravesicular fractions of the neutral acetic acid species; 𝐻𝑖+and 𝐻𝑜+ are 
the intra- and extravesicular proton concentrations; 𝐾2 is the dissociation constant of the 
calcium acetate complex; 𝐾𝑎𝑎𝑐 (1.78 x 10
-5) is the ionization constant of acetic acid; 𝐶𝑎𝑖+2 
is the intravesicular calcium concentration; 𝑥 is the ratio of extravesicular volume (𝑉𝑜) to 
the total intravesicular volume (𝑉𝑖) within the dialysis tube; 𝑃𝑚𝑎 is the permeability 
coefficient of the neutral acetic acid species; and 𝑅 is the radius of the vesicles. 
Various calcium complexes were considered in the intraliposomal aqueous compartment. 
The intravesicular concentrations of calcium and its complexes with acetate and 
hydroxide are given as follows:  
𝐶𝑎(𝐴𝑐)𝑖+ = 𝐶𝑎𝑖2+𝐴𝑐𝑖−𝐾2                 (5.1𝑒) 
𝐶𝑎(𝑂𝐻)𝑖+ = 𝐶𝑎𝑖2+𝑂𝐻𝑖−𝐾1              (5.1𝑓) 
𝐶𝑎𝑖
2+ = 𝐾1𝐾2((𝐾1𝐾2) + (𝐾2𝑂𝐻𝑖−) + (𝐾1𝐴𝑐𝑖−))𝐶𝑖02              (5.1𝑔) 
𝐴𝑐𝑖
− = 𝐾𝑎𝑎𝑐𝐾2𝐶𝑖((𝐻𝑖+𝐾2) + (𝐾𝑎𝑎𝑐𝐾2) + (𝐾𝑎𝑎𝑐𝐶𝑎𝑖2+))                  (5.1ℎ) 
𝐴𝑐𝑜
− = 𝐾𝑎𝑎𝑐𝐶𝑜
𝐻𝑜
+ + 𝐾𝑎𝑎𝑐             (5.1𝑖) 
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where 𝐶𝑎(𝐴𝑐)𝑖+ and 𝐶𝑎(𝑂𝐻)𝑖+ are intravesicular complexes of calcium with acetate and 
hydroxide ions respectively; 𝑂𝐻𝑖− is the intravesicular hydroxide ion concentration; 𝐴𝑐𝑖− 
and 𝐴𝑐𝑜− are the intravesicular and extravesicular acetate ion concentrations; and 𝐾1 is the 
dissociation constant of the calcium hydroxide solution complex. The extravesicular 
calcium concentration is considered to be negligible. 
Substituting Eq. (5.1g) into (5.1h) and simplifying it to the quadratic form,  
𝐴𝑐𝑖
− = (−𝐵 ± (√𝐵2 − 4𝐴𝐶)2𝐴               (5.1𝑗) 
where  
𝐴 = 2𝐾1𝐾2(𝐻𝑖+ + 𝐾𝑎𝑎𝑐)              (5.1𝑗 − 𝑖) 
𝐵 = 2𝐻𝑖+𝐾1�𝐾22� + 2𝐻𝑖+𝑂𝐻𝑖−�𝐾22� + 2𝐾𝑎𝑎𝑐𝐾1�𝐾22� + 2𝐾𝑎𝑎𝑐𝑂𝐻𝑖−�𝐾22� + 𝐾𝑎𝑎𝑐𝐾1𝐾2𝐶𝑖0
− 2𝐾𝑎𝑎𝑐𝐾1𝐾2𝐶𝑖                                                     (5.1𝑗 − 𝑖𝑖) 
𝐶 = −2𝐾𝑎𝑎𝑐𝐾22𝐶𝑖(𝐾1 + 𝑂𝐻𝑖−)                   (5.1𝑗 − 𝑖𝑖𝑖) 
Solving Eqs. (5.1a)-(5.1j) combined with the appropriate charge balance equation for the 
intravesicular compartment using Scientist (Micromath Inc.), the change in intravesicular 
pH as a function of time due to release of acetic acid can be estimated. 
Active Drug Loading Step 
Sink conditions inside the liposomes were created by the high intraliposomal pH (which 
results in conversion of AR-67 lactone to its ring-opened carboxylate mono- and di-anion 
species) and maintained by acetic acid exchange for the lactone entering the liposome. 
Intraliposomal membrane binding of AR-67 further contributed to the maintenance of a 
chemical potential gradient for the lactone. Thus, when liposomes were exposed to a 
supersaturated AR-67 solution at pH 7.5 the unionized lactone form of the drug 
permeated from the external solution into the liposomes in response to its concentration 
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gradient. The mathematical model was utilized to simulate the pH and liposomal AR-67 
concentration versus time for varying degrees of supersaturation of the drug loading 
solution. 
Details of the model development are presented below and the relevant constants used in 
simulations are given in Table 5.1. The equations were solved using Scientist® 
(Micromath Scientific Software, St. Louis, MO) software. 
 
𝑑(𝐼𝑡𝑖)
𝑑𝑡
= 𝑘𝑚(𝐼𝑜𝑤 − 𝐼𝑖𝑤)              (5.2𝑎) 
𝑑(𝐼𝑡𝑜)
𝑑𝑡
= 𝑘𝑚
𝑥
(𝐼𝑖𝑤 − 𝐼𝑜𝑤) + 𝑘𝑑(𝐼𝑏 − 𝐼𝑜𝑤) + 𝑘𝑑(𝐼𝐼𝐼𝑏 − 𝐼𝐼𝐼𝑜𝑤) + 𝑘𝑑𝑐𝑑(𝐼𝑏𝐶𝐷𝑏 − 𝐼𝑜𝐶𝐷𝑜)+ 𝑘𝑑𝑐𝑑(𝐼𝐼𝐼𝑏𝐶𝐷𝑏 − 𝐼𝐼𝐼𝑜𝐶𝐷𝑜)                 (5.2𝑏) 
𝑑(𝐶𝐷𝑡)
𝑑𝑡
= 𝑘𝑑𝑐𝑑 (𝐶𝐷𝑏 − 𝐶𝐷𝑜) + 𝑘𝑑𝑐𝑑(𝐼𝑏𝐶𝐷𝑏 − 𝐼𝑜𝐶𝐷𝑜)+ 𝑘𝑑𝑐𝑑(𝐼𝐼𝐼𝑏𝐶𝐷𝑏 − 𝐼𝐼𝐼𝑜𝐶𝐷𝑜)              (5.2𝑐) 
𝐼𝑡 = 𝐼𝑡𝑖𝑥 + 𝐼𝑡𝑜                (5.2𝑑) 
where, 𝐼𝑡𝑖 is the total intravesicular drug concentration and 𝐼𝑡𝑜 is the total extravesicular 
drug concentration; 𝐼𝑖𝑤and 𝐼𝑜𝑤 are the intravesicular and extravesicular aqueous 
concentrations of the lactone form (permeable species) of the drug, respectively; 𝐼𝐼𝐼𝑜𝑤, 
𝐼𝑜𝐶𝐷𝑜, 𝐼𝐼𝐼𝑜𝐶𝐷𝑜 are the extravesicular free carboxylate, lactone/SBE-CD complex, and 
carboxylate monoanion/SBE-CD complex concentrations, respectively; and 𝐼𝑏 , 𝐼𝐼𝐼𝑏, 
𝐼𝑏𝐶𝐷𝑏, 𝐼𝐼𝐼𝑏𝑜𝐶𝐷𝑏 are the free lactone, free carboxylate, lactone/SBE-CD complex, and 
carboxylate monoanion/SBE-CD complex concentrations in the bulk loading solution, 
respectively. 𝑘𝑚 is the rate constant for lactone transport through the given lipid bilayer 
and  𝑥 is the ratio of extravesicular to intravesicular volume in the dialysis tube, as 
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described before. 𝑘𝑑 and 𝑘𝑑𝑐𝑑 are the rate constants for the free drug and cyclodextrin 
complexed drug (or free cyclodextrin) across the dialysis membrane, respectively. The 
intrinsic permeability coefficient, 𝑃𝑚 , is related to the rate constant for lactone transport 
by 𝑃𝑚 = 𝑘𝑚 ∗ 𝑉𝑖 𝐴⁄ = 𝑘𝑚 ∗ 𝑅 3⁄  where 𝑅 and 𝐴 are the radius and area of the liposome, 
respectively. 
The mass balance of total drug inside the liposomes is 
𝐼𝑡
𝑖 = 𝐼𝑖𝑤 + 𝐼𝐼𝐼𝑖𝑤 + 𝐼𝑉𝑖𝑤
𝑎
+ 𝐼𝑖𝑚 + 𝐼𝐼𝐼𝑖𝑚 + 𝐼𝑉𝑖𝑚
𝑏
 �𝑎 = 𝑉𝑖
𝑉𝑖
𝑤 ;  𝑏 = 𝑉𝑖𝑉𝑖𝑚�            (5.2𝑒) 
where 𝐼𝑖𝑤, 𝐼𝐼𝐼𝑖𝑤, 𝐼𝑉𝑖𝑤 are internal aqueous concentrations of lactone, carboxylate 
monoanion and carboxylate dianion, respectively; 𝐼𝑖𝑚, 𝐼𝐼𝐼𝑖𝑚, 𝐼𝑉𝑖𝑚 are internal membrane 
bound concentrations of lactone, carboxylate monoanion and carboxylate dianion, 
respectively; 𝑎 and 𝑏 are volume ratios to account for the differences in aqueous and 
membrane volumes with respect to the total intravesicular volume; 𝑉𝑖 is the total 
liposomally entrapped aqueous volume plus the lipid volume in the inner bilayer leaflet 
of liposomes in the suspension; 𝑉𝑖𝑤 and 𝑉𝑖𝑚 are the volumes of the inner aqueous 
compartment and inner monolayer in each vesicle, respectively. 
Substituting, 
𝐼𝑡
𝑖 = 𝐼𝑖𝑤 + 𝐾𝑎𝑤 𝐼𝑖𝑤𝐻𝑖+ + 𝐾𝑎𝑤 𝐾𝑎2𝑤  𝐼𝑖𝑤(𝐻𝑖+)2
𝑎
+ 𝐾𝑝1𝐼𝑖𝑤 + 𝐾𝑝2𝐼𝐼𝐼𝑖𝑤 + 𝐾𝑝3𝐼𝑉𝑖𝑤
𝑏
                     (5.2𝑓) 
where 𝐾𝑎𝑤 and 𝐾𝑎2𝑤  are the ionization constants of AR-67 in the aqueous phase and 
𝐾𝑝1,𝐾𝑝2,𝐾𝑝3 are the membrane/water partition coefficients of the lactone, carboxylate 
monoanion and carboxylate dianion, respectively. The values of all these parameters 
(𝐾𝑎𝑤,𝐾𝑎2𝑤 ,𝐾𝑝1,𝐾𝑝2,𝐾𝑝3) have been determined previously (126, 132, 187, 213).  
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Expressing the total intravesicular concentration in terms of free aqueous lactone 
concentration, 
𝐼𝑡
𝑖 = 𝐼𝑖𝑤
⎩
⎨
⎧1 + 𝐾𝑎𝑤
𝐻𝑖
+ + 𝐾𝑎𝑤𝐾𝑎2𝑤(𝐻𝑖+)2
𝑎
+ 𝐾𝑝1 + 𝐾𝑝2𝐾𝑎𝑤𝐻𝑖+ + 𝐾𝑝3𝐾𝑎𝑤𝐾𝑎2𝑤(𝐻𝑖+)2
𝑏
⎭
⎬
⎫                 (5.2𝑔) 
𝐼𝑡
𝑖 = 𝐼𝑖𝑤{𝑎𝑖 + 𝑏𝑖} … 
⎝
⎜
⎛
𝑎𝑖 = 1 + 𝐾𝑎𝑤𝐻𝑖+ + 𝐾𝑎𝑤𝐾𝑎2𝑤(𝐻𝑖+)2𝑎 ;  𝑏𝑖
= 𝐾𝑝1 + 𝐾𝑝2𝐾𝑎𝑤𝐻𝑖+ + 𝐾𝑝3𝐾𝑎𝑤𝐾𝑎2𝑤(𝐻𝑖+)2
𝑏
⎠
⎟
⎞                (5.2ℎ) 
The intravesicular aqueous unbound concentration of lactone can be described in terms of 
total intravesicular concentration; 
𝐼𝑖
𝑤 = 𝑢𝑏𝑖 (𝐼𝑡𝑖) … �𝑢𝑏𝑖 = 1𝑎𝑖 + 𝑏𝑖�                    (5.2𝑖) 
where 𝑢𝑏𝑖 is the intravesicular unbound fraction of the drug. 
Now, considering the extravesicular drug equilibrium with cyclodextrin and the mass 
balance of the total drug in the bulk loading solution, 
𝐼𝑡
𝑜 = 𝐼𝑜𝑤 + 𝐼𝐼𝐼𝑜𝑤 + 𝐼𝑜𝐶𝐷𝑜 + 𝐼𝐼𝐼𝑜𝐶𝐷𝑜
𝑐
+ 𝐼𝑜𝑚 + 𝐼𝐼𝐼𝑜𝑚
𝑑
 �𝑐 = 𝑉𝑜
𝑉𝑜
𝑤 ;  𝑑 = 𝑉𝑜𝑉𝑜𝑚�              (5.3𝑎) 
where, 𝐼𝑡𝑜 is the total extravesicular drug concentration, 𝐼𝑜𝑤 and 𝐼𝐼𝐼𝑜𝑤 are unbound 
extravesicular aqueous concentrations of lactone and carboxylate monoanion, 
respectively; 𝐼𝑜𝐶𝐷𝑜 and 𝐼𝐼𝐼𝑜𝐶𝐷𝑜 are the aqueous concentrations of lactone and 
carboxylate monoanion complexes with SBE-CD;  𝐼𝑜𝑚 and 𝐼𝐼𝐼𝑜𝑚 are the membrane bound 
extravesicular drug concentrations, respectively; c and d are volume ratios to account for 
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the differences in aqueous and membrane volume with respect to the total extravesicular 
volume in the dialysis tube; 𝑉𝑜 is the extravesicular aqueous volume along with the 
volume of lipid in the outer bilayer leaflet of suspended liposomes in the dialysis tube; 
𝑉𝑜
𝑚 is the volume of the outer monolayer in each vesicle and 𝑉𝑜𝑤 is the volume of the 
extravesicular aqueous compartment in the dialysis tube. 
Note: In the mass balance of extravesicular drug concentrations, only lactone and 
carboxylate monoanion species are considered because the extravesicular pH was 
maintained at pH 7.5 where the concentration of carboxylate dianion species is assumed 
to be negligible ( 𝑝𝑘𝑎2𝑤=8.67). 
𝐼𝑜
𝑤 + 𝐶𝐷𝑜 𝐾𝑐𝑑1�⎯� 𝐼𝑜𝐶𝐷𝑜 …  �𝐼𝑜𝐶𝐷𝑜 = 𝐾𝑐𝑑1(𝐼𝑜𝑤)(𝐶𝐷𝑜)�                    (5.3𝑏) 
𝐼𝐼𝐼𝑜
𝑤 + 𝐶𝐷𝑜 𝐾𝑐𝑑2�⎯� 𝐼𝐼𝐼𝑜𝐶𝐷𝑜 …  �𝐼𝐼𝐼𝑜𝐶𝐷𝑜 = 𝐾𝑐𝑑2(𝐼𝐼𝐼𝑜𝑤)(𝐶𝐷𝑜)�        (5.3𝑐) 
where, 𝐶𝐷𝑜 is the free extravesicular concentration of SBE-CD and 𝐾𝑐𝑑1 and 𝐾𝑐𝑑2 are the 
complexation constants of AR-67 lactone and carboxylate monoanion with SBE-CD, 
respectively (experimentally determined in this study). 
Substituting Eqs. (5.3b and 5.3c) into Eq. (5.3a), 
 
𝐼𝑡
𝑜 = 𝐼𝑜𝑤 + 𝐼𝐼𝐼𝑜𝑤 + 𝐾𝑐𝑑1(𝐼𝑜𝑤)(𝐶𝐷𝑜) + 𝐾𝑐𝑑2(𝐼𝐼𝐼𝑜𝑤)(𝐶𝐷𝑜)
𝑐
+ 𝐼𝑜𝑚 + 𝐼𝐼𝐼𝑜𝑚
𝑑
              (5.3𝑑) 
𝐼𝑡
𝑜 = 𝐼𝑜𝑤 + 𝐾𝑎𝑤𝐼𝑜𝑤𝐻𝑜+ + 𝐾𝑐𝑑1(𝐼𝑜𝑤)(𝐶𝐷𝑜) + 𝐾𝑐𝑑2𝐾𝑎𝑤𝐼𝑜𝑤𝐶𝐷𝑜𝐻𝑜+
𝑐
+ 𝐾𝑝1𝐼𝑜𝑤 + 𝐾𝑝2 𝐾𝑎𝑤𝐼𝑜𝑤𝐻𝑜+
𝑑
       (5.3𝑒) 
𝐼𝑡
𝑜 = 𝐼𝑜𝑤 �1 + 𝐾𝑎𝑤𝐻𝑜+ + 𝐾𝑐𝑑1(𝐶𝐷𝑜) + 𝐾𝑐𝑑2𝐾𝑎𝑤𝐶𝐷𝑜𝐻𝑜+𝑐 + 𝐾𝑝1 + 𝐾𝑝2 𝐾𝑎
𝑤
𝐻𝑜
+
𝑑
�                 (5.3𝑓) 
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𝐼𝑡
𝑜 = 𝐼𝑜𝑤 ��1 + 𝐾𝑎𝑤𝐻𝑜+� + 𝐶𝐷𝑜(𝐾𝑐𝑑1 + 𝐾𝑐𝑑2𝐾𝑎𝑤𝐻𝑜+ )𝑐 + 𝐾𝑝1 + 𝐾𝑝2 𝐾𝑎
𝑤
𝐻𝑜
+
𝑑
�                   (5.3𝑔) 
 
Considering the mass balance of extravesicular total cyclodextrin, 
𝐶𝐷𝑡 = 𝐶𝐷𝑜 + 𝐼𝑜𝐶𝐷𝑜 + 𝐼𝐼𝐼𝑜𝐶𝐷𝑜             (5.3ℎ) 
where 𝐶𝐷𝑡 is the total concentration of extravesicular cyclodextrin. 
𝐶𝐷𝑡 = 𝐶𝐷𝑜 + 𝐾𝑐𝑑1(𝐼𝑜𝑤)(𝐶𝐷𝑜) + 𝐾𝑐𝑑2 𝐾𝑎𝑤𝐻𝑜+ (𝐼𝑜𝑤)(𝐶𝐷𝑜)             (5.3𝑖) 
𝐶𝐷𝑜 = 𝐶𝐷𝑡1 + 𝐾𝑐𝑑1(𝐼𝑜𝑤) + 𝐾𝑐𝑑2 𝐾𝑎𝑤𝐻𝑜+ (𝐼𝑜𝑤)              (5.3𝑗) 
Substituting eq. 5.3j into 5.3g,   
𝐼𝑡
𝑜 = 𝐼𝑜𝑤
⎩
⎪
⎨
⎪
⎧�1 + 𝐾𝑎𝑤𝐻𝑜+� + 𝐶𝐷𝑡1 + 𝐾𝑐𝑑1(𝐼𝑜𝑤) + 𝐾𝑐𝑑2 𝐾𝑎𝑤𝐻𝑜+ (𝐼𝑜𝑤) (𝐾𝑐𝑑1 + 𝐾𝑐𝑑2𝐾𝑎
𝑤
𝐻𝑜
+ )
𝑐
+ 𝐾𝑝1 + 𝐾𝑝2 𝐾𝑎𝑤𝐻𝑜+
𝑑
⎭
⎪
⎬
⎪
⎫               (5.3𝑘) 
Rearranging and simplifying it to the quadratic form, 
𝐼𝑜
𝑤 = (−𝐵1 ± (�𝐵12 − 4𝐴1𝐶1)2𝐴1               (5.3𝑙) 
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where,  
𝐴1 = �1 + 𝐾𝑎𝑤𝐻𝑜+�𝐾𝑐𝑑1 + �1 + 𝐾𝑎𝑤𝐻𝑜+� �𝐾𝑐𝑑2𝐾𝑎𝑤𝐻𝑜+ � + 𝐾𝑝1 + (𝐾𝑝2 𝐾𝑎
𝑤
𝐻𝑜
+)
𝑑
𝐾𝑐𝑑1𝑐
+ 𝐾𝑝1 + (𝐾𝑝2 𝐾𝑎𝑤𝐻𝑜+)
𝑑
𝑐 �
𝐾𝑐𝑑2𝐾𝑎
𝑤
𝐻𝑜
+ �              (5.3𝑙 − 𝑖) 
 
𝐵1 = �1 + 𝐾𝑎𝑤𝐻𝑜+� + �𝐾𝑐𝑑1 + 𝐾𝑐𝑑2𝐾𝑎𝑤𝐻𝑜+ � 𝐶𝐷𝑡 + 𝐾𝑝1 + (𝐾𝑝2 𝐾𝑎
𝑤
𝐻𝑜
+)
𝑑
𝑐 − 𝐼𝑡
𝑜𝐾𝑐𝑑1𝑐
− 𝐼𝑡
𝑜𝑐 �
𝐾𝑐𝑑2𝐾𝑎
𝑤
𝐻𝑜
+ �                (5.3𝑙 − 𝑖𝑖) 
𝐶1 = −𝐼𝑡𝑜𝑐              (5.3𝑙 − 𝑖𝑖𝑖) 
 
Similarly, considering the mass balance in the bulk loading solution,  
𝐼𝑡
𝑏 = 𝐼𝑏 + 𝐼𝐼𝐼𝑏 + 𝐼𝑏𝐶𝐷𝑏 + 𝐼𝐼𝐼𝑏𝐶𝐷𝑏                (5.4𝑎) 
where, 𝐼𝑡𝑏 is the total drug concentration in the bulk loading solution, 𝐼𝑏 and 𝐼𝐼𝐼𝑏 are 
unbound bulk aqueous concentrations of lactone and carboxylate monoanion, 
respectively; 𝐼𝑏𝐶𝐷𝑏 and 𝐼𝐼𝐼𝑏𝐶𝐷𝑏 are the aqueous concentrations of lactone and 
carboxylate monoanion complexes with SBE-CD in the bulk. 
𝐼𝑡
𝑏 = 𝐼𝑏 + 𝐾𝑎𝑤𝐼𝑏𝐻𝑜+ + 𝐾𝑐𝑑1(𝐼𝑏)(𝐶𝐷𝑏) + 𝐾𝑐𝑑2 �𝐾𝑎𝑤𝐼𝑏𝐻𝑜+ � (𝐶𝐷𝑏)                 (5.4𝑏) 
𝐼𝑡
𝑏 = 𝐼𝑏 �(1 + 𝐾𝑎𝑤𝐻𝑜+) + 𝐶𝐷𝑏(𝐾𝑐𝑑1 + 𝐾𝑐𝑑2𝐾𝑎𝑤𝐻𝑜+ )�                   (5.4𝑐) 
Considering the mass balance of total cyclodextrin in the bulk loading solution, 
𝐶𝐷𝑡𝑏 = 𝐶𝐷𝑏 + 𝐼𝑏𝐶𝐷𝑏 + 𝐼𝐼𝐼𝑏𝐶𝐷𝑏                   (5.4𝑑) 
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where, 𝐶𝐷𝑡𝑏 is the total cyclodextrin concentration in the bulk loading solution. 
𝐶𝐷𝑡𝑏 = 𝐶𝐷𝑏 + 𝐾𝑐𝑑1(𝐼𝑏)(𝐶𝐷𝑏) + 𝐾𝑐𝑑2 𝐾𝑎𝑤𝐻𝑜+ (𝐼𝑏)(𝐶𝐷𝑏)               (5.4𝑒) 
𝐶𝐷𝑏 = 𝐶𝐷𝑡𝑏1 + 𝐾𝑐𝑑1(𝐼𝑏) + 𝐾𝑐𝑑2 𝐾𝑎𝑤𝐻𝑜+ (𝐼𝑏)                  (5.4𝑓) 
 
Substituting eq. 5.4f into 5.4c,   
𝐼𝑡
𝑏 = 𝐼𝑏 ��1 + 𝐾𝑎𝑤𝐻𝑜+� + ( 𝐶𝐷𝑡𝑏1 + 𝐾𝑐𝑑1(𝐼𝑏) + 𝐾𝑐𝑑2 𝐾𝑎𝑤𝐻𝑜+ (𝐼𝑏))(𝐾𝑐𝑑1 + 𝐾𝑐𝑑2𝐾𝑎
𝑤
𝐻𝑜
+ �               (5.4𝑔) 
Rearranging and simplifying it to the quadratic form, 
𝐼𝑏 = (−𝐵2 ± (�𝐵22 − 4𝐴2𝐶2)2𝐴2                      (5.4ℎ) 
where,  
𝐴2 = �1 + 𝐾𝑎𝑤𝐻𝑜+�𝐾𝑐𝑑1 + �1 + 𝐾𝑎𝑤𝐻𝑜+� �𝐾𝑐𝑑2𝐾𝑎𝑤𝐻𝑜+ �                (5.4ℎ − 𝑖) 
𝐵2 = �1 + 𝐾𝑎𝑤𝐻𝑜+� + �𝐾𝑐𝑑1 + 𝐾𝑐𝑑2𝐾𝑎𝑤𝐻𝑜+ � 𝐶𝐷𝑡𝑏 − 𝐼𝑡𝑏𝐾𝑐𝑑1 − 𝐼𝑡𝑏 �𝐾𝑐𝑑2𝐾𝑎𝑤𝐻𝑜+ �                (5.4ℎ − 𝑖𝑖) 
𝐶2 = −𝐼𝑡𝑏          (5.4ℎ − 𝑖𝑖𝑖) 
Charge Balance 
𝐻+ + 2𝐶𝑎2+ + 𝐶𝑎(𝑂𝐻)+ + 𝐶𝑎(𝐴𝑐)+−𝐴𝑐− − 𝑂𝐻−
𝑎
− 𝐼𝐼𝐼− − 2𝐼𝑉2− = 0           (5.4𝑖) 
Eqs. (5.1a)-(5.1j), (5.2a-5.2i) (5.3a)-(5.3l) and (5.4a)-(5.4i) constitute the comprehensive 
set of equations used to model active drug loading into calcium acetate-containing 
liposomes. (Eqs. (5.1a)-(5.1j) describe the establishment of the pH gradient due to acetic 
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acid transport and Eqs. (5.2a-5.2i, 5.3a-5.3l and 5.4a-5.4i) account for active drug loading 
as a function of time. 
Experimentally, the pH gradient was established in a separate step where 1 ml of 
liposome was dialyzed against 1000 ml of 0.9% NaCl solution.  The drug loading step 
was then carried out in 200 ml of supersaturated drug solution following the pH gradient 
step. However, for the purposes of modeling, the equations governing the pH gradient 
were solved simultaneously with drug loading equations. 
Sodium Acetate Vesicles 
Similarly, while using the sodium acetate-containing vesicles instead of calcium acetate-
containing vesicles, the equations remain the same except that the equilibria involving 
calcium are absent. Sodium acetate (NaAc) dissociates completely in water.  
𝑁𝑎𝐴𝑐 → 𝑁𝑎+ + 𝐴𝑐−             (5.5𝑎) 
𝑁𝑎+ = 𝐶𝑖0                   (5.5𝑏) 
where 𝐶𝑖0 is the total initial acetate concentration (t=0). 
𝑓𝑖 = 𝐻𝑖+𝐻𝑖+ + 𝐾𝑎𝑎𝑐             (5.5𝑐) 
and 𝑓𝑖 is the fraction of unionized acetic acid. 
Charge Balance 
𝐻+ + 𝑁𝑎+−𝐴𝑐− − 𝑂𝐻−
𝑎
− 𝐼𝐼𝐼− − 2𝐼𝑉2− = 0            (5.5𝑑) 
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Table 5.1 Values of the constants used in the model simulation 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
#From the calculations described in the mathematical model section; $ from references 
(126, 131, 132, 187, 212, 213), & Avg. ± 95% CI (determined in this study); *calculated 
using Chemist® (Microsoft Scientific Software), ¥ from model fitting of experimental data 
in this study (Avg. ± 95% CI). 
  
Parameter Values Parameter Values 
a  1.08 # Kcd1 9788 (±820) M-1 & 
b 12.86 # Kcd2 1385 (±170) M-1 & 
c 1.0272 # K1 0.05 M * 
d 39.15 # K2 0.066 M * 
x 3.2118 # Kaac 1.78E-5 M * 
Kaw  3.4E-7 M $ k 1.77E5  hr-1 $ 
Ka2w 2.7E-9 M $ km 287 (±43) hr-1 ¥ 
Kp1 2443 $ kd 0.71(±0.06) hr-1 ¥ 
Kp2 141 $ kdcd 0.33(±0.04) hr-1 ¥ 
Kp3 73 $   
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RESULTS 
Liposome Characterization 
The particle size of blank liposomes was in the range of 180-190 nm, with a 
polydispersity index in the range of 0.075-0.087, indicating monodisperse formulations. 
Passive and active loading of liposomes with AR-67 did not alter the particle size 
significantly as drug loaded liposomes exhibited particle sizes within the range of 175-
185 nm, polydispersity index of 0.080-0.091. The extrusion procedure employed in this 
study was previously shown by 31P-NMR to produce unilamellar vesicles (141).  
Passive Loading  
Based on the pH-solubility profile of AR-67 (Figure 5.2), passive loading could not be 
successfully carried out with the lactone form of the drug due to its extremely poor 
aqueous solubility at pH 4.2 (1.11x 10-4 mg/ml). In order to overcome the limitations of 
low solubility at pH 4.2, passive loading at pH 9.5 was carried out. Despite an 
improvement in solubility of about four orders of magnitude, the drug-to-lipid ratio 
achieved was only 3x10-5. The low drug-to-lipid ratio achieved by passive loading led to 
consideration of the active loading method. 
Preliminary Active Loading Studies  
At high intravesicular pH, lactone (I) undergoes ring-opening and ionization to give 
carboxylate monoanion (III) and dianion forms (IV), providing sink conditions for 
uptake. Preliminary active loading of AR-67 into calcium acetate vesicles in the presence 
of excess solid at 37°C resulted in a drug-to-lipid ratio of only 0.0016 even after 70 hours 
(Figure 5.3A). Model simulations also predicted a very slow uptake under these 
conditions due to the low solubility of AR-67 at this temperature. In order to expedite the 
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 Figure 5.1 (A) Equilibria between AR-67 lactone (I), AR-67 carboxylic acid (II), AR-67 
carboxylate monoanion (III) and dianion (IV). (B) Possible chemical equilibria inside and 
outside the liposomes and transport processes during active drug loading in calcium 
acetate liposomes.  
Kaac is the dissociation constant for acetic acid; k is the rate constant for acetic acid transport; K1 and K2 are 
the dissociation constants of calcium hydroxide and calcium acetate complexes respectively. M is calcium 
metal ion, Iiw, IIIiw, IViw refer to intravesicular lactone, monoanion and dianion form of AR-67 respectively; 
Iim, IIIim, IVim are corresponding intravesicular membrane bound species. Kaw and Ka2w are ionization 
constants of AR-67 in water and Kam and Ka2m are ionization constants of membrane bound AR-67. Kp1, 
Kp2 and Kp3 are bilayer water partition coefficients for lactone, monoanion and dianion form of AR-67 
respectively, km is release rate constant of AR-67 through bilayer. Iow and IIIow are extravesicular lactone 
and monoanion form of AR-67 respectively; I-CD and III-CD are their corresponding cyclodextrin 
complexes in the extravesicular supersaturated drug solution. Kcd1 and Kcd2 are the binding constants of 
lactone and monoanion AR-67 with SBE-CD. The subscripts i and o denote intravesicular and 
extravesicular, respectively; superscripts w and m refer to water and membrane phases, respectively. Note: 
Dialysis tube is not shown in the figure but was considered in the development of the mathematical model. 
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Figure 5.2 pH-solubility profile of AR-67 in aqueous solution at 25°C (●) from ref [27] 
and solubility data generated in this study at 37°C and pH 6.5, 7.0 and 7.5 at 0% SBECD 
(□) and at 2% SBECD (▲). Solubility data at 37°C are averages of three independent 
determinations; the error bars are buried in the symbol itself. 
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uptake process, active loading in the presence of excess solid was also carried out at 60°C 
(i.e., above the gel→liquid crystalline phase transition temperature of DSPC of 55°C) as 
shown in Figure 5.3B. The intraliposomal pH-gradient stability was compromised at this 
high temperature, as evident from the significant increase in the fraction of intraliposomal 
lactone as a function of time (Figure 5.3B inset). The pH gradient was much more stable 
at 37°C, as shown by the inset in Figure 5.3A, although some drift in the fraction of 
lactone was apparent over the 70 hour time frame of these studies.  
To overcome the low solubility problems and subsequent low loading encountered using 
the active loading method even in the presence of excess solid, supersaturated solutions 
were produced by the pH adjustment method (Method I) and liposome uptake was 
monitored from these solutions at either 37°C or 60°C. Loading from supersaturated 
solutions increased dramatically compared to the results obtained in the presence of 
excess solid without supersaturation, as shown by the results in both Figures. 3A and B. 
Interestingly, the rate and extent of loading from the supersaturated drug solution was 
lower at 60°C (Figure 5.3B) compared to 37°C (Figure 5.3A) and at 60°C, the fraction of 
lactone increased rapidly as a function of time, exceeding 0.5 after 5 hrs (Figure 5.3B). 
Liposomal concentrations of AR-67 also peaked at 5 hours at 60°C and gradually 
declined thereafter, consistent with the evidence of instability in the pH gradient as 
monitored by the fraction of intraliposomal lactone. At 37°C, the fraction of lactone 
remained relatively stable and below 0.2 over at least 96 hours (Figure 5.3A inset), 
indicating that the high intraliposomal pH was maintained.  Consistent with this result, 
the liposomal uptake of AR-67 from the supersaturated solution at 37°C continued to 
increase over the entire 120 hr duration of the loading experiment (Figure 5.3A). 
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Figure 5.3 Active loading in 0.25 M calcium acetate liposomes at pH 7.5 and 37°C (A) or 
60°C (B) in the presence of excess solid and from supersaturated AR-67solutions 
(Method I). Inset shows intraliposomal % lactone during loading. a and b denotes 
replicates for the experiments at 37ºC. 
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Maintenance of Supersaturation  
The solubility profiles of AR-67 at pH 6.5, 7.0 and 7.5 with increasing concentrations of 
the cyclodextrin ([CD]) are shown in Figure 5.4. The linear solubility profiles indicate 
that 1:1 complexes predominate. Assuming [CD]>> 𝑆𝑜 and carboxylate dianion is 
negligible in the pH 6.5-7.5 region, complex formation constants for the neutral lactone 
(Kcd1) and carboxylate monoanion (Kcd2) were calculated from the following equation 
(185): 
𝑆 = 𝑆𝑜(1 + 𝐾𝑎10𝑝𝐻 + 𝐾𝑐𝑑1𝐶𝐷 + 𝐾𝑐𝑑2𝐶𝐷𝐾𝑎10𝑝𝐻)  (5.6) 
where 𝑆𝑜 is the intrinsic solubility of lactone. A linear least-squares fit of the data in 
Figure 5.4 to the above equation yielded Kcd1 =9788 (±820) M-1 and Kcd2 =1385 (±170) 
M-1 (the values in the bracket are ± 95% S-plane confidence intervals). 
Creating a supersaturated drug solution significantly increased the drug loading 
achievable but to maintain the supersaturation achieved by the pH adjustment method 
(Method I), frequent re-dissolution of precipitates formed over time by raising and then 
lowering the pH was required - a tedious and poorly reproducible process. Incorporation 
of a low (2%) concentration of SBE-CD into the pH 7.5 supersaturated solutions 
produced by the pH adjustment method was found to dramatically inhibit drug 
precipitation. The equilibrium solubility of AR-67 at pH 7.5 in the presence and absence 
of 2% SBE-CD was determined to account for the increase in the equilibrium solubility 
that would result from the complexation of AR-67 with SBE-CD and to assess the degree 
of supersaturation that could be achieved in loading solutions containing 2% SBE-CD. 
The equilibrium solubilities of AR-67 (± SD) were experimentally determined to be 1.35 
± 0.07 μg/ml and 26.5 ± 0.2 μg/ml in the absence and presence of 2% SBE-CD,  
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Figure 5.4 Plots of equilibrium solubility of AR-67 at 37°C as a function of SBE-CD 
concentration in buffered aqueous solutions at pH 6.5, 7.0 and 7.5. Each value is the 
average of three independent determinations; error bars are the standard deviations. 
Straight lines are least squares fits using Eq. 5.6. 
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respectively, at a pH of 7.5 at 37°C. Total supersaturated solution concentrations 
achieved by pH adjustment and maintained in the presence of 2% SBE-CD ranged from 
0.1-0.6 mg/ml. Figure 5.5 depicts the degree of supersaturation achieved in different 
loading solutions after normalizing to the appropriate equilibrium solubility value. The 
equilibrium solubilities of AR-67 at pH 7.5 with and without 2% SBE-CD were 
significantly different (p<0.05). Dramatic increases in concentrations of the permeable, 
free lactone were possible using this method (Method II). 
Active Loading from Drug Solutions Varying in Degree of Supersaturation 
Active loading of AR-67 in liposomes using an acetate pH gradient method was carried 
out in supersaturated loading solutions containing different drug concentrations (0.1, 0.2, 
0.4 and 0.6 mg/ml). Evidently, an increase in total drug concentration and a 
corresponding increase in lactone concentration in the loading solution resulted in 
increased intravesicular loading (Figure 5.6). 
Furthermore, a linear relationship was observed between the extent of loading and 
loading time with slopes that increased linearly with the drug concentration in the loading 
solution. This linearity is demonstrated in Figure 5.7, where liposome suspension 
concentration at 48 hr are plotted versus the drug concentration in the loading solution. 
The highest intraliposomal drug-to-lipid ratio of 0.17 was achieved when the drug 
concentration of 0.6 mg/ml was used in the external loading solution. Furthermore, the 
intraliposomal carboxylate fraction was found to remain above 0.86 in all cases (Figure 
5.8), indicating that the high intraliposomal pH was stable over the entire time frame of 
the loading experiments. Studies at the lowest (0.1 mg/ml) (n=3) and highest (0.6 mg/ml)  
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Figure 5.5 Enhancement of the total drug solubility and corresponding lactone 
concentration at pH 7.5 in the presence of 2% SBE-CD at equilibrium and in 
supersaturated solutions of varying degree. (Degree of supersaturation was calculated 
with respect to equilibrium solubility in 2% SBE-CD). * denotes the two values are 
significantly different from each other (p<0.05).  
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Figure 5.6 Liposome suspension concentrations of AR-67 versus time during active 
loading in calcium acetate-containing liposomes in supersaturated loading solutions 
(Method II) at different drug concentrations (0.1, 0.2, 0.4 and 0.6 mg/ml) at 37°C. Solid 
lines are the least-squares fits using the active loading model (Eqns. 5.2a-5.2d). 
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Figure 5.7 Experimental and predicted relationship between liposome drug loading upto 
48 hours and 37°C and total drug concentration in the external supersaturated loading 
solution. 
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 (n=4) loading solution concentrations were repeated and the results were found to be 
reproducible.   
Drug-to-lipid ratios obtained in all drug loading experiments described above are 
summarized in Table 5.2.   
Effect of counter ions on loading  
The active loading experiments reported above were carried out in liposomes prepared 
from 0.25 M calcium acetate.  Active loading of AR-67 was also carried out in liposomes 
prepared in 0.5 M sodium acetate using supersaturation Method II at the highest solution 
concentration of drug (0.6 mg/ml) to determine the role of the entrapped counter ion on 
loading. No significant difference was found in either the rate or extent of loading in 
sodium acetate vs. calcium acetate containing vesicles at various time points up to 48 
hours (Figure 5.9). 
Model Predictions 
Dialysis experiments in the absence of liposomes were necessary to obtain the reversible 
first-order rate constants for the transport of AR-67 in either its lactone and carboxylate 
forms (kd) and SBE-CD or SBE-CD/AR-67 complexes (kdcd) across the dialysis 
membrane. The values found for kd and kdcd are shown in Table 5.1 with their 95% 
confidence limits generated from a total of five independent concentration versus time 
profiles as described in the methods section. The values obtained for kd and kdcd in the 
absence of liposomes within the dialysis tube were assumed to be the same when 
liposomes were present.  
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Table 5.2 Drug/Lipid ratios for liposome formulations of AR-67 under passive and active 
loading conditions 
Initial 
extravesicular 
solution drug 
conc. (mg/ml) 
Loading type/Conditions 
Lipid 
Conc# 
(mM) 
AR-67 conc. 
(mM) in the 
liposome 
suspension 
Drug/Lipid 
ratio 
0.8 Passive/ pH 9.5 18.0 5.3E-4 3.0E-5 
0.00135 Active/Excess Solid 67.4 0.11 0.0016 
0.1* Active/ Supersaturated 67.4 1.91±0.44 0.027±0.006 
0.2 Active/ Supersaturated 67.4 4.26 0.060 
0.4 Active/ Supersaturated 67.4 6.58 0.089 
0.6* Active/ Supersaturated 67.4 11.95±0.99 0.170±0.015 
 
# For calculation of lipid concentration, normalized molecular weight of lipid was used, 
DSPC: mPEG-DSPE 95:5 mol%, Mol. Wt.= (0.95*Mol. Wt. of DSPC)+(0.05*Mol. Wt. 
of mPEG-DSPE)  
* Replicate experiments were conducted under these two extreme loading conditions to 
test the reproducibility of the loading method. Averages of three (at 0.1 mg/ml) and four 
(at 0.6 mg/ml) loading experiments are reported along with standard deviations. 
Drug/lipid ratios were calculated based on intravesicular drug concentrations. 
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The permeability coefficient for AR-67 lactone (permeable species) was determined from 
model fitting at different loading conditions (total external drug concentration of 0.1, 0.2, 
0.4 and 0.6 mg/ml) to be 2.13x10-7 ± 0.38 cm/s (95% confidence interval). Simulations 
can be performed, using the determined permeability value, to predict the loading as a 
function of the degree of supersaturation. While some of the constants and parameters 
(aqueous and membrane bound ionization constants of the drug, membrane partition 
coefficients of each species) employed in these model simulations were from previously 
published experimental studies from our lab (126, 132, 187), the permeability coefficient 
of the lactone was the only fitted parameter generated from the liposome loading data, as 
the rate constants for free and bound drug across the dialysis membrane were determined 
from separate experiments. Figure 5.6 shows the model fitting of the experimental data 
demonstrating the linear increase in intravesicular drug concentrations with time. The 
slopes of the fits increased linearly with drug concentration consistent with the model 
prediction indicated by the dashed line in Figure 5.7. The model simulations also gave 
identical results with sodium and calcium acetate liposomes for the liposomal 
concentration vs. time (Figure 5.9) indicating that the nature of the intraliposomal cation 
(i.e., Na+ vs. Ca++) was inconsequential for loading. 
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Figure 5.8 Liposomal suspension fraction of carboxylate and lactone versus time during 
active loading in calcium acetate-containing liposomes in supersaturated loading 
solutions (Method II) at different total drug concentrations (0.1, 0.2, 0.4 and 0.6 mg/ml) 
at 37°C. The points are the experimental data and the lines are the model simulations. 
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Figure 5.9 Comparison of active loading in 0.5 M sodium acetate and 0.25 M calcium 
acetate-containing liposomes in the presence of supersaturated solutions (Method II) 
containing 0.6 mg/ml AR-67 concentration at 37°C. 
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DISCUSSION 
Liposomal delivery of antitumor agents is highly desirable to passively target these drugs 
to tumor tissues and minimize unwanted side effects (214). Achieving high liposomal 
loading may be particularly challenging for new, highly lipophilic antitumor agents 
exhibiting very low water solubility. AR-67, a novel camptothecin analogue that is 
currently in clinical studies, serves as an example and was therefore chosen as a model 
drug for this study. 
Passive Loading 
The intraliposomal drug concentrations achieved by passive loading, the conventional 
method of drug loading into liposomes, depends on entrapped aqueous volume, lipid 
concentration, and the solubility and partition coefficient of the drug (48). For the lipid 
concentration (16 mg/ml) employed in this study, the entrapped aqueous volume can be 
estimated to be ~ 6.4%. Passively loading liposomes using AR-67 solutions at a low pH 
of 4.2 was not feasible due to the poor drug solubility at this pH. An attempt to improve 
drug uptake by carrying out passive loading at a higher pH of 9.5, where an aqueous 
solubility of 0.8 mg/mL could be achieved (Table 5.2), resulted in a very low drug to 
lipid ratio (D/L=3x10-5). Theoretically, based on the solubility at pH 9.5 and the aqueous 
entrapped volume, a D/L of ~3x10-3 can be estimated with no contribution of 
intraliposomal membrane binding. The much lower loading ratio achieved may reflect 
poor permeation of the hydrophilic dianionic species which predominates at pH 9.5 
through the lipid film layers during the hydration step prior to vesicle formation. 
Moreover, based on the profile for AR-67 membrane binding versus pH (126) and its pH-
solubility profile (185), there exists an interplay between solubility and membrane  
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Figure 5.10 Model simulations for different intraliposomal and extraliposomal species. 
(A) Loss of intraliposomal acetic acid and corresponding intraliposomal AR-67 gain 
during active loading along with comparison of acetic acid loss in the absence of drug; 
(B) Intravesicular and extravesicular pH during active loading of drug in 0.25 M calcium 
acetate liposomes at 37°C. 
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partitioning with changes in pH. While the solubility of AR-67 increases from 1.11x10-4 
mg/ml at pH 4.2 to 0.8 mg/ml at pH 9.5, the bilayer/water partition coefficient decreases 
from 2443 ± 230 at pH 4.1 to 57 ± 5 at pH 9.5 (212). Thus, in terms of passive loading, 
the advantage of increased solubility at high pH is offset in part by decreased membrane 
binding. 
Active Loading 
Active loading is primarily driven by a chemical potential gradient across the bilayer as 
given by Eq. 5.7.  
𝐹𝑙𝑢𝑥 𝛼 𝑃𝑚(𝐶𝑓𝑟𝑒𝑒𝑜𝑢𝑡 − 𝐶𝑓𝑟𝑒𝑒𝑖𝑛 )  (5.7) 
where 𝑃𝑚 is the intrinsic permeability coefficient for the unionized species, 𝐶𝑓𝑟𝑒𝑒𝑜𝑢𝑡  is the 
free concentration of the unionized species in the external medium and 𝐶𝑓𝑟𝑒𝑒𝑖𝑛  is the free 
intraliposomal concentration of the same species assuming that only the unionized 
species is permeable. 
Enhancement of the External Driving Force for Active Loading 
To enhance liposome loading of AR-67, a pH-gradient active loading approach was 
explored in which a high intraliposomal pH was created by preparing liposomes in the 
presence of high concentrations of either calcium acetate or sodium acetate. As indicated 
in Eq. 5.7, the driving force for active loading of AR-67 is the external to internal free 
lactone concentration gradient. Partial release of acetic acid creates a high intraliposomal 
pH resulting in a reduction in 𝐶𝑓𝑟𝑒𝑒𝑖𝑛 , providing sink conditions for liposomal uptake of 
AR-67. Eq. 5.7 also indicates that the rate of uptake (flux) can be increased by enhancing 
the trans-membrane permeability of the drug, for example, by increasing temperature. 
Under conditions in which 𝐶𝑓𝑟𝑒𝑒𝑜𝑢𝑡  is limited by the equilibrium solubility of AR-67, it was 
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reasoned that maintaining this concentration by conducting drug loading in the presence 
of excess solid would be beneficial. Therefore, active loading studies were initially 
conducted in the presence of excess solid drug at 37°C, although model predictions 
suggested that this approach would have limited success due to the very low equilibrium 
solubility of the drug. Slow uptake was indeed observed at 37°C, as shown by the data in 
Figure 5.3A. To increase Pm (and perhaps AR-67 solubility) loading experiments were 
also conducted at 60°C, as above the phase transition temperature for DSPC (55°C), the 
liposome bilayer is in a more permeable liquid crystalline form (131). This resulted in a 
modest increase in uptake rate (Figure 5.3B) but as illustrated by the inset in Figure 5.3B, 
the fraction of the intraliposomal lactone species which is dominant only at a lower pH 
increased dramatically with time at 60°C indicating that within 5-10 hrs the pH gradient 
had dissipated. Previous reports (215, 216) have confirmed losses in pH gradients during 
active loading in cholesterol free liposomes above the phase transition temperature 
attributed to membrane destabilization, leading to a decline in loading with time. 
Dissipation of pH gradients above the phase transition temperature may be attributable to 
increased permeability of hydrochloric acid, hydrogen ions, or ion pairs, etc. (215, 217-
220). Liposomes containing 40-50% cholesterol may be more resistant to these effects 
due to stabilization of bilayers by cholesterol above the phase transition (206, 221, 222).  
In an attempt to overcome the limitations in liposomal uptake imposed by the low 
aqueous solubility of AR-67, which results in a low driving force (cf., Eq. 5.7), 
supersaturated drug solutions of AR-67 was created, first simply by pH adjustment 
(Method I). Supersaturation increased the aqueous concentration of the drug, including 
free lactone, and dramatically enhanced liposomal uptake rates at both 37°C (Figure 
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5.3A) and 60°C (Figure 5.3B), although the aforementioned dissipation in pH gradient 
and a resulting decline in drug loading now became clearly evident at 60°C. Because 
Method I was ineffective in maintaining supersaturation over a prolonged period, the use 
of SBE-CD to inhibit nucleation and crystal growth was evaluated. Previously, 20% 
SBE-CD had been shown to inhibit the crystallization of 2 mg/ml supersaturated 
solutions of AR-67 after reconstitution from lyophiles for at least three days (185). Here, 
2% solution concentrations of SBE-CD were employed to minimize the fraction of 
lactone present in inclusion complexes while maintaining high supersaturated 
concentrations. As demonstrated in Table 5.2 and Figure 5.5, supersaturated solution 
concentrations as high as 0.6 mg/ml were maintained using this approach, resulting in 
substantial increases in drug loading at 37°C, with D/L ratios as high as 0.17 (Table 5.2) 
and with no apparent dissipation in the pH gradient (Figure 5.8).  
Mechanism-Based Mathematical Model Development  
A mathematical model was developed to explore intraliposomal properties that may be 
important both for loading and drug release and to predict drug loading under various 
conditions. A key assumption in the model is that the driving force for drug uptake is the 
transbilayer concentration gradient of the free lactone. The model incorporates the 
experimentally determined ionization and membrane binding constants of each species of 
the drug along with equilibrium constants for the formation of cyclodextrin complexes of 
AR-67 lactone and its ring-opened monoanion. The incorporation of the permeability 
coefficients enables the prediction of rates of drug uptake, representing an important 
advance in comparison to previous models (223-225). 
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Experimental data generated at various loading concentrations (0.1, 0.2, 0.4 and 0.6 
mg/ml) were fitted to the developed model to determine the permeability coefficient of 
the lactone under active loading conditions. The intrinsic permeability value for AR-67 
lactone obtained in this study from km (see Table 5.1) is 2.13x10-7 ± 0.38 cm/s, which lies 
between a previously reported experimental value determined from liposomal release 
studies by Joguparthi et al (212) and a predicted value using the “barrier-domain” 
solubility diffusion model (130, 212).  
While one would expect the permeability coefficient to be the same for both uptake and 
release the determination of the driving forces (lactone concentration gradient) governing 
drug uptake or release rates is not trivial. If the driving force is not determined accurately, 
the permeability coefficient obtained by experiment will also be inaccurate. Estimating 
the driving force governing drug release requires determination of the aqueous 
concentration of free lactone inside the liposome, which depends on the intraliposomal 
pH and membrane binding of each AR-67 species inside the liposome. AR-67 is 
extensively bound intraliposomally due to its high membrane binding coefficients and the 
high membrane surface to volume ratio inside the liposomes [19, 20]. The driving force 
for drug uptake is somewhat easier to determine, although one must either analyze the 
free lactone concentration or use a mathematical model that includes transport across the 
dialysis membrane to obtain the steady-state extravesicular lactone concentration inside 
the dialysis tube.  In the present study, the dialysis membrane did partially contribute to 
the overall barrier for drug-loading but reliable estimation of the intrinsic permeability 
coefficient of AR-67 was still possible. The extravesicular free lactone concentration at 
steady-state was 2.4 times lower than the free lactone concentration in the bulk solution 
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outside the dialysis tube due to the resistance of the dialysis membrane barrier. In the 
absence of this barrier, a maximum increase of ~2.5 fold in the rate of loading might have 
been achievable. It can be expected that using a dialysis membrane of higher molecular 
weight cut-off would have had some benefit, but much less than this maximum.   
Differences in the uptake rate and extent of AR-67 loading up to 48 hours into calcium 
acetate-containing liposomes under various loading conditions can be accurately 
predicted by the mathematical model using the permeability value determined for AR-67 
(Eqs. 5.2a-5.2d) as illustrated in Figures 5.6 and 5.7. Simulations using the same model 
were conducted to further explore the role of intraliposomal acetate in establishing the pH 
gradient. A high intraliposomal pH is produced by the transbilayer concentration gradient 
of acetic acid, which is a highly permeable weak acid (𝑃𝑚𝑎=1.6 (± 0.2)x10
-4 cm/s across 
DSPC bilayers (131)). Figure 5.10B shows the simulated increase in intraliposomal pH 
during the initial dialysis step to remove unentrapped buffer (Eqs. 5.1a-5.1j). This high 
intraliposomal pH is maintained by the continuous transport of acetic acid from inside the 
vesicles in exchange for incoming lactone. Figure 5.10A shows the direct relationship 
between acetate loss and intraliposomal drug loading. For each molecule of lactone 
internalized, two molecules of acetic acid are lost due to the predominance of the AR-67 
dianion at this intraliposomal pH. Model predictions of the fractions of lactone and 
carboxylate in the liposome suspension during the course of loading compare favorably 
to the experimental observations except at the initial time points. In the initial stages of 
loading, the contribution of the extravesicular drug concentration to the total suspension 
concentration is relatively high and the discrepancy in this early region may be 
attributable to the fact the solution initially introduced into the dialysis tube is a poorly 
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buffered dilute calcium acetate solution in 0.9% NaCl that may have a higher initial pH 
than the bulk loading solution. The model assumes a constant extravesicular and bulk pH 
of 7.5. Also, there may be some error associated with quenching the carboxylate to 
lactone conversion during sample preparation and prior to HPLC analysis. In their 
validation of an analytical method for the determination of the lactone and carboxylate 
concentrations in mouse plasma, Horn et al. reported a carboxylate to lactone conversion 
of about 3.7% prior to sample analysis [44]. Nevertheless, experimental analysis of both 
lactone and carboxylate fractions during drug loading under different conditions revealed 
relatively stable, high intraliposomal carboxylate fractions, indicative of a high 
intraliposomal pH. 
The high intraliposomal pH demonstrated in both simulations and experimentally in this 
study results in a low intravesicular fraction of free lactone (I), caused by base-catalyzed 
ring-opening of the lactone to its carboxylate form (III and IV) at the high intraliposomal 
pH. Internal membrane binding further reduces the intraliposomal lactone concentration, 
creating intraliposomal sink conditions. The uptake rate during active loading is therefore 
primarily governed by the extravesicular driving force (i.e., free lactone concentration 
enhanced by supersaturation to varying degrees). These increases in drug loading with 
higher lactone concentrations in the supersaturated loading solutions are illustrated in 
Figures. 5.5 and 5.6. Experimentally, the maximum drug-to-lipid ratio demonstrated 
within 48 hours was 0.17.  However, as mentioned previously, the rate of loading may 
have been modestly enhanced by using a dialysis membrane of higher molecular weight 
cut-off to increase dialysis membrane transport rates. Model simulations predict that a 
very high extent of loading (D/L of 0.8) could be achieved at equilibrium, provided 
 148 
supersaturation could be maintained for a prolonged period of time. Also, loading may be 
further enhanced by intraliposomal precipitation of the calcium salt of AR-67, as 
governed by its solubility product (226). While the model developed herein does not 
consider possible intraliposomal salt precipitation, the rates of uptake and extent of 
loading within 48 hrs would not have been affected by this possibility because 
intraliposomal sink conditions were maintained throughout this time frame even in the 
absence of salt precipitation. No significant difference could be detected between the rate 
and extent of loading at 48 hours from 0.6 mg/ml supersaturated drug concentrations 
when liposomes prepared in 0.5 M sodium acetate were employed rather than those 
containing 0.25 M calcium acetate (Figure 5.9). This further suggests that the enhanced 
active loading is mainly dependent upon establishment and maintenance of the pH 
gradient leading to intraliposomal sink conditions and increases in the external driving 
force by supersaturation.  
Active loading in response to a transmembrane chemical gradient is dependent upon the 
properties of the individual drug (208). Zucker et al. suggested an aqueous solubility of 
1.9 mM to be a reasonable solubility for active drug loading (48). While the aqueous 
solubility of a drug is important, it is the concentration of the unionized permeable 
species that provides the driving force for active loading (cf., Eq. 5.7). A detailed analysis 
of the factors responsible for the maximum liposome loading achieved by others (39, 41, 
44, 46-48, 84, 206, 208, 227) using the active loading technique is difficult, but the 
evidence suggests that reasonable loading required either a moderate solubility of the 
unionized species, or, in some cases, the authors may have unknowingly created 
supersaturated solutions during loading. In the present study, achieving the high drug to 
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lipid ratio of 0.17 clearly required a combination of the transmembrane pH gradient 
approach and supersaturation. 
CONCLUSIONS 
A novel method of active loading was developed for a poorly soluble model compound, 
AR-67, a third generation potent camptothecin analogue, using supersaturated drug 
solutions along with a high intraliposomal pH produced by a transmembrane acetate 
gradient. Maintenance of supersaturation was aided by use of a cyclodextrin (SBE-CD) to 
inhibit drug crystallization during loading. Furthermore, a mechanism-based 
mathematical model was developed to understand the loading process, assuming that the 
driving force for drug uptake across the membrane is the concentration gradient of the 
free unionized species. Loading was mainly driven by the establishment of a pH gradient 
(high pH inside) produced by the loss of acetic acid, intraliposomal drug ionization, and 
internal membrane binding of the drug leading to near intraliposomal sink conditions. 
Improved liposome loading of AR-67 was achieved by developing a novel method for 
creating and maintaining supersaturation of this hydrophobic, water insoluble drug during 
the active loading process. The model was successful in fitting the rates of drug-loading 
(up to 48 hours, period of time supersaturation was maintained using SBE-CD) at several 
degrees of supersaturation to obtain a single intrinsic membrane permeability coefficient. 
The developed model can be used to further predict the rate and extent of loading under 
different loading conditions. This proposed loading methodology may be useful in 
meeting the formulation challenges presented by the increasing number of poorly soluble 
anticancer agents emerging from drug discovery. 
Copyright © Sweta Modi 2013 
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CHAPTER SIX 
Optimization of Liposome Release Kinetics of a Corticosteroid Phosphate Based on 
pH and Lipid Composition 
INTRODUCTION 
Dexamethasone (Dex) acts as an anti-inflammatory and immunosuppressive agent by 
inhibiting the production of pro-inflammatory cytokines. Since inflammatory responses 
play an important role in tumor progression and metastasis, dexamethasone was shown to 
enhance the anti-tumor efficacy of certain chemotherapeutic agents. Wang et al. found in 
pre-clinical studies that pre-treatment with Dex significantly enhanced the antitumor 
activity of carboplatin and gemcitabine and increased their tumor accumulation (90-92). 
These observations were further supported by phase II randomized clinical studies (228) 
and Dex has been proposed as an adjuvant (chemoprotectant and/or chemosensitizer) in 
cancer chemotherapy to reduce some of the associated side effects (nausea, 
hematotoxicity) and increase the efficacy of antitumor drugs. Although Dex has 
numerous therapeutic applications, its use is limited by the side-effects such as 
immunosuppression, hyperglycemia etc. (229, 230). In addition, due to its rapid clearance 
from the body, frequent high doses are required to achieve efficacy which in turn causes 
serious side effects (84). This leads to the demand for a targeted and sustained delivery of 
dexamethasone to maximize its therapeutic potential and minimize the side effects. It was 
in fact demonstrated that a sustained delivery over 3-4 days was more effective compared 
to the 1-day pre-treatment in reducing the carboplatin induced hematologic toxicity (231-
233). 
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Liposomal drug delivery systems play an important role in targeted delivery of anti-tumor 
agents (20). The steady-state drug concentration at the site of action is a function of the 
local input and elimination rates. Thus, the rate of drug release from the formulation is an 
important factor governing the availability of drug at the target site (52). There may be a 
need to modulate drug release rates based on the tumor type and size in order to provide 
safe and efficacious concentrations at the tumor site. As a result, it would be highly 
desirable to design formulations with tunable and predictable drug release rates that can 
be tailored according to the therapeutic requirement. Generally, drug release half-lives of 
approximately 24 hours or more are needed so that liposomes retain a majority of their 
drug payload prior to reaching their maximum accumulation at the tumor site (234-236). 
Previously, half-lives of dexamethasone (Dex) in liposomes varying in lipid composition 
were determined.  The longest half-life obtained was in DSPC, a densely packed 
phospholipid that is in its gel state at 37C and therefore more highly resistant to 
permeability than shorter chain lipids, but the half-life was only 14 hours..  
Due to the higher permeability and poor solubility of dexamethasone, the water soluble 
21-phosphate prodrug was considered. Along with the advantage of enhanced solubility, 
the phosphate prodrug of Dex is ionizable, thus allowing the exploration of pH as a 
formulation variable to tailor its release kinetics. As reported in chapter five for AR-67 
and in previous publications from this laboratory (189, 237), lipid bilayer permeabilities 
of neutral drug species are often orders-of-magnitude higher than their ionized species. 
Therefore, the release kinetics of liposome encapsulated ionizable drugs can potentially 
be controlled by modulating the intravesicular pH, providing that the intravesicular pH 
can be maintained at the desired value. Previous studies have shown that maintaining 
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intravesicular pH in the alkaline region can be challenging due to the dissipation of the 
pH gradient due to CO2 uptake into liposomes under physiological conditions (126).  
However, phosphate prodrugs possess the advantage of having a low first pKa (~2) and 
consequently do not require an alkaline pH for ionization (133).  
In addition to pH control, the barrier properties of the bilayer can be altered by varying 
the lipid composition. The effect of bilayer chain density on permeability has been taken 
into account in the barrier domain model (131, 189). The decrement in permeability due 
to chain ordering in this model depends exponentially on the ratio of solute size to bilayer 
free surface area. The relationship between trans-bilayer transport and bilayer free surface 
area has been tested for small solutes (61, 62, 122, 131, 189, 237, 238) while the present 
study offers the opportunity to test the applicability of the theory to larger drug-like 
molecules. 
A fundamental understanding of the physicochemical factors governing drug transport 
across lipid bilayers is essential to predict the release kinetics from liposome 
formulations. The key for both tunability and predictability is the development of 
quantitative mathematical models that will take into account the physicochemical 
properties of the drug and the bilayer membrane along with the intraliposomal and 
external local environments.  
The goal of the present study was to develop a mechanism-based mathematical model of 
drug release kinetics to account for the physicochemical properties of the drug (e.g., ionic 
equilibria, membrane binding, etc.), the barrier properties of the bilayer membrane, and 
the intraliposomal pH microenvironment. The hypothesis was that liposomal release rates 
could be prolonged significantly by modulating the intravesicular pH and entrapping the 
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drug in the membrane impermeable ionized form.  In addition, changes in the free surface 
area of the bilayer brought about by changing the lipid composition were expected to 
further affect the trans-bilayer solute permeability. This study explores liposomal 
delivery systems of a corticosteroid phosphate, dexamethasone phosphate (Dex-P), that 
provide a range of release half-lives.  Such information will also be useful in extending 
previously developed quantitative relationships between lipid bilayer permeability and 
factors such as intravesicular pH, lipid composition, and permeant size to larger 
molecules having a size more typical of most drugs. 
MATERIALS AND METHODS 
Dexamethasone sodium phosphate USP (Dex-P)  was purchased from Spectrum 
Chemical Mfg. Corp, New Brunswick, NJ and dexamethasone (Dex) (≥98%, powder) 
was purchased from Sigma-Aldrich Co., St. Louis, MO. Lipids (DSPC (1,2-distearoyl-sn-
glycero-3-phosphatidylcholine, >99% purity), DPPC (1,2-dipalmitoyl-sn-glycero-3-
phosphocholine, >99% purity), DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine, 
>99% purity), m-PEG DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy (polyethylene glycol)-2000]), m-PEG DPPE (1,2-dipalmitoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]) and m-PEG DMPE (1,2-
dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-
2000])) were purchased as powders from Avanti Polar Lipids (Alabaster, AL). Dialysis 
tubes (Float-A-Lyzer®, MWCO: 100 kD) were purchased from Spectrum Laboratories 
(Rancho Dominguez, CA). HPLC grade solvents and other chemicals were purchased 
from Fisher Scientific (Florence, KY).  
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Determination of ionization constant 
The second ionization constant of Dex-P was determined at room temperature by the pH-
titration method. Dexamethasone sodium phosphate USP (Dex-P) solution (4 ml) at about 
4 mM in deionized water was titrated with 8 mM HCl solution under continuous stirring 
and pH was monitored after each addition. Plots of pH versus volume of titrant added 
were fitted to the following implicit equation.  
𝐻+ + 𝐶𝑑𝑟𝑢𝑔𝑉𝑜 𝑃
𝑉𝑜 +  𝑉𝑎 = 𝐶𝐻𝐶𝑙  𝑉𝑎𝑉𝑜 +  𝑉𝑎 + 𝐾𝑤 𝐻+ + 𝐾𝑎2 𝐾𝑎2 + 𝐻+ 𝐶𝑑𝑟𝑢𝑔𝑉𝑜 𝑃𝑉𝑜 + 𝑉𝑎             (6.1) 
where 𝑉𝑜 is the initial volume of Dex-P solution and 𝑉𝑜 is the volume at each titration 
point. 𝐾𝑤 is the ion product of water and 𝐾𝑎 is the second ionization constant of Dex-P. P 
is the purity of the drug. The data was also analyzed by plotting the change in pH/ml of 
acid added Vs volume of titrant added. 
Determination of Critical Aggregation Concentration (CAC) 
Fluorescence Method 
CAC of dexamethasone sodium phosphate USP (Dex-P) was determined by the 
fluorescence method using pyrene (Sigma) as a probe molecule and a Varian Cary 
Eclipse spectrofluorometer with a 10 mm path length quartz cuvette. Excitation was at a 
wavelength of 335 nm and the emission spectrum was recorded from 350-500 nm. The 
excitation slid width was maintained at 5 nm and emission slit width at 1.5 nm, at a slow 
setting. Pyrene was dissolved in acetone to give 0.1mg/ml concentration, 65-100µl of this 
solution was added to blank test tubes and acetone was then evaporated under nitrogen. 
To these test tubes, 2 ml of different concentrations (0-85 mM) of Dex-P solution was 
added and vortexed. Data were acquired using Cary Eclipse software from Varian at 
25°C. 
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Solubility Method 
Dexamethasone sodium phosphate USP (Dex-P) solutions were made from 0.01-0.5M 
concentration range. Excess Dex was added to each solution and equilibrated at 25°C for 
48 hours. After equilibration, the suspensions were filtered using 13 mm 0.45µ PVDF 
syringe filters (Fisherbrand) and the first 10 drops were discarded to minimize possible 
effects of filter adsorption. Successive 10 drop fractions were collected and compared to 
ensure that filter adsorption had no effect on the results.  The filtrates were diluted with 
mobile phase (32:68 acetonitrile:aqueous buffer containing 2% triethylamine acetate) 
before analysis by HPLC. 
Liposome Preparation 
Dex-P loaded liposomes for transport experiments were prepared based on a previously 
reported method (127). Briefly, DMPC: mPEG DMPE, DPPC: mPEG DPPE or DSPC: 
mPEG-DSPE (95:5 mol%, 80 mg) were separately dissolved in about 2 ml of chloroform. 
The solvent was evaporated under a stream of nitrogen and the resulting film was dried 
overnight in a vacuum oven. The lipid film (DMPC, DPPC and DSPC) was hydrated with 
2 ml of buffer (50 mM glycine buffer at pH 2 or 50 mM citrate buffers at pH 3, 4, 5 and 
6)) containing dexamethasone sodium phosphate (Dex-P) (2-3 mM) to give a lipid 
concentration of 40 mg/ml.  The pH of the drug solutions were adjusted back to the 
desired pH after Dex-P addition before hydrating the lipid films. After alternate vortexing 
and heating in a water bath at a temperature above the phase transition temperature of the 
respective lipids to uniformly suspend the lipid, the suspension was extruded 10 times 
through two stacked 100 nm polycarbonate membranes using an extruder at 30°C, 50°C 
and 60°C for DMPC, DPPC and DSPC, respectively, to obtain unilamellar liposomes 
 156 
(141). Liposomes were allowed to cool to room temperature for 3 hours and used for 
release studies. Particle sizes of Dex-P loaded liposomes were measured at 25°C by 
dynamic light scattering (DLS) using a Delsa™ Nano submicron particle size analyzer 
(Beckman Coulter Inc., Brea, CA). The liposomes were diluted in the same buffer as that 
used in their preparation. 
Determination of Liposomal Drug Release Kinetics  
Dex-P loaded liposomes were separated from free drug by passing through a Sephadex® 
G25 column pre-equilibrated in the same buffer as that used in the preparation of 
liposomes. Drug loaded liposome suspensions (0.1-0.5 ml) were added to the Sephadex 
column, eluted with 2-5 ml of buffer, and eluting fractions were analyzed for drug and 
lipid concentration.  
The liposome containing eluent fractions were diluted in the same buffer (if needed), 
introduced into a dialysis tube (Float-a-lyzer, MWCO (Molecular Weight Cut Off) 100 
kD, Spectrum Laboratories), immersed into a 1000 ml of aqueous reservoir (sink 
conditions) containing the same pH buffer as that used for the liposome preparation and 
dialyzed at 37°C. Since some of the release studies were monitored for several days, 
0.05% sodium azide was added to the buffers to inhibit microbial growth. Total drug 
concentration in the tube was monitored versus time by HPLC by withdrawing 50-100 µl 
samples from inside the dialysis tube at various time points and diluting with an 
appropriate volume of methanol. The kinetics of disappearance of free Dex-P from 
solution (800 µM) from the dialysis tube was also studied in a similar fashion. 
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HPLC Analysis of Dex and Dex-P 
Samples from solubility studies (for pKa2 determination) and liposome release studies 
were analyzed using an isocratic HPLC method with UV detection. A Waters Alliance 
2695 Separations Module coupled to a UV detector (Waters 996, Photodiode Array 
Detector) was employed with wavelength of maximum absorption at 240 nm. A Waters 
Symmetry® C18 column (5 µm, 3.9 X 150 mm) and guard column (3.9 X 20 mm) were 
used with a mobile phase composition of 32% acetonitrile and 68% (v/v) pH 5.5 
triethylamine acetate (2%) buffer. The retention times at an injection volume of 10 µl and 
a flow rate of 1 ml/min were about 2.3 and 6.4 min for Dex-P and Dex, respectively. Four 
independent standards for Dex-P (100-800 µM) in water and Dex (100-800 µM) in 
methanol were prepared. The relative standard deviation for the response factor was less 
than 3%.  
Lipid Analysis 
Lipids were analyzed using HPLC and ELSD (Evaporative Light Scattering Detector) as 
reported previously (126). Briefly, separation was done using an Allsphere™ silica 
column (Grace Davison Discovery Sciences, Deerfield, IL) (5 µ, 4.6X150 mm) with a 
guard column (Allsphere silica, 5µ, 7.5 X 4.6mm). A linear gradient method was used; 
mobile phase A was 80% chloroform: 19.5% methanol: 0.5% (v/v) ammonium hydroxide 
solution (28-30%) and mobile phase B consisted of 80% methanol: 19.5% water and 
0.5% (v/v) ammonium hydroxide. Each run began with 100% (v/v) mobile phase A, 
changing to 80% mobile phase A: 20% mobile phase B at 3 min, maintaining the 
composition (80%A: 20%B) until 7 min and changing back to 100% mobile phase A at 
14 min. The total run time was 15 min at a flow rate of 1 ml/min with the following 
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ELSD settings:  gain, 8; pressure, 3.4 bar; and temperature, 40°C. The sample 
compartment temperature was maintained at 4°C and the column was at ambient 
temperature. Standards were in mobile phase A and log-log plots of peak area versus 
concentration were linear. Aliquots of drug loaded liposomes (10-20 µl) for lipid analysis 
were transferred to test tubes, dried under nitrogen, and stored at -20°C until further 
analysis. For analysis, the dried lipid films were re-constituted in mobile phase A. Lipid 
concentration was evaluated versus time during the course of transport studies in 
representative DPPC liposomes at various pH values. 
DATA ANALYSES 
Equilibrium pH-Permeability Model 
Dex-P is n amphiphilic, ionizable drug that can exist as three different species depending 
on the pH (Figure 6.1). A mathematical model to explain the pH dependent permeability 
of a solute across the liposome and its evaluation by dynamic dialysis method was 
developed in chapter five and in previous publications from this laboratory (126, 132). A 
similar model with some modifications has been adopted and explained here. The model 
takes into account the ionization, membrane binding, and transport of possible permeable 
species. Instantaneous equilibrium between the various species is assumed both within 
and outside the liposomes. The model considers the internal and external volume in the 
liposomal suspension along with the volume occupied by the aqueous (inner and outer) 
and membrane phases (inner and outer leaflets of the bilayer), the membrane/water 
partition coefficients of the various drug species and the fractions bound inside and 
outside the liposomes. The kinetics of release of the encapsulated drug from the 
liposomes and the transport of free drug across the dialysis membrane into a sufficiently 
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large volume of dialysate to ensure sink conditions in the reservoir are incorporated into 
the rate equations. Samples taken from inside the dialysis tube at various time points 
were analyzed for the total Dex-P remaining. 
Two types of models were considered in the pH-permeability studies of Dex-P (Figure 
6.2). The membrane-water partition coefficient of the monoanionic species was found to 
be either small (DMPC) or negligible (DPPC and DSPC) in the lipid systems used for 
release studies (Chapter three). Therefore, initially, the following mathematical model 
(Model I) that ignored binding of the drug to the liposomal membrane was employed.  
Model I 
𝐼𝑖
𝑡 = 𝐼𝑖 + 𝐼𝐼𝑖 + 𝐼𝐼𝐼𝑖          (6.2) 
𝐼𝑖
𝑡 = 𝐼𝑖  �1 + 𝐾𝑎1𝐻𝑖 + 𝐾𝑎1𝐾𝑎2𝐻𝑖2 �            (6.3) 
𝐼𝑖 = 𝐼𝑖𝑡1 + 𝐾𝑎1𝐻𝑖 + 𝐾𝑎1𝐾𝑎2𝐻𝑖2                  (6.4) 
Similarly,  
𝐼𝑜 = 𝐼𝑜𝑡1 + 𝐾𝑎1𝐻𝑜 + 𝐾𝑎1𝐾𝑎2𝐻𝑜2             (6.5) 
𝑑(𝐼𝑡𝑖)
𝑑𝑡
= −𝑘𝑚𝑎 (𝐼𝑖 − 𝐼𝑜)−𝑘𝑚𝑏 (𝐼𝐼𝑖 − 𝐼𝐼𝑜)−𝑘𝑚𝑐 (𝐼𝐼𝐼𝑖 − 𝐼𝐼𝐼𝑜)            (6.6) 
𝑑(𝐼𝑡𝑜)
𝑑𝑡
= 𝑘𝑚𝑎
𝑥
(𝐼𝑖 − 𝐼𝑜) + 𝑘𝑚𝑏𝑥 (𝐼𝐼𝑖 − 𝐼𝐼𝑜) + 𝑘𝑚𝑐𝑥 (𝐼𝐼𝐼𝑖 − 𝐼𝐼𝐼𝑜) − (𝑘𝑜𝑛 + 𝑘𝑑)𝐼𝑡𝑜+ 𝑘𝑜𝑛
𝐾
𝐷𝑚            (6.7) 
𝑑(𝐷𝑚)
𝑑𝑡
= 𝑘𝑜𝑛𝛼𝑜𝐷𝑜 − 𝑘𝑜𝑛𝐾 𝐷𝑚              (6.8) 
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where, 𝐼𝑡𝑖 and 𝐼𝑡𝑜 are the total intravesicular and extravesicular drug concentrations (in 
molar); 𝑘𝑚 and 𝑘𝑑 are the rate constants for drug transport across the lipid bilayer and 
dialysis membrane, respectively, and  𝑥 is the ratio of extravesicular to intravesicular 
volume in the dialysis tube. 𝐼𝑖, 𝐼𝐼𝑖, 𝐼𝐼𝐼𝑖 and 𝐼𝑜, 𝐼𝐼𝑜, 𝐼𝐼𝐼𝑜 are the intravesicular  and 
extravesicular neutral, monoanion and dianion concentrations, respectively. 𝐷𝑚 is the 
drug concentration bound to the dialysis membrane; 𝑘𝑜𝑛 and 𝑘𝑜𝑓𝑓 are the association and 
dissociation constants for binding of drug to the dialysis membrane �𝐾 = 𝑘𝑜𝑛 𝑘𝑜𝑓𝑓⁄ �.  
Model II 
Model I was inadequate for explaining the release data obtained in DPPC and DSPC 
liposomes for Dex-P. As a result, a more elaborate model (Model II) that took into 
account the binding of different species to the liposome membrane was considered.  
𝐼𝑖
𝑡 = 𝐼𝑖𝑤 + 𝐼𝐼𝑖𝑤 + 𝐼𝐼𝐼𝑖𝑤
𝑎
+ 𝐼𝑖𝑚 + 𝐼𝐼𝑖𝑚 + 𝐼𝐼𝐼𝑖𝑚
𝑏
         (6.9) 
𝐼𝑖
𝑡 = 𝐼𝑖𝑤(1 + 𝐾𝑎1𝑤𝐻𝑖 + 𝐾𝑎1𝑤𝐾𝑎2𝑤𝐻𝑖2 )
𝑎
+ 𝐼𝑖𝑤(𝐾𝑝1 + 𝐾𝑝2𝐾𝑎1𝑤𝐻𝑖 + 𝐾𝑝3𝐾𝑎1𝑤𝐾𝑎2𝑤𝐻𝑖2 )
𝑏
            (6.10) 
 𝐿𝑒𝑡 𝐼𝑖𝑤(1 + 𝐾𝑎1𝑤𝐻𝑖 + 𝐾𝑎1𝑤𝐾𝑎2𝑤𝐻𝑖2 )
𝑎
= 𝑎𝑖 , 𝐼𝑖𝑤(𝐾𝑝1 + 𝐾𝑝2𝐾𝑎1𝑤𝐻𝑖 + 𝐾𝑝3𝐾𝑎1𝑤𝐾𝑎2𝑤𝐻𝑖2 )𝑏 = 𝑏𝑖, 1𝑎𝑖 +  𝑏𝑖= 𝑢𝑏𝑖,  
𝐼𝑖
𝑤 = 𝑢𝑏𝑖 𝐼𝑖𝑡             (6.11) 
𝐼𝐼𝑖
𝑤 = 𝑢𝑏𝑖 𝐼𝑖𝑡  𝐾𝑎1𝑤𝐻𝑖 𝑎𝑛𝑑 𝐼𝐼𝐼𝑖𝑤 = 𝑢𝑏𝑖 𝐼𝑖𝑡  𝐾𝑎1𝑤𝐾𝑎2𝑤𝐻𝑖2  
where 𝑎 and 𝑏 are volume ratios to account for the differences in aqueous and membrane 
volumes with respect to the total intravesicular volume 
Similarly,  
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𝐼𝑜
𝑤 = 𝑢𝑏𝑜 𝐼𝑜𝑡           (6.12) 
𝐼𝐼𝑜
𝑤 = 𝑢𝑏𝑜 𝐼𝑜𝑡  𝐾𝑎1𝑤𝐻𝑜 𝑎𝑛𝑑 𝐼𝐼𝐼𝑜𝑤 = 𝑢𝑏𝑜 𝐼𝑜𝑡  𝐾𝑎1𝑤𝐾𝑎2𝑤𝐻𝑜2  
𝐿𝑒𝑡 𝐼𝑜𝑤 �1 + 𝐾𝑎1𝑤𝐻𝑜 + 𝐾𝑎1𝑤𝐾𝑎2𝑤𝐻𝑜2 �
𝑐
= 𝑎𝑜 , 𝐼𝑜𝑤 �𝐾𝑝1 + 𝐾𝑝2𝐾𝑎1𝑤𝐻𝑜 + 𝐾𝑝3𝐾𝑎1𝑤𝐾𝑎2𝑤𝐻𝑜2 �𝑑 = 𝑏𝑜 ,  1
𝑎𝑜 + 𝑏𝑜 = 𝑢𝑏𝑜  
where 𝐾𝑎𝑤 and 𝐾𝑎2𝑤  are the ionization constants of Dex-P in the aqueous phase and 
𝐾𝑝1,𝐾𝑝2,𝐾𝑝3 are the membrane/water partition coefficients of the neutral, monoanion 
and dianion, respectively. 
𝑑(𝐼𝑡𝑖)
𝑑𝑡
= −𝑘𝑚𝑎 (𝐼𝑖𝑤 − 𝐼𝑜𝑤)−𝑘𝑚𝑏 (𝐼𝐼𝑖𝑤 − 𝐼𝐼𝑜𝑤)−𝑘𝑚𝑐 (𝐼𝐼𝐼𝑖𝑤 − 𝐼𝐼𝐼𝑜𝑤)              (6.13) 
𝑑(𝐼𝑡𝑜)
𝑑𝑡
= 𝑘𝑚𝑎
𝑥
(𝐼𝑖𝑤 − 𝐼𝑜𝑤) + 𝑘𝑚𝑏𝑥 (𝐼𝐼𝑖𝑤 − 𝐼𝐼𝑜𝑤) + 𝑘𝑚𝑐𝑥 (𝐼𝐼𝐼𝑖𝑤 − 𝐼𝐼𝐼𝑜𝑤) − (𝑘𝑜𝑛 + 𝑘𝑑) 𝐼𝑡𝑜+ 𝑘𝑜𝑛
𝐾
𝐷𝑚             (6.14) 
𝑑(𝐷𝑚)
𝑑𝑡
= 𝑘𝑜𝑛𝛼𝑜𝐷𝑜 − 𝑘𝑜𝑛𝐾 𝐷𝑚         (6.15) 
where 𝐼𝑖𝑤, 𝐼𝐼𝑖𝑤, 𝐼𝐼𝐼𝑖𝑤 are the unbound aqueous intravesicular neutral, monoanion, and 
dianion  concentrations, respectively, while 𝐼𝑜𝑤, 𝐼𝐼𝑜𝑤, 𝐼𝐼𝐼𝑜𝑤 are the unbound aqueous 
extravesicular neutral, monoanion, and dianion concentrations, respectively. In the 
present study, the pH was assumed to remain constant and not change due to ionization of 
the drug because the buffer concentration (50 mM) was about 1000-fold higher than the 
drug concentration (40-60 µM).  
The apparent permeability at each pH can be expressed as: 
𝑃𝑎𝑝𝑝 = 𝑃𝐼𝑓𝑢𝑏𝐼 + 𝑃𝐼𝐼𝑓𝑢𝑏𝐼𝐼 + 𝑃𝐼𝐼𝐼𝑓𝑢𝑏𝐼𝐼𝐼               (6.16) 
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where PI, PII and PIII represent the permeability coefficients of the unionized, monoanion 
and dianion Dex-P with fub representing the fraction unbound for each species. The 
dianion was assumed to be membrane impermeable (PIII=0). Substituting the terms for 
the fraction unbound of the unionized and monoanionic species from Eq. 6.11, the 
apparent permeability coefficient of Dex-P can be expressed as: 
𝑃𝑎𝑝𝑝 = 𝑃𝐼 1𝑎𝑖 + 𝑏𝑖 + 𝑃𝐼𝐼 𝐾𝑎1𝑤𝐻𝑖 1𝑎𝑖 + 𝑏𝑖              (6.17) ( 1
𝑎𝑖 +  𝑏𝑖 = 𝑢𝑏𝑖 = 𝑓𝑢𝑏𝐼 ) 
Bilayer Free Surface Area-Permeability model 
Historically, passive permeability through lipid bilayers has been described by the “bulk 
solubility diffusion” model that assumes the membrane to be homogenous and isotropic, 
resembling a bulk hydrocarbon solvent. According to this model, permeability is given 
as: 
𝑃𝑜 = 𝐾𝑚/𝑤 𝐷𝑚ℎ𝑚               (6.18) 
where Po is the permeability coefficient, Km/w and Dm are the membrane/water partition 
coefficient and diffusion coefficient across the membrane, respectively, and hm is the 
membrane thickness. However, unlike bulk solvents, lipid bilayers are heterogeneous, 
interfacial and anisotropic systems. The lipid bilayer can be roughly divided into three 
regions: an ordered, polar interfacial head group region, a highly ordered hydrocarbon 
chain region and a relatively disordered hydrocarbon chain region towards the center of 
the bilayer (189). As permeant moves across the bilayer, it encounters variations in the 
barrier environment.  For very small polar molecules the transport is primarily governed 
by a distinct region within the bilayer interior (i.e. the highly ordered chain region). 
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Solubility diffusion theory fails to account for the effects of lipid bilayer chain order on 
the permeability coefficient of a permeant. Xiang and Anderson have addressed this issue 
by introducing a scaling factor that must be applied to permeability prediction from 
solubility-diffusion theory. The permeability coefficient for small molecules, according 
to this new “barrier-domain” solubility diffusion model is  
𝑃𝑚 = 𝐾𝑏𝑎𝑟𝑟𝑖𝑒𝑟 𝑤𝑎𝑡𝑒𝑟⁄ ∗ 𝐷𝑏𝑎𝑟𝑟𝑖𝑒𝑟ℎ𝑏𝑎𝑟𝑟𝑖𝑒𝑟 = 𝑓 ∗ 𝑃𝑜            (6.19) 
where Kbarrier/water and Dbarrier are the partition coefficients from water into and diffusion 
coefficient of the permeant within the barrier domain, respectively, and hbarrier is the 
barrier thickness. Thus, Pm is the product of Po from solubility-diffusion theory and a 
scaling factor f, the permeability decrement due to chain ordering effects (61, 131). 
The permeability decrement factor, f can be defined in terms of the two-dimensional 
packing structure of the bilayer, as characterized by the free surface area per lipid 
molecule, af, and cross-sectional area of the permeant, as, as follows (61, 131): 
𝑓 = 𝑓𝑜𝑒𝑥𝑝�−𝜆𝜆 𝑎𝑠 𝑎𝑓⁄ �            (6.20) 
where fo and 𝜆𝜆 are constants independent of permeant size and bilayer packing structure. 
Thus, the scaling factor that accounts for the decrease in permeability due to chain 
ordering is exponentially dependent on the ratio of permeant size to the free surface area 
of the membrane. It was proposed that non-spherical solutes orient their long axes along 
the bilayer normal and the permeation across the bilayer occurs with the creation of a free 
volume with a cross-sectional area equal to or greater than the minimum cross-sectional 
area of the diffusing permeant. Alternative models have employed a power law in 
permeant volume instead of the minimum cross-sectional surface area to rationalize the 
molecular size dependence of membrane permeability (131, 239). Mitragotri et al. also 
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analyzed the size selectivity of solute permeability in lipid bilayers using scaled-particle 
theory. They evaluated the relative contributions of both partitioning and diffusion 
processes across the ordered chain region and suggested the dependence of each on the 
solute size and bilayer parameters (168). 
RESULTS 
Dex-P and Liposome Characterization 
The state of ionization is important for rationalizing the pH dependent liposome 
permeability of Dex-P. The accurate determination of pKa values less than about 2 by the 
potentiometric method is challenging.  However, Derendorf et al. calculated a pKa1 of 1.9 
by studying the partition coefficient of Dex-P as a function of pH.  This value was 
therefore assumed in the present study.   The value of pKa2 of Dex-P, as determined by 
pH-titration method and fitting the data to Eq. 6.1, was 6.27 ± 0.13 (Figure 6.5), which is 
in good agreement with the reported value of 6.4 (133). Although the experimental 
determination of pKa2 was performed at room temperature, the temperature sensitivity 
for phosphate pKa values is known to be insignificant where d(pKa)/dT for pKa1 is about 
0.0044 and for pKa2, it is -0.0028 (240, 241). This suggests a change in pKa1 of 0.05 and 
pKa2 of -0.03 units with change in temperature from 25 to 37°C (240, 241). 
Figure 6.3 shows the change in fluorescence emission spectra of pyrene (excitation at 335 
nm) in increasing concentrations of Dex-P solution (0-84 mM). The ratio of the first 
vibrational band (372 nm), the highest energy vibrational band, to that of the vibrational 
band at 383 nm is considered to be an index of polarity of its environment. In water the 
ratio (I1/I3) is around 1.6-1.8, in ethanol about 1.1, and in hydrocarbon solvents around 
0.57-0.61. Left inset shows the ratio of I1/I3 of pyrene as a function of Dex-P 
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concentration. In the presence of micelle forming systems at concentrations below the 
CMC, the intensity of the highest energy vibrational band normalized against the 
intensity of third peak decreases. There was a sharp breakpoint at the CAC (34 mM) and 
above the CAC the ratio was constant. As an additional confirmation of CAC values, the 
intensity of the excimer peak (at 475 nm) relative to first peak (IE/I1) was plotted against 
the Dex-P concentration and was observed to show a peak at CAC concentration (Figure 
6.3 right inset).  
The critical aggregation concentration (CAC) of Dex-P determination, by solubility 
method (Figure 6.4) gave an apparent value of ~120 mM with no sharp deflection point 
observed in the solubility curve. The inset of Figure 6.4 shows the rise in solubility of 
Dex even at lower concentrations of Dex-P (<50 mM) suggesting smaller aggregate 
(dimer, trimer etc.) formations prior to true aggregation. 
Dex-P loaded liposomes of DMPC, DPPC and DSPC prepared at different pH values 
exhibited particle sizes in the range of 87-102 nm, with polydispersity indices in the 
range of 0.06-0.09, indicating monodisperse formulations. The drug and lipid 
concentrations during release studies at different pH values were determined using 
previously developed and validated HPLC methods. For the analysis of Dex-P, samples 
were taken from inside the dialysis tube at various time points, diluted with methanol and 
analyzed for both, Dex-P and its hydrolytic product, Dex. There was no degradation of 
Dex-P observed during the time period of transport studies at any pH. Based on the 
literature,, the half-life Dex-P at pH 4.06 and 70°C is about 4.6 days (242). Flynn and 
Lamb studied solvolysis of several corticosteroid phosphates and found that the nature of 
the steroid nucleus has little effect on the monoanion hydrolysis rate constant.  They 
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Figure 6.1 Equilibria between neutral, unionized Dex-P (I), its monoanion (II) and 
dianion (III). pKa1 and pKa2 are the first and second ionization constants, respectively. 
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Figure 6.2 The pH-permeability model considered to explain Dex-P liposomal release 
profiles at different pH values determined by dynamic dialysis (model II). 
I, II and III refer to the unionized, monoanion and dianion concentrations of Dex-P, 
respectively. Subscripts i and o refer to the intravesicular and extravesicular 
compartments. Superscripts m and w refer to the membrane and aqueous phases. The 
binding parameters (Kp1, Kp2 and Kp3) were assumed to be negligible in model I. 
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suggested that stability data for methylprednisolone-21-phosphate could be considered to 
be representative of related steroid phosphates as well (242). Therefore, using the 
activation energy reported for methylprednisolone-21-phosphate, the half-life for 
hydrolysis of Dex-P at pH 3.32 and 37°C should be about 347 days, well beyond the time 
frame of the present studies. 
The lipid concentration in the dialysis tube during the transport studies was in the range 
of 0.6-2.0 mg/ml. Shown in Figure 6.9 are DPPC concentration versus time profiles 
during transport studies at pH 2, 3, 4, 5 and 6. Table 6.2 shows the parameters from 
regression analysis at each pH along with 95% C.I for slope and intercept. The % 
coefficient of variation for the determination of initial value (t=0) was 8-20% and the 
slope was not significantly different from zero (P>0.05). Therefore, the total 
concentration of lipid remained constant during the release studies. Additionally, 
previous studies on stability of saturated phosphatidylcholines (DSPC and natural 
soybean PC) have shown that the half-life of degradation is greater than 3 months at pH 9 
and 40°C and more than 2 months for DMPC at pH 4 and 30°C (142, 143, 243, 244). 
Although in the same order of magnitude, a small increase in hydrolysis rate constant 
(Kobs) from 3.2 x 10-4 hr-1  to 4.7 x 10-4 hr-1 was reported with increase in fatty acid chain 
length of liposomes from C12 (DLPC) to C18 (DSPC) at pH 4 and 30 °C (245, 246). 
The membrane water partition coefficient of Dex-P monoanion was previously 
determined by equilibrium dialysis for DMPC, DPPC and DSPC liposomes (pH 4) to be 
62 ± 8, 2 ± 4 , 6 ± 2, respectively. In addition, the study of Dex-P binding at different pH 
values in DMPC liposomes showed significant binding of the neutral form (241 ± 38) 
relative to the ionized species.  
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Kinetics of Drug Release from Liposomes at Different pH  
The kinetics of free drug disappearance from dialysis tubes (100 kD) that were used in 
the pH-permeability studies was evaluated. Previous dynamic dialysis studies for release 
of Dex from liposomes indicated free drug binding to the dialysis membrane. Therefore, 
the kinetics of free Dex-P disappearance from aqueous solutions during dynamic dialysis 
was evaluated for a sufficient time to capture the effect of binding to the dialysis 
membrane, if present. Figure 6.6 indicates that a biphasic profile was observed for Dex-P 
disappearance from solution very similar to that observed for Dex. The similarity in the 
biphasic profiles for free Dex and Dex-P despite the differences in their physicochemical 
properties suggests membrane binding rather than partitioning into the membrane. The 
rate and equilibrium constants obtained from the fitting of free drug profiles were used in 
modeling the transport of Dex-P from liposomes.  
The concentration versus time profiles for the release of Dex-P from DPPC and DSPC 
liposomes at different pH values are shown in Figure 6.7. Concentration versus time 
profiles for Dex-P release from drug loaded liposomes at all pH values (pH 2, 3, 4, 5 and 
6) were simultaneously fit to equations 6-8 (Model I) to obtain the rate constants for 
permeation of the neutral and monoanionic species (with the assumption that the di-anion 
is impermeable) and the apparent pKa1 of Dex-P. The second ionization constant was 
fixed because all the pH values explored were below pKa2. The values of pKa1 obtained 
from the simultaneous fitting of the pH dependent transport data across DPPC and DSPC 
were 2.8 (95% CI of 2.6-3.3) and 3.4 (95% CI of 3.3-3.6), respectively.  
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 Figure 6.3 Fluorescence spectra of pyrene recorded at increasing concentrations of Dex-P 
and the corresponding decrease in peak intensity at 372 and 383 nm The inset shows the 
breakpoint when the ratio of the I1/I3 is plotted against the Dex-P concentration and a 
peak when the ratio of excimer peak (475 nm) relative to first peak is plotted against the 
Dex-P concentration. 
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Figure 6.4 Solubility of Dex with increasing concentrations of Dex-P at 25°C. The inset 
shows the magnified view of the region between 0-100 mM Dex-P. 
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Figure 6.5 Change in pH of a 4 mM Dex-P solution on addition of HCl titrant. The data 
points are the experimental recording while the solid line is the model predictions on 
solving Eq. 6.1. Inset shows the ratio of the change in pH per ml of acid against the 
volume of HCl and the peak in the plot corresponds to the half-equivalence point.  
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Figure 6.6 Fractions of initial amount of Dex-P in solution remaining in the dialysis tube 
with time. Error bars are the standard deviations from the replicate experiments (n=3). 
The kinetics of free Dex is also shown for comparison.  
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Figure 6.7 Fraction of Dex-P remaining (mean ± S.D) in dialysis tubes containing Dex-P 
loaded liposomes at pH values of 2, 3, 4, 5 and 6. Solid lines are simultaneous fits based 
on the equilibrium pH-permeability model (Eqs. 6.13-6.15).  Error bars are the standard 
deviations from the replicate (n=2) experiments (A) DPPC (B) DSPC.  
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The apparent permeability constants (calculated from apparent first order rate constants) 
at each pH from transport data across DPPC and DSPC liposomes were plotted versus 
pH. The pH-permeability profiles of Dex-P from DPPC and DSPC liposomes shown in 
the log-linear plot in Figure 6.8 indicate an upward shift in first pKa, from 1.9 to 2.8 in 
DPPC and to 3.4 in DSPC liposomes.  
Since previous studies on membrane binding of Dex-P in DMPC liposomes indicated 
significant binding of the neutral form, inclusion of a term for neutral species binding to 
account for the apparent shift in pKa was considered.  Model II including a binding 
parameter was used to simultaneously fit the release data at different pH values with the 
first and second ionization constants fixed at 1.9 and 6.4, respectively. Rate constants for 
the transport of the neutral and monoanionic Dex-P species, kma and kmb, in DPPC were 
4.2 ± 1.8 and 9 ± 3 x 10-3 hr-1 (95% C.I.) while in DSPC the values were 0.54 ± 0.14 and 
8 ± 2 x 10-4 hr-1, respectively. The intrinsic permeability coefficients of the neutral Dex-P 
across DPPC and DSPC were calculated to be 1.74 (±0.74) x 10-9 cm/s and 2.24 (±0.59) x 
10-10 cm/s (95% C.I.), respectively. The partition coefficients of the neutral form, 
obtained from the fitting were 42 ± 35 and 186 ± 68 (95% C.I.) in DPPC and DSPC 
respectively.  
Quantitative Relationship between Permeability and Chain Ordering (Free Surface 
Area)  
Transport data for Dex-P at pH 4 were available for unilamellar vesicles composed of 
DMPC, DPPC and DSPC, as shown in Figure 6.10.  The apparent half-lives obtained 
were 1.2, 10.8 and 169 hours, respectively. These lipids varied in their acyl chain length 
and bilayer chain density, which also brought about changes in phase structure (gel or 
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liquid crystalline phase). At 37°C, DMPC (Tm of 23°C) is in a disordered liquid-
crystalline phase, DPPC is in a gel phase but very close to its phase transition temperature 
(Tm of 41°C) and DSPC is in the highly ordered gel phase (Tm of 55°C). The chain 
ordering can be quantified in terms of surface density or free surface area, as 
demonstrated earlier (122, 131). To test the dependence of apparent permeability of Dex-
P on the order parameter, the log of apparent permeability was plotted versus the inverse 
of free surface area and a linear dependence was observed (Figure 6.11). A least-squares 
fit of the data gave a slope of -0.53 and correlation coefficient of 0.99. 
Table 6.1 shows the observed half-lives for release obtained at various pH values and 
different liposome compositions. The experimental half-life for Dex-P release from 
liposomes ranged from 1.2 h at pH 4 in DMPC liposomes to 892 hours at pH 6 in DSPC 
liposomes. The broad range of release kinetics was obtained by modulation of two 
formulation variables in liposomes i.e. pH and lipid composition. 
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Figure 6.8 Log of apparent permeability of Dex-P vs pH across DMPC, DPPC and DSPC 
liposomes at 37°C. The solid lines for DPPC and DSPC represent the predicted values 
based on model II and Eq. 6.17.  
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Table 6.1 The half-life (t1/2) for liposome retention of Dex-P as a function of liposome 
composition and intraliposomal pH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*The values are mean ± Std. Dev.  
Liposome pH Retention Half-life (hrs)* 
DMPC 4 1.2 ± 0.05 
DPPC 2 1.9 ± 0.1 
DPPC 3 2.2 ± 0.3 
DPPC 4 10.8 ± 2.3 
DSPC 2 32 ± 2 
DSPC 3 48 ± 3 
DPPC 5 58 ± 9 
DPPC 6 58 ± 5 
DSPC 4 169 ± 6 
DSPC 5 579 ± 82 
DSPC 6 892 ± 78 
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Figure 6.9 Concentration-time profiles for DPPC liposomes at pH 2, 3, 4, 5 and 6 during 
transport studies of Dex-P by dynamic dialysis.  
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Table 6.2 Regression analyses of lipid concentration Vs time data at different pH of 
release studies 
  
pH Slope (95% C.I) Intercept (95% C.I.) 
P value 
(Is slope significantly 
non-zero?) 
2 -0.0041 (-0.0101 to 0.0019) 1.429 (1.131 to 1.726) 0.1368 (>0.05) 
3 -0.0020 (-0.0153 to 0.0113) 1.338 (0.675 to 2.002) 0.7134 (>0.05) 
4 -0.0015 (-0.0030 to 0.00005) 0.961 (0.739 to 1.184) 0.0566 (>0.05) 
5 -0.0008 (-0.0017 to 0.00001) 1.245 (1.034 to 1.456) 0.0529 (>0.05) 
6 -0.0003 (-0.0012 to 0.0006) 1.109 (0.8828 to 1.335) 0.4300 (>0.05) 
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Figure 6.10 Fraction of Dex-P remaining in dialysis tube from DMPC, DPPC and DSPC 
liposomes at pH 4. Error bars are the standard deviations from replicate experiments 
(n=2). 
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Figure 6.11 Dependence of the natural logarithm of apparent permeability of Dex-P on 
the inverse of free surface area of the liposome bilayer.  Points represent permeability 
coefficients in DMPC, DPPC, and DSPC.  
 183 
DISCUSSION  
Liposomes hold the promise of enhancing the therapeutic index of drugs by reducing the 
toxicity and increasing drug efficacy (20). To accomplish the goal of selectively 
delivering the drug to the target site, the drug needs to remain entrapped inside the 
liposomes while the nanoparticles are circulating in the blood and then release once at the 
target site. Even at the site of action, drug release should ideally be optimized as per the 
therapeutic need. Therefore, there is a great need for the ability to tune the release 
kinetics of drugs from liposomes in response to the therapeutic requirement. Depending 
on the therapeutic need, half-lives ranging from a few hours to several days may be 
required. To meet this end, quantitative relationships that could provide predictive 
capability based on the drug and delivery vehicle properties would be highly desirable. 
Such a universal quantitative model would also greatly enhance mechanistic 
understanding of release kinetics from the delivery system. In this study, two simple 
liposomal formulation variables, pH and phospholipid chain length were explored to 
obtain a range of release kinetics. The mathematical modeling of the release data enables 
an understanding of the release kinetics under different conditions and the ability to 
design systems having a predetermined release rate. 
CAC Determination 
Hydrophobic solutes or compounds having a large surface area of exposed organic 
groups or aromatic rings have a tendency to self-associate in water at higher 
concentration. As opposed to molecules containing flexible chains that organize into 
typical micellar structures above a particular critical concentration, organic compounds 
containing rigid aromatic fused rings rather have a more diffuse concentration range 
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where they associate to a different extent (247, 248). Also, such molecules do not form 
the typical micellar structures but rather form aggregates due to stacking of the rigid 
aromatic rings.  The critical concentration for aggregate formation is often referred to as 
Critical Aggregation Concentration (CAC) instead of Critical Micelle Concentration 
(CMC) (249).  
Pyrene is a very common fluorescent probe used in the determination of CMC of 
amphiphiles owing to the dependence of its emission characteristics on the polarity of its 
environment (250). As the concentration of aggregate forming agent (Dex-P) increases, 
pyrene molecules experience a more hydrophobic environment than water due to 
premicellar aggregates and a lowering of the intensity ratio (I1/I3) is observed (Figure 6.3 
inset, below CAC). Above the  CAC, with increase in Dex-P concentration there is no 
increase in monomer concentration and the ratio of the pyrene intensity peaks (I1/I3) is 
constant due to incorporation of pyrene into the hydrophobic region of micelles or 
aggregates (250, 251).  
Excited pyrene monomers form an excimer complex with a ground state pyrene monomer 
and show an emission peak at 475 nm. Pyrene excimer formation is a concentration 
dependent phenomenon in organic solution. Owing to the low solubility of pyrene in 
water, pyrene excimer formation is not observed in pure water. Solubilization of pyrene 
by micelle forming agents allows excimer formation in aqueous solution. The 
measurement of excimer emission as a function of surfactant concentration allows the 
determination of aggregation number of micelles (252). As the concentration of micelle 
forming agent increases, IE/I1 ratio increases owing to movement of pyrene molecules 
from premicellar aggregates to micelles resulting in a rise in average occupancy of 
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pyrene molecules in micelles. Above the CAC, the number of micelles increases causing 
the lowering of an average occupancy and thereby lowering the probability of excimer 
formation and hence the decrease in IE/I1 ratio (253).  
The CMC of methylprednisolone-21-phosphate has been reported by surface tension 
measurements to be 0.017 M (242), which is on the same order of magnitude as the CAC 
for Dex-P of 0.034 M as determined by the fluorescence method. However, Shah et al 
have determined the CAC of Dex-P to be 0.0034 mol/kg at 25 °C by measuring the 
electrical conductivities of increasing concentrations of the drug solution (254). The 
reported value is about ten times lower than that determined for Dex-P in our study by 
fluorescence method. The differences in these various techniques probably reflect the 
different properties being probed where conductivity may be more sensitive to very small 
aggregates. Additionally, Flynn and Lamb also used the conductivity method for the 
study of CMC of methylprednisolone-21-phosphate at pH 7.5 at various temperatures 
including 25 °C but did not find a sharp break point and obtained a range of 0.01 to 0.02 
M between which the CMC values lies (242).  
The CAC determined by the solubility method is only an apparent value because of the 
curvature in the solubility curve instead of distinct discontinuity and therefore differs 
significantly from the value obtained by fluorescence method. Since the solubility 
method does not allow for direct calculation of the monomer concentration, the presence 
of premicellar aggregates complicates the data interpretation. If the aggregates formed are 
sufficiently large, containing more than 20 monomers, a simple monomer-micelle model 
adequately describes the equilibria.  Such systems are characterized by a distinct sharp 
break point in plots of any properties versus its concentration. However, steroidal 
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molecules, such as Dex-P, are known to form pre-micellar aggregates prior to true 
aggregation resulting in curvature rather than a distinct break-point in the plots (255) as 
seen in Figure 6.4 and the inset highlighting the increase in Dex solubility even at lower 
Dex-P concentration (~50 mM). 
For drugs with a smaller hydrophilic portion relative to their hydrophobic portion, a trend 
of decreasing CMC or CAC values with an increase in temperature has been observed 
(256). In particular, the CAC of Dex-P was found to increase with temperature and was 
attributed to greater dehydration of polar head groups than those of hydrophobic groups 
leading to repulsion between them and difficulty in aggregation (254). Based on this, the 
CAC of Dex-P at 37°C would be expected to be higher than that determined at 25°C. 
Although the CAC values at lower pH where the free acid predominates was not 
investigated, the low solubility of Dex-P at low pH would preclude the determination 
(242). 
The present studies were conducted at concentrations well below the determined CAC 
value of 34 mM or even 3.4 mM as reported by Shah et al. The Dex-P conc. range in 
loading and release studies were less than 1 mM. Also, since the release studies were 
conducted at 37 °C and the CAC of Dex-P is known to increase with temperature, it 
further ensures the absence of aggregates in the transport experiments. Additionally, the 
release studies at different pH values were conducted at much lower concentrations (<1 
mM) because structural resemblance between the corticosteroid phosphates and the 
surface active bile acids raises the possibility of mixed micellization and potential bilayer 
disruption at higher concentrations (257, 258). This could also be a likely explanation for 
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inefficient loading of Dex-P by passive loading methods despite its high water solubility, 
as observed in our and other studies (259, 260). 
pH Dependence of Bilayer Permeability Coefficients 
The method of pH adjustment to modulate bilayer transport of ionizable drugs was 
studied long back by Xiang and others, mostly for small molecules such as α and β-
naphthoic acids (238), p-toluic acid and their analogues (189, 237) etc., where they also 
demonstrated a quantitative relationship between pH and permeability. However, mostly 
with the goals of understanding the barrier properties of the bilayers, they studied the pH-
permeability relationship in an attempt to explore the pH region where the flux of the 
highly permeable carboxylic acids was membrane controlled and changed several orders 
of magnitude (189, 237, 238). 
The pH-gradient strategy has also been explored and applied to a great extent for active 
loading of weak acids and bases in liposomes but the approach of intravesicular pH 
modification has not been explored as much for the retention of large-drug like molecules 
for the purpose of achieving controlled or tunable release. Joguparthi et al. developed the 
pH-permeability model for drug permeability in liposomes for a hydrophobic model drug, 
AR-67, a camptothecin analogue (126). Since this can be a very valuable and simple 
formulation approach for the modulation of release kinetics of both hydrophobic and 
hydrophilic ionizable compounds, there is a need to extend the applicability of the 
relationship to more drugs having structural diversity. Here, this effect was demonstrated 
for a hydrophilic steroidal compound, Dex-P. 
The bilayer properties were assumed to be independent of pH in the range explored in 
this study (pH 2-6) based on the previous studies from this laboratory. Xiang et al. 
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showed there was no change in apparent permeability with change in pH for α-D-glucose 
across DHPC and DPPC bilayers and for acetamide across egg-lecithin bilayers, both 
non-ionizable compounds, indicating pH-independence of the barrier properties of the 
bilayers (189). Additionally, Joguparthi et al. found no change in barrier properties of 
DSPC liposomes at pH 4.1 and 9.5 by comparing the permeability of 14C-thiourea to that 
reported previously (126).  
At a given pH, an ionizable drug exists partially in its neutral and ionized forms, 
depending upon the ionization constants. The change in apparent permeability with pH 
can be attributed to different permeability coefficients of the neutral and ionic species and 
changes in the relative fractions of those species with pH. The bilayer permeability of the 
neutral form of Dex-P could not be determined directly from experiments due to the low 
pKa1 of 1.9 and the lipid stability concerns that would arise in conducting transport 
studies at pH values below the pKa (142, 243, 244).  However, the permeability of the 
neutral species could be estimated from the simultaneous model fitting of the release 
profiles at various pH values. Since the rate constant for the monoanion was more than 
500 fold smaller than that for the neutral species, the permeability of the monoanion and 
dianion was assumed to be negligible. Transport of ionic species across liposome bilayers 
is energetically unfavorable due to the tremendous energetic penalty incurred in their 
transfer from water into the non-polar hydrocarbon-like region in the bilayer (62). 
Although the permeability of monoanion was about 500 fold smaller than the unionized 
species, the difference is smaller compared to that obtained between neutral and ionized 
species of some small carboxylic acids (189, 261). This can be attributed to the 
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possibility of ion pair transport through the membrane, although the evidences for it have 
not been explored here. 
Model I was inadequate in satisfactorily describing the data in Figure 6.8 and therefore 
model II which considers the intra and extra-vesicular membrane binding of the different 
species was tested. The membrane binding of Dex-P has been described in detail in 
chapter three. Although the binding of Dex-P mono-anion (at pH 4) was negligible in 
DPPC and DSPC liposomes, based on the pH-partition profile in DMPC, the binding of 
neutral Dex-P in DPPC and DSPC could not be neglected. Considering the binding of the 
neutral species accounted for the shift in the pKa observed from the pH-permeability 
profile when no binding was considered. The bilayer membrane transport is primarily 
governed by the concentration gradient of the aqueous free neutral species. The 
simultaneous binding and ionization deplete the free aqueous concentration of permeable, 
neutral species that is the driving force for the transport of drug across the liposome. 
Owing to the large intraliposomal surface-to-volume ratio, there is significant 
intraliposomal binding of a drug even for low partition coefficient values. The depletion 
of the free neutral drug, attributed to binding and ionization, therefore needs to be taken 
into account for accurate determination of the permeability coefficient. Thus, the 
retention of the weak acid drugs in liposome would depend upon the pKa of the drug, 
membrane partitioning of the neutral and ionized species and the intraliposomal pH.  
The fitting of the pH-permeability data of Dex-P to model II suggested the membrane 
partition coefficients of the unionized neutral Dex-P to be 42 ± 35 and 186 ± 68 (95% 
C.I.) in DPPC and DSPC, respectively. The predicted higher partition coefficient in 
DSPC liposomes as compared to DPPC is in contrast to the expected dependence of 
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membrane partition coefficients on free surface area, as reported in the literature (55, 121, 
122) and chapter three. Since DPPC has a smaller acyl chain length and a lower chain 
density leading to a higher free surface area as compared to DSPC, the partition 
coefficient would be expected to be higher in DPPC. However, the large 95% confidence 
intervals of the predicted partition coefficients are quite large, thus complicating the 
interpretation of these results. One of the reasons for the wide confidence intervals is the 
low pKa1 of Dex-P and the absence of permeability data at pH values below pKa1. 
Considering the release profiles shown in Figure 6.7, the experimental pH values mainly 
explore the pH region where the drug is predominantly in the monoanionic form. 
Moreover, the profiles at pH 2 and pH 3 were not significantly different from each other 
and in DPPC they very similar to the profile observed for free Dex-P.  More reliable data 
at low pH may require the use of a different transport method.   
Quantitative Relationship between Permeability and Free Surface Area 
Depending on the properties of the permeant, the rate-limiting or barrier region for 
liposomal release may differ. If the polarity of solute is sufficient to establish the bilayer 
membrane as rate-limiting, then it might be reasonable to expect a dependence of the 
permeability coefficient on the available free surface area of the bilayer. Indeed, Xiang 
and Anderson discovered using acetic acid as a model solute that the bilayer free-surface 
area was a "universal" variable that quantitatively related solute permeability to chain 
packing in both liquid-crystalline and gel phases (122, 131). They further demonstrated 
the dependence of the permeability decrement (f=Pm/Po), a factor that  accounts for the 
effects of chain ordering, on the inverse of the bilayer free surface area for several short-
chain monocarboxylic acids (61). Thus, it has long been demonstrated that the effects of 
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bilayer packing on trans-bilayer transport can be rationalized in terms of a dependence of 
permeability on the two-dimensional packing structure, as characterized by the free 
surface area per lipid molecule, afree. However, there has been no systematic attempt to 
test such a quantitative relationship using larger drug-like molecules. Such a quantitative 
model could provide a significant contribution by enhancing the predictive capability for 
drug release across liposomal delivery systems. 
The effects of lipid chain packing in gel and liquid crystalline lipid bilayers on 
permeability was investigated for the larger solute Dex-P by measuring its release 
kinetics from DMPC, DPPC and DSPC liposomes at pH . As shown in Figure 6.11, the 
natural logarithm of Papp was found to correlate linearly with the inverse of the bilayer 
free surface area. The slope is the measure of the sensitivity of the apparent permeability 
of Dex-P on bilayer chain density. Particularly noteworthy is the finding that the apparent 
permeability coefficient for Dex-P across gel phase DSPC bilayers is 16-fold smaller than 
that across co-existing gel-liquid crystalline phase DPPC bilayers, which in turn is 9-fold 
smaller than that across the liquid crystalline DMPC bilayer. In other words, the apparent 
permeability across highly ordered gel phase of DSPC is nearly 2 orders-of-magnitude 
smaller than that across the disordered liquid crystalline bilayer of DMPC, demonstrating 
a significant role of bilayer chain ordering on solute transport.  
In chapter three, the concept of surface density or free surface area and its effect on 
membrane partition coefficients was explained. A similar relationship was observed here 
with apparent permeability of Dex-P across the liposomes. However, the degree of 
changes in apparent permeability with decrease in free surface area is higher than that 
observed for partitioning as demonstrated by the steeper slope of -0.5 for apparent 
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permeability versus a slope of -0.2 for partitioning of Dex-P (Chapter Three). This is 
attributed to the requirement for passage of solute across the bilayer for permeation as 
opposed to partitioning and thereby a higher sensitivity to the chain density. In 
partitioning, depending on the nature of the solute and its location and specific 
interactions with the bilayer, there may be only partial insertion of the solute into the 
bilayer. For permeation, the solute has to travel from one side of the bilayer to the other 
and may encounter a large penalty in free energy for insertion into the highly ordered 
barrier domain.  Thus, the permeation process probes a different region of bilayer than 
the partitioning process. Additionally, variations in free surface area have an additional 
effect on solute diffusivity in lipid bilayers which does not affect solute partitioning. Both 
the barrier domain/water partition coefficient and the diffusion coefficient within the 
barrier domain may be functions of afree and have a combined effect on trans-bilayer 
permeability.  
CONCLUSIONS 
A range of liposome release rates for Dex-P corresponding to half-lives from 1 hour to 
892 hours were obtained by varying the lipid composition and the intravesicular pH. 
Changes in bilayer free surface area by varying the lipid composition and intravesicular 
pH are the simple formulation variables that can be exploited to tune drug release 
kinetics. Moreover, the ability to quantitatively relate the permeability across liposomes 
to physicochemical factors and bilayer barrier properties can be tremendously helpful in 
tailoring the release kinetics as per the therapeutic need. Although the free surface area 
was varied in this study by using lipids of different acyl chain length, it can also be 
modified by changing the temperature and inclusion of different percentages of 
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cholesterol in the bilayer. The prediction of permeability of a drug molecule across the 
bilayer is also relevant for the mechanistic understanding of the drug absorption process. 
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CHAPTER SEVEN 
Conclusions and Future Directions 
In the design of liposomal delivery systems, predictive strategies are needed to maximize 
drug loading and optimize drug retention regardless of the physicochemical properties of 
the drug. Drug candidates that are either highly hydrophobic or hydrophilic may pose 
particular challenges in their formulation design and for such compounds the 
optimization of both loading and release kinetics, if achieved at all, is usually done 
empirically.   It would be highly beneficial to have a universal, comprehensive 
mathematical model relating the drug and bilayer properties to the rate and extent of 
loading and release kinetics in liposomes. In view of this objective, one of the principal 
goals of this work was to explore the factors affecting the bilayer partitioning, loading 
and permeability of model solutes using mechanism-based mathematical models to 
predict these processes in liposomes based solely on the structure of the solute, 
composition of the lipid membrane, and the local environmental conditions.  
The investigation of the influence of liposome composition on membrane partitioning 
behavior of two solutes differing in physicochemical properties demonstrated a 
quantitative relationship between bilayer/water partitioning and the bilayer chain ordering 
(free surface area). Thus, knowledge of the membrane partition coefficient of a particular 
drug in a given phospholipid bilayer would enable the prediction of the same quantity in 
another bilayer varying, for example, in lipid chain length solely from the difference in 
bilayer free surface area. Relationships between solute structure and lipid bilayer 
membrane binding, if sufficiently comprehensive, would not only be useful for 
determining how much of a drug of interest would be bound to a liposomal membrane, 
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which is an essential term in understanding and modeling both drug loading and release, 
but it would also be an important piece of the puzzle in understanding how drugs 
distribute in vivo. However, a more comprehensive set of compounds with diverse size, 
structure and properties needs to be evaluated to establish universally applicable 
structure-binding relationships. 
To properly design nanoparticle release kinetics, one must have the right mathematical 
models to describe drug release as well as proper methods to test those models. The 
analysis of the dynamic dialysis method for the determination of release kinetics from 
nanoparticles as conducted in this work should greatly enhance understanding of the 
central mechanisms involved in dynamic dialysis and provide the ability to evaluate the 
reliability of data generated by this method. The proposed mathematical models will 
enable the deconvolution of the true release rate constant from the apparent kinetics 
where drug binding effects and/or dialysis membrane transport may be partially 
contributing. 
The novel active loading method developed in this study using supersaturated drug 
solutions should be valuable in overcoming formulation challenges associated with the 
liposomal delivery of poorly soluble, ionizable anticancer agents. In terms of drug release 
kinetics, the a priori design of liposomal release kinetics may play an important role in 
the selection of optimal systems tailored to specific tumor types. Mechanistic 
understanding of the thermodynamic and kinetic factors governing the trans-bilayer 
activity gradient of a drug is the key to predicting its release kinetics. It was shown that a 
varying range of release kinetics from few hours to several days can be obtained by 
modulation of formulation variables such as intraliposomal pH and bilayer barrier 
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properties. A quantitative relationship between membrane permeability, the 
intraliposomal microenvironment, and bilayer chain ordering was demonstrated. 
However, the connection between mechanistic models for in vitro release in aqueous 
buffers and the in vivo release kinetics from the same systems in the systemic circulation 
and local tumor environment has not yet been established. Mechanism-based models such 
as those developed in this study should also be beneficial in understanding and 
minimizing differences between in vitro and in vivo behavior of drug-loaded liposomes 
when such differences emerge.  
In the near term, evaluation of the in vivo performance of optimized liposomal 
formulations in order to test the applicability of models based on in vitro observations to 
in vivo behavior should be considered. The long term goal would be to evaluate the 
applicability of such binding, loading and release models with a diverse set of compounds 
varying in size and structure in order to contribute towards the ultimate vision of 
establishing global, comprehensive mathematical models that can predict in vitro drug 
loading and both in vitro and in vivo release kinetics of various liposomally loaded drugs. 
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